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Cyclin-Dependent Kinase 5 belongs to the broad class of serine/threonine kinases, 
which play an important role in neurophysiology. Because of its implicated role in 
Alzheimer’s pathology, CDK5 has been an attractive therapeutic target for 
Alzheimer’s disease. In this study, we applied various bioinformatics tools to unravel 
vital information that is required for structure based drug design.  
Chapter1 introduces briefly background to Cyclin dependent Kinase 5 and its basic 
neurophysiological role. Then structural aspects of CDK5 were explained including 
deregulation of its function. At the end, discussed implicated role of CDK5 in 
Alzheimer’s pathology. 
Chapter 2 discuss the state-of-the art bioinformatics tools in drug discovery process 
and some of key areas technology were briefly introduced including MSA, phylogeny 
analysis, protein structure prediction, prediction of molecular interactions, and protein 
dynamic. 
Chapter 3 defines aims and objectives of each chapter.  
Chapter 4 covers various biological aspects of CDK5 i.e. function, structure, 
regulation and role in Alzheimer’s pathology.  Networking analogy was applied to the 
structure of CDK5 to understand intricate interaction between the amino acid 
residues. Various network based topology measures such closeness centrality, 
betweenness centrality and cluster coefficient were calculated to weight relative 
significance of each residue. Further using between centrality, hinge residues that 
responsible structural domain motions were predicted and this prediction was 
substantiated by geometry simulations coupled with Gaussian network model.  
xiii 
 
Chapter 5 Deals with creation of inactive/active CDK5-ATP templates suitable for 
virtual screening studies.  Further extensive molecular docking studies were 
performed with various chemotypes to delineate key intermolecular interaction that 
helps to understand inhibitory action of CDK5 inhibitors. In addition, inactive CDK5 
conformation was used to predict possible multi-target inhibitors. 
Chapter 6 deals with multi step virtual screening procedure that includes ensemble of 
protein conformations to identify most viable CDK5 inhibitors. Then a simple four 
point pharmacophore model was used to filter most selective compounds that make 
necessary hinge site interactions. In the following step vigorous genetic algorithm 
based molecular docking procedure was used and using key interactions (pair wise 
linear potential) active compounds were distinguished from inactive. In the final step, 
Hit compounds selected based on key molecular contacts.  Among the hit compounds 
several triazino indole compounds were identified. 
Chapter 7 covers the peptide based drug design strategy   to design  tau competitive 
peptide inhibitors . in this study, we could successfully model large number of 
CDK5/p25-substrate complexes using flexible docking simulations by considering 
back bone flexibility. Histone peptide (HHASPRK) that obtained from CDK2/cyclin 
complex (1QMZ) was shown to have highest rosetta score among all substrates.   In 
the next step, using the constraints obtained from CDK5/p25-substrate complexes, we 
designed inhibitor peptides by replace serine/threonine from the phosphorylation site.  
Novel in situ peptide design strategy was applied, which optimize the peptides in the 
binding site, to design novel inhibitory peptides. All these peptides were thoroughly 
analysed and their interaction with CDK5 was confirmed using MD simulations.   
xiv 
 
Chapter 8 deals with alternative drug design strategy using N-terminal portion of p35 
as a potential target site. .  In this study, we modelled truncated N-terminal domain of 
p35 using ab initio strategies. Then the predicted model was used to predict the 
natural binding conformation with respect to CDK5. Following the model 
development and validation, alternative druggable site were explored.   
Chapter 9 covers the analysis of global structural dynamics of CDK5 and its 
associated proteins. We analysed collective motions of CDK5 in different state (active 
and inactive) and different conditions such in the presence of activator, inhibitor, and 
substrate. Further this study was extended to analyse p25 activator protein and CIP 
inhibitor protein. MD/EDA and Anisotropic network modes were used to find the 
global motions that are functionally relevant.  
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1.1 Alzheimer’s disease 
Alzheimer’s Disease (AD) is one of the most threatening neurodegenerative disorder 
characterized by severe form of dementia with an estimated number of 24 million 
cases people worldwide. AD was first described by Dr.Alois Alzheimer. In 2005, 
Delphi study1 estimated that number would rise by 2020 to 42.3 million and 81.1 
million by 2040. Although prevalence of disease varies from country to country and 
region to region, China accounts for the largest number of affected people in the 
world followed by USA and West Europe. Dr.Alois Alzheimer described the AD first 
time in 1906 with two main pathological hallmarks: the amyloid plaques composed of 
extraneuronal deposits of amyloid β (Aβ) and neurofibrillary tangles (NFT) primarily 
composed of intraneuronal deposits of hyperphosphorylated tangles. The amyloid 
cascade hypothesis2 suggests that the cleavage of Amyloid Precursor Protein (APP) 
into Aβ peptides (Aβ1-42 and Aβ1-40) by α, β, γ-secretases. Aggregation of these 
insoluble peptides (Aβ1-42 readily aggregates than Aβ1-40) is suggested to be 
responsible for the formation of toxic amyloid plaques which eventually lead to 





answered in this hypothesis e.g. It is not obvious that how Aβ formation occurs and 
how Aβ causes neuronal damage.  The second major hallmark of AD is formation of 
neurofibrillory Tangles (NFT)3. Structural changes in soluble Tau protein is proposed 
to trigger insoluble β-sheet aggregates before formation of neurofibrillary tangles. 
This eventually leads to structural and functional disruption of neuron and this 
hypothesis is popularly known as Tau hypothesis (details in following section) but the 
link between Aβ-peptides formation and tau protein is yet unclear.  The symptoms of 
AD usually develop slowly with common form of dementia with gradual progression, 
ending up with memory loss and severe cognitive damage. Chemical and structural 
changes in the brain slowly destroy the ability to create, remember, learn, reason, and 
relate to others.  As critical cells die, drastic personality loss occurs and body systems 
fail. Current, AD therapies begins with identification of onset of dementia based on 
family history. Accurate detection of AD onset is still far from the reality. Although 
there are treatment methodologies available, mainly their effectiveness is limited to 
alleviate the symptoms or in delaying the disease progression. There is pressing need 
to devote huge resources in research to understand pathogenesis of disease and early 
onset symptoms and also to develop efficient diagnostic methods and therapies for the 
reversal of symptoms.  
1.2 Tau Hypothesis 
Tau hypothesis4 was proposed, from structural studies in association with signalling 
cascade in neurodegenaration pathways, to elucidate NFT formation in AD and its 
relation with Aβ aggregation. The increasing evidence suggests that tau 
Hyperphosphorylation provides the closest approximation to clinical observations. 
Tau is a filamentous low molecular weight protein that is associated with 





conditions.  The tau protein binds to microtubules through the repeat domains and 
flanking domains in C-terminal, to help in polymerization. Neuropathology revealed 
several clues pertaining to the relation between tau Hyperphosphorylation and PHFs 
formation. Although the relation link between Hyperphosphorylation and PHPs 
formation is unclear, Deregulation of many phosphokinases have been implicated in 
Hyperphosphorylation of tau e.g. Glycogen Synthase Kinase 3β (GSK3β)5, Cyclin 
Dependent Kinase 5 (CDK5)6, Extracellular signal related kinase 2 (ERK2)7.  
Pathological conditions such as hyperglycemia, disorder in lipid metabolism, chronic 
infections, and oxidative conditions trigger likely endogenous damage, which 
gradually leading to the formation of paired helical filaments (PHFs)8 through 
aggregation. 
1.3 Cyclin-Dependent Kinase 5 (CDK5) 
Cyclin-dependent kinase (CDK)9 family is comprised of 11 small(30 – 35 Kda) 
serine/threonine kinases, numbered according to their discovery (CDK1–DK11). 
CDKs are important family of protein kinases regulating the cell cycle in addition, 
they are important for neuron differentiation, apoptosis, senescence and gene 
transcription. CDKs in native state are not functionally active; these are regulated by 
activator proteins known as cyclins (A, B, D, E, H and T). Without cyclins, CDKs 
have exhibit no activity or little activity and cyclins regulate CDKs activity through 
various stages and functions. Protein kinases were names after the residue of 
phosphorylation on their substrates; CDK family proteins phosphorylate their 
substrates on either serine or threonine. Since CDKs play significant role in cell cycle 
regulation, they are vital targets for anti-cancer therapies. Cyclin-dependent kinase5 





take part in cell cycle regulation, although it has been shown to have influence on 
retinoblastoma protein (PRb)11, a key regulator of cell division.  Similar to other 
members of CDK family, cdk5 requires an association in order to be activated. 
1.3.1 Functional Role of CDK5 
CDK5 has been regarded to be one of the central molecules that maintain several 
neurological functions12 (Fig 1.1). In early experiments, mice lacks of CDK5 were 
shown to have developed defects in their neuronal system and replenishment of 
CDK5 was shown to have recovered from the defects.  CDK5 performs several 
presynaptic13 by direct phosphorylation of substrate proteins such as regulation of 
exocytosis of synaptic vesicles through phosphorylation of pcaire protein. CDK5 also 
regulate kinases like dynamin and amphiphysinI14, proteins essential for clathrin 
mediated endocytosis. Additionally, cdk5 mediated phosphorylation of synaptojanin 1 
inhibits its phosphatase activity and recruitment to the membrane. CDK5 
phosphorylates DARPP3215, a neostriatum-specific protein that modulates dopamine 
signalling in dopaminoceptive neurons. 
CDK5 has been known to be critical in presynaptic function but recent evidence 
points out its likely role in Postsynaptic function.  Recently, a requirement for CDK5 
in the development of the neuromuscular junction was shown. It was observed that 
CDK5 and p35 are highly concentrated at the neuromuscular junction, where they co-
localize with the acetylcholine receptor on the postsynaptic muscle membrane. In 
addition CDK5 is up-regulated by Neuregulin16 in C2 cells, indicating that CDK5 is a 
component of neuregulin signalling. Interestingly, p35–CDK5 was found to 
phosphorylate ERBB, the neuregulin receptor, due to which blockage of expression of 





of CDK5 in post-synaptic activities in neuro-muscular junctions.  CDK5 is also 
known to associate with the microtubule cytoskeleton, and can be purified from 
bovine brain microtubule. Several microtubule-associated proteins (MAPs), including 
MAP1B and Tau, are substrates CDK5.  
 
Fig 1.1: Functional roles of CDK5 
CDK5 has also been proved to have involvement in several cellular processes such 
neuronal migration, actin dynamics, microtubule stability, cell adhesion, axonal 
guidance, myogenesis, membrane transport. CDK5 plays important role in neuronal 
migration which is evident from CDK5/p35 deficient mice exhibit defects in neuron 
positioning. CDK5 regulate phosphorylation of RAC effector (pak1)17 that further 
control actin dynamics. Several microtubule-associated proteins (MAPs) are 
substrates of CDK5, and regulate microtubule polymerization. Tau, a filamental 
protein that wrap itself around microtubules, phosphorylation effectively control the 
polymerization of microtubules.  
 Phosphorylation of Rac effector (pak1) is known to be regulated by CDK5.  The role 





the N-cadherin–β-catenin complex resulting inhibition of adhesion. CDK5 is also 
known to play key role in synaptic development by phosphorylating several synaptic 
proteins that modulate dopaminergic signalling18 and development of the 
neuromuscular junction. The kinase activity of CDK5 is known to induce expression 
of MyoD and Mrf419 protein which regulate myogenesis. CDK5 phosphorylates the 
Munc18–syntaxin1 complex and amphyphysin, indicating a possible role in 
membrane fusion, neurosecretion and endocytosis. 
1.3.2 Structure of CDK5 
CDK5 structure is typical bilobular structure that is observed and conserved 
throughout kinase family. Bilobular structure characterized by ATP binding site 
located between N-terminal lobe with predominantly β-sheets and C-terminal lobe 
predominantly characterized by α-helices. Kinases achieve their primary role of 
phosphorylation of their substrates by tightly controlling ATP binding site that is 
located strategically between N- and C-terminal lobes. CDK5 tightly controls the 
phosphorylation activity by exhibiting two varied conformational states (inactive and 
active) through relative motions of N-terminal lobe and C-terminal lobe. Upper N-
terminal region of CDK is an important regulator of ATP binding site that is 
characterized by G-loop located on the roof of binding site, which helps ATP to align 
in correct conformation for phosphotransfer activity.   This process is in turn 
controlled by external kinases (abl kinase) that control G-loop through 
phosphorylation of Thr14 and Tyr15.      C-terminal lobe is known not to have any 
regulatory function but critical for the placement of substrates in correct conformation 
with respect to ATP binding site. In other words, this region mediates substrate 





feature that strongly influences the kinase activity is t-loop which spans about 24 
residues (145-172), hindering the binding site partially in inactive state  
Fig 1.2 : CDK5/p25  (left) and CDK2/CylinA (right) 
CDK5/p25 crystal structure20 throws light on several structural features that are 
critical for regulation of CDK5 activity. P35 or p25, a truncated form of p35, seems to 
approach CDK5 from αC-helix region and drive the helix in to the ATP binding 
cavity resulting rearrangement of t-loop and substrate binding site. Interestingly, 
given meagre similarities with cyclins, p25 exhibits conserved Cyclin binding fold 
(CBF) that directly interacts with C-helix.  
Despite the similarities between CDK5 and other CDKs, CDK5 structure by 
mapellil20 et al ., suggests several intriguing revelations. First and foremost, CDK5 is 
activated by neurospecific activator proteins such as p35, p3921 and C-terminal 
truncations of p35 (p25). In contrast, other CDK’s have been reported to be activated 
by cyclin proteins.  Despite the similar Cyclin-like binding fold exhibited by p35/p25, 
CDK5 is still averse to Cyclin interactions. CyclinD22 reported to have interaction 





phosphorylation independent activation on t-loop, whereas other CDK’s mandate the 
phosphorylation on t-loop (Thr160 in CDK2) to achieve complete activation. In 
addition, it was suggested that phosphorylation of Ser159 on t-loop of CDK5, 
analogous to Thr160 of CDK2, diminish the kinase activity.  Lack monomeric form of 
CDK5 severely curtails our understanding in this  direction.  
1.3.3 Deregulation CDK5 
CDK5 is known to phosphorylate6 tau protein, a microtubule stabilizing protein, at 
certain positions (396, 404) which enabling tau to maintain the integrity of 
microtubules and neurons. In pathogenic conditions, excessive activation of CDK5 
leads to hyperphosphorylation of tau and loss of its affinity to microtubules 
subsequently microtubule disassembly, interruption of axonal transport and neuronal 
death. CDK5 activity is usually deregulated under oxidative conditions or due to 
neurotoxic insults consequently fragmentation of p35 (neurospecific activator).  The 
elevation of calcium levels in neurotoxic condition is responsible for the activation 
calpian23, a serine protease, which fragments p35 into C-terminal p25 and N-terminal 
p10.  The accumulation of p25, C-terminal fragment of p35, was reported and was 
proposed to be main a culprit.  The truncated activator p2524 resembles p35 in binding 
pattern as well as activation mechanism. However, loss of N-terminal myristoylation 
sequence that present in p35, changes its subcellular localization of CDK5-p25 
complex with respect to CDK5-p35. In addition, CDK5-p25 complex is more stable 
with the half-life of ~ 5 folds longer than that of CDK5-p35 complex.  Consequently, 
p25 interaction with CDK5 causes mislocalization and prolonged activation resulting 






1.4 Prospects of Drug Discovery 
Several reports25-27 suggested CDK5 as a key therapeutic target in Alzheimer’s 
pathology so there is an urgent need to develop drug discovery strategies. Emergence 
of state-of-the-art computational28 tools allow to understand several aspects of drug 
discovery even before very existence of such molecules via prediction of drug 
molecules and  assessment of intermolecular interactions  or process via fragment 
based design and structure based design.  
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2.1 In silico Methods in Drug Discovery and Design  
 Rapid growth in the biological sciences due to advances in structural biology, 
genetic, molecular biology and biotechnology mandate the use of computational 
means to decipher ever increasing amount of the data. Currently state-of-the-art 
computational algorithms have penetrated into the core of every branch and 
complementing several experimental techniques. For example, protein structure 
prediction algorithms are helping to generate large scale 3D dimensional models, 
which essentially complement slower structural biology techniques such as X-ray and 
NMR. Further assessment of intermolecular interactions between protein-ligand is a 
key area of research which helps in optimization of lead compounds. The available 
experimental protein-ligand complexes are meagre in number but molecular docking 
techniques greatly complementing this area. In short, in today’s pharmaceutical drug 
discovery, bioinformatics is an integral process which is implemented in various 
levels at various stages of discovery process. Fig 2.1 illustrates the typical discovery 






Fig 2.1: Role of various Computational Techniques in Drug Discovery 
The Computational techniques play crucial role in initial phases of drug discovery as 
it is shown the Fig 2.1.  Target identification is the first crucial step in the drug 
discovery pipeline wherein a molecular target, in general a protein that play critical 
role in causing the symptom of a human disease. Typical gene knock-out or 
chemogeneomic techniques are popular to identify novel targets. Bioinformatics 
techniques such as protein interaction databases, protein-protein interaction networks 
as well as in silico target fishing approaches have been used to speed up the process of 
identifying reliable molecular target. The complexity of the validation process has 
been witnessed by the slow turnout rate of novel targets, despite the recent genomic 
and proteomic revolution. The complexity lies in the fact that most diseases originate 
at the genetic level, and all the genes and gene products are interconnected in a 
complicated network of different pathways. Protein-protein networks facilitate 
assessment of possible synergic effects or centrality of a target in the interaction 
network. Further assessment of target comes from prediction of druggability. Several 





druggable sites, and prediction of possible ligand molecules. The third step, lead 
discovery process, is again enormously supported by in silico techniques such as 
virtual library screening, structure based drug design, molecular docking. The final 
step, lead optimization significantly benefits from strategies like toxicity predictor, 
analysis ADME, and fragment based drug design techniques (FBDD). In addition, 
latest entrants in drug discovery such as molecular dynamic simulations, normal mode 
analysis, elastic network techniques as well as protein structure networks, are known 
to provide alternative targets (allosteric sites). As well as their ability to sample 
flexibility of the target protein substantially improve the drug design process thereby 
binding efficiency and selectivity of drug molecules will be improved significantly. In 
the following section some of popular in silico techniques were discussed in length.   
2.2 Analysis of Protein Sequences 
Analysis of protein sequence forms the first step in proteomics analysis, which 
elucidates information about all conserved motifs, protein domains, secondary 
structure, and conserved residues. Computational techniques are very helpful to 
handle this ever increasing sequence data and as well as to mine the hidden 
information.  Two most common methods in this regard are multiple sequence 
analysis and phylogeny analysis. 
2.2.1 Multiple Sequence Alignment (MSA) 
 Sequence alignment1 is a very prominent technique in bioinformatics for visualizing 
relationship between residues in a given set of evolutionary related proteins. 
Alignment displays equivalent residues in columns by highlighting conservation and 
variance distinctly. The problem of sequence alignment becomes complicated when 





sequence alignment (MSA).    Most modern MSA programs consist of two important 
components.  Objective function: assess the quality of alignment of input sequences, 
and Optimization procedure: responsible for the identification of highest scoring 
alignment with respect to objective function. Based on alignment pattern, MSA are 
either global or local, CLUSTAL is one of such program achieved dramatic popularity 
and quickly became gold standard for global sequence alignment. Later on, several 
other programs such as MUSCLE2, MAFFT3, T-COFFEE4, PROBCONS were 
reported in this category to have achieved better performance and sensitivity than 
CLUSTALW.  Local alignment methods ignore full length of sequence and more 
focus local homologues regions of the sequences, which were reported to improve 
accuracy significantly. These algorithms achieve the extra sensitivity by incorporating 
addition data from PSI-BLAST and building profiles i.e. PRODA and CONTRalign5.  
Most alignment programs depend on SP scoring function (sum-of-pairs) which is 
defined as summation of substitution scores, for the matched pairs of characters in the 
sequence being aligned, and gaps penalties. MSA is extremely helpful for biologists, 
to understand evolutionary changes, to identify conservation pattern among closely 
related species and it is very essential step in   molecular systematic and modern 
structure prediction methods. 
2.2.2 Phylogeny Analysis 
 Phylogenetic analysis is another area where sequence analysis techniques are used 
widely, which infers evolutionary relationship among the given set of protein or 
nucleotide sequences. In other words, phylogenetic analysis evaluates changes 
occurring in different organism during the evolution to identify evolutionary ties 
between organisms (ancestral pattern). Often phylogenetic analysis is performed in 





sequences is carried out. In the second step, MSA is subjected to one of the tree 
building methods based on similarity between sequences. There have been different 
algorithms proposed to construct the tree based on MSA.  Distance based methods are 
known be less accurate, computationally less expensive and rapid6 i.e. 
Neighbourhood-Joining, UPGMA methods. Character methods are designed to 
perform accurately but computationally expensive i.e. Maximum parsimony and 
Maximum likelihood. In the third step, trees are validated using bootstrap method (or 
jack-knife) by re-sampling in multiple aligned groups of sequences through creating 
new alignments and replacing the original datasets. Method of choice heavily depends 
on conservation among the sequence dataset. If sequences are closely related, distance 
method or maximum parsimony7 (MP) is preferable. Otherwise, maximum likelihood6 
(ML) method yields best results for the datasets having high dissimilarity.  
2.3 Computational Protein Structure Prediction 
Drug discovery process is heavily dependent on availability of protein structures 
which acts as therapeutic targets. The progress in structural biology has been slow and 
expensive. Protein structure prediction methodologies act as an inexpensive 
alternative to experimental techniques such as X-ray crystallography and NMR. 
According to Anfinsen8 (1973) protein sequences are folded into native structure 
spontaneously without the help of biological process. This first principle based 
method is called thermodynamic hypothesis. Later Baldwin9 et al., proposed protein 
are folded into native tertiary structures through fast secondary structure folding 
followed by slow territory structure folding. Several methods have been proposed to 
model protein structures and these methods can be divided into three main categories:  






2.3.1 Comparative Modelling  
Comparative modelling relies on concept that sequences of evolutionarily similar 
protein share similarities in their structures. In other word, sequence similarity 
suggests structural similarity, which is a guiding principle for comparative modelling 
approaches.  The model building process of a target protein is carried out four steps: 
(1) identification of known 3D structure(s) of a related protein that can serve as 
template; (2) sequence alignment of target and template proteins; (3) model building 
for the target based on the 3D structure of the template and the sequence alignment; 
(4) refinement of side chains, varied regions, and missing regions. The entire 
modelling process is iterated and validated several times until satisfactory model is 
obtained. The accuracy of model prediction depends on amount of similarity between 
target and template sequences. If the similarity is more than 50%, predictions are of 
high quality and Kopp et al.,10 proved that these models are as accurate as low 
resolution X-ray predictions. It was also proved that sequence similarity fall below 
30%, the prediction is most likely contain significant errors. MODELLER is one of 
the best comparative modelling algorithms by Sali11 et al., which construct the model 
by satisfying spatial constraints.  
2.3.2 Threading or Fold recognition 
Fold recognition methods are based on popular notion that protein structure is more 
evolutionary conserved than the sequence. As a result, the number of different folds, 
estimated by clustering of known structures in PDB, is far less than suggested by 
sequence diversity. Threading process attempt to identify a model fold for a given 
sequence among known folds even if remote sequence similarity can be detected. 
These methods are popular when target and template sequence fall below twilight 





10% wherein 60% or more of helix/strand structure is correctly assigned, then model 
can be predicted reliably. Typical threading methods incorporate advanced sequence 
similarity protocols, secondary structure prediction and comparison with fold 
databases. Secondary structure information is commonly used in these methods and 
incorporation of addition sequence based parameters like hydrophobicity, solvent 
accessibility also suggested enhancing the quality of prediction.  
2.3.3 Ab initio methods 
When there is no suitable template structure or fold can be found in databases, first 
principle methods have been proposed.  These methods utilize either fragment 
recombination methods or hybrid methods that use combination of multiple sequence 
alignment, threading, Monte Carlo methods and clustering methods. Fragment 
recombination methods depend on assembly of fragments those obtained from search 
fragment database using target sequence.  These methods based on assumption that 
local environment is well conserved and, therefore short fragments that represent local 
environment are assembled into complete protein. Baker12 et al., proposed distribution 
of local structures up to 10 amino acids. Target sequence is matched against the 
fragment databases and suitable template fragments are identified. Then these 
peptides are assembled using an optimized and best native like structures are 
identified using scoring function.  Other methods such as one proposed by Zhang13 et 
al., use hybrid methods combining threading and MSA and clustering methods. 
Molecular dynamics methods were also reported to be useful for predicting protein 
structure through folding structure but these methods are limited to the small peptides 






2.4 Prediction of Intermolecular Interactions  
Proteins are complex biological molecules which interact with small molecules, other 
proteins, nucleic acids and surfaces by complex array of intermolecular interactions.  
As these interactions are key factors that determine the final binding of various 
molecules to each other, accurate interpretation and prediction of these interactions is 
still a challenging problem in computational biology.   Several fundamental 
interactions have been identified and have been widely used in various algorithms 
such as hydrogen bonds, van der waal interactions, hydrophobic forces, and 
electrostatic interactions. In biological systems, estimation of contributions of these 
forces between protein-ligand and protein-protein is very difficult.  
     
Fig 2.2: Schematic representation of Protein Structure Prediction (left) and Molecular Docking protocol 
(right) 
 
Protein interactions with small molecules and other proteins are controlled by 
complex array of intermolecular interactions. Such interactions are either specific 
interactions that are found inside the binding site or non-specific forces that are found 
outside the binding site, usually on surfaces. The interplay between specific and non-
specific forces leads to a wide range of interactions ranging from small molecular 





molecular forces that regulate the biological interactions and to utilize this 
information to manipulate protein interactions, in other words protein function, for 
designing new interactions with ligands as well as other proteins. These molecular 
interactions14 form the basis for all protein engineering and design studies which aim 
to devise new functionalities or new projectiles that target other proteins i.e. ligands. 
These molecular forces and their physiochemical origins are calculated either from 
equilibrium binding kinetics or molecular modelling studies. Properties and energies 
of these interactions are used to understand physical and chemical properties of 
proteins behaviour and function. These energy calculations are usually feasible for 
small molecules using Density Function Theory (DFT) calculations. But the size and 
complexity of biomolecules pose barrier for such calculations. Usually energies of 
interactions derived from small molecules are approximated to proteins as well as 
statistical methods are in wide use for estimating such interactions. In the following 
section, we discuss major classes of biological interactions and various methods to 
estimate the strength of these interactions.  
2.4.1 Protein-Ligand Interactions 
 
Several small molecular substrates such as ATP, NDPH, and FAD are known to 
establish interactions with several proteins and participate in various physiological 
functions. Protein-ligand interactions are special class of molecular interactions where 
the interaction is established between small ligand and large biomolecule. Lock and 
key hypothesis postulates that these small molecules or ligands bind to very small 
area or in confined binding cavities through strong intermolecular forces such as 
hydrogen bonding interactions, hydrophobic interactions and ionic-ionic interactions. 
Understanding and estimation of physiochemical properties of these interactions is 





counterparts.  Prediction and estimation of molecular interactions is a twofold 
problem: prediction of correct natural conformation of ligand in the binding site and 
quantification of interactions i.e. binding energy calculation or prioritization of 
binding poses. Several molecular docking algorithms have been designed for this 
purpose. 
The molecular docking algorithms15 have been designed to predict the ligand 
conformation and orientation within the protein target binding site. Although most of 
the algorithms are accurate in prediction of correct orientation, they suffer from 
weakness like inclusion of induced fit effects, conformational changes induced upon 
protein-ligand interaction, and emulation of protein-water interactions. Docking 
process involves orientation of ligand into active site and sampling degree of freedom 
with sufficient accuracy to identify the best ligand conformation that matches target 
protein. Docking algorithms represent protein and ligand in either atomic 
representation of surface representation. Atomic representation is computationally 
expensive and is implemented using potential energy grid schemes (van der waals and 
electrostatic). Surface representation is mostly implemented in protein-protein 
algorithms. Ligand flexibility is handled by various algorithms: systematic search 
methods (incremental construction), conformational search, stochastic methods 
(genetic algorithm and Monte Carlo algorithm) and molecular dynamics methods. 
Docking algorithms are usually responsible for generating conformations or multiple 
binding modes including the binding modes found in crystallographically determined 
protein-ligand complexes. Then the scoring functions play key role in identifying the 
correct binding mode or binding affinity. In the docking process, all the ligand 
conformations generated are thoroughly evaluated in terms of interaction with target 





force field based methods16, empirical scoring methods17, and knowledge based 
methods18. Force field scoring functions use molecular mechanics for energy 
calculation and they estimate binding energy by the sum of van der Waals and 
electrostatic energies. Non-polar contributions are calculated from solvent accessible 
surface area and non-bonded interactions are treated with a cut-off distance. Various 
functionally similar force fields have been proposed with different sets of parameters 
and these methods require energy minimization before binding energy calculations. 
Empirical scoring functions estimate binding energy based weighted structural 
parameters by fitting scoring functions to experimentally determined binding 
constants of a set of protein-ligand complexes. These scoring functions introduce bias 
from complexes but very simple to evaluate than force field based scoring functions. 
Although these methods appear to be simple and easy to evaluate, suffer from 
incomplete description for estimating solvation and dissolvation effects in the scoring 
functions. The third class of scoring functions is knowledge based scoring functions 
where binding affinity is estimated by considering protein-ligand atomic interactions. 
Similar to empirical scoring functions, these potentials are derived from experimental 
complexes, where interatomic distances are converted into distance dependent 
interaction free energies. Knowledge based scoring functions are simple, which are 
mainly designed to reproduce experimental structures and also permit easy scoring of 
large databases. To circumvent the weaknesses of these scoring functions, consensus 
scoring functions have been proposed which combine different scoring functions and 
balance the errors in single scoring functions. These scoring functions are designed to 
improve the efficient identification of true conformation or true ligand.  
Several state-of-the- art algorithms equipped with reliable scoring functions have been 





DOCK6 (dock3.5 score, amber score), MDOCK (itscore), GOLD (chemscore), 
GLIDE, GEMDOCK (plp), and AUTODOCK VINA (viva score).  
2.4.2 Protein-Protein Interactions 
 
As many biological processes involve formation of protein-protein complexes, 
Protein-Protein interactions are another major class of interaction between 
biomolecule i.e. antibody-antigen interactions. An understanding and prediction 
protein-protein interactions19 is currently one of major area of research in 
computational biology.    Contrary to protein-ligand interactions, protein-protein 
interaction form at large surface area and determinants of binding are slightly 
different from that of protein-ligand interactions. Although the basic intermolecular 
forces are the same in protein-protein and protein-ligand interactions i.e. hydrogen 
bonding, hydrophobic and ionic interactions, they act in different degrees at protein-
protein interfaces.  There are several fundamental properties that characterize the 
protein-protein interfaces: size and shape, surface complementarities, interface 
residual propensities, hydrophobicity and hydrogen bonding, secondary structure and, 
conformational changes on complex formation.  Protein-protein complex prediction, 
at atomic level, is a very important issue in biology. Most of the structures deposited 
in protein databank are single structure and only 10% of them are complexes. To fill 
the gap, there are several protein-protein docking algorithms proposed to predict the 
complexes with reasonable accuracy. 
Protein-protein docking20 can be divided into rigid and flexible. In the rigid docking, 
the interacting proteins are assumed to be rigid bodies by allowing any 
conformational changes as they interact with each other. While in flexible docking, 
conformational flexibility of molecules is taken into account. In the rigid docking 





into account on the other hand, in flexible docking; torsional angle changes are added 
to conformational space and this computationally very expensive. In general docking 
is performed in two steps, in the first step rigid global docking is performed followed 
by the high resolution flexible docking limited to selected areas. Over all, two 
components are essential for accurate prediction of protein-protein complexes: 
accurate global conformational search algorithm and a free energy function that can 
accurate distinguish native conformations from non-native conformations. Given the 
inaccuracies in the free energy function, multiple conformations are produced instead 
of choosing the lowest energy conformation as the final binding pose. 
Most popular algorithms21 in this category are ZDOCK, FTDOCK, HEX, CLUSPRO, 
GRAMM-X, RosettaDOCK, PatchDock, and Fiberdock. Most of these algorithm 
works based on rigid body assumption and score the output by various energy 
function such hydrophobic, electrostatic, and solvation energy.  
2.5 Structural Dynamics of Proteins  
Protein dynamics22 furnish important insights about protein conformational change 
over the time as well as how global and local motions impact on function of protein. 
The dynamic nature of proteins plays a critical role in molecular recognition23. An 
understanding of ligand-recognition and binding dynamics is the major challenge with 
impact on drug discovery. Yet, progress in this field has been impeded by the 
complexity and specificity of interactions, the multiplicity of conformations 
accessible under equilibrium conditions, as well as insufficient data on the structure 
and energetics of protein-ligand interactions.   Broadly speaking, protein dynamics 
can be divided into two types based on level of details that is considered during the 






2.5.1 Molecular Dynamics 
For biological systems, molecular dynamic simulation24 method is the best theoretical 
tool that provides great insights about time dependent properties of molecular system. 
Molecular Dynamic (MD) simulations is now a routine tool that allows to investigate 
fluctuations and conformational changes occur in proteins and nucleic acids and also 
applied to investigate dynamics and thermodynamics of proteins and protein 
complexes. The molecular dynamics method was first introduced by Alder and 
Wainwright25 in the late 1950's to study the interactions of hard spheres. The first 
molecular dynamics simulation of a realistic system was done by Rahman and 
Stillinger26 in their simulation of liquid water in 1974. The first protein simulations27 
appeared in 1977 with the simulation of the bovine pancreatic trypsin inhibitor 
(BPTI). Now, it has become a routine technique for addressing variety of biological 
problems including solving NMR and X-ray structures.  
MD simulations use force field or empirical potential function for calculating 
interactions between the atoms of a protein. These force field parameters are obtained 
by fitting experimental data to a known molecule. This approach is limited by 
requirement for new parameters for new molecules such as ligands. Then the force 
field is used to calculate multi-dimensional hyperspace. Trajectories of MD 
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Acceleration a, together with the prior position r and velocity of each atom determine 
their new positions after small time step.  Since in most of the simulations, static 





Boltzmann distribution, velocities are assigned randomly based temperature. Force 
acting on each atom is determined by the negative gradient potential energy surface 
which is contributed by bonded and non-bonded interactions.  
( )= - ( )F r V r    
 = bonded non bondedV E E   
Typically bonded interactions are defined by following set of potential energy 
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The stretching and bending energy equations are based on Hooks law that estimates 
the energy associated the energy associated with equilibrium bond length and angle. 
Dihedral angle describes the bond rotation. 
The non-bonded interactions are described by Lennardo-Jones potentials that 
represent van der waals interactions and coulomb potential representing electrostatic 
interactions between all particles of i and j with r distance.  In the second equation, r 
represents charge on atoms with relative di electric constant. MD simulations can 
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Principle Component Analysis or Essential Dynamics 
Molecular dynamic simulations provide great detail about atomistic details of 
molecules like proteins but it is very difficult to extract collective motions or low 
frequency motions which are indicative essential global motions. Principle component 
analysis or essential dynamics28 is a powerful technique that identifies nature and 
relative importance of the essential deformation modes from MD snapshots. Original 
atomic fluctuations are diagonalized about the average structure through covariance 
matrix. A set of eigenvalues and eigenvectors is obtained, which represents nature of 
deformation motions in Cartesian space and amount of variance explained by each 
motion, respectively.  The main advantage with principle component analysis is that it 
can extract dynamic modes from MD trajectory by applying quasiharmonic 
approximation. Although MD/PCA is a useful technique, it is not obvious from MD 
trajectory that the amount of time need to be simulated to extract meaningful 
collective motions. In addition, it is not suitable to study large domain motions and 
opening/closing motions.  Cij covariance matrix is calculated for each Cα-atom (x) 
Cij= ((xi – (xi)) (xj-(xj))) 
 
C = ࡼસࡼࢀ 
 
The covariance matrix C is decomposed into Principle components (P) and 







2.5.2 Elastic Network Analysis 
As alternative to MD simulations to study large scale domain motions, several coarse 
grain methods have been proposed among them most prominent ones are normal 
mode analysis29, elastic network analysis30 and geometry simulations.  NMA is one of 
prominent coarse graining technique that decomposes complex motions into a sum of 
independent vibrational modes within the harmonic approximation. In NMA the mass 
weighted Hessian matrix is calculated.  
ࡴ ൌ ࡹି૚/૛	ࡷࡹି૚/૛	 
The eigenvalues λ and eigenvectors are then calculated by solving |H - λI| = 0. 
Diagnoalising the mass weighted Hessian matrix H gives U such that D = U -1HU 
where D is the diagonal matrix of eigenvalues and U is the matrix of eigenvectors.  
Standard normal mode analysis (NMA), using an atomic force-field representation of 







NMA predicts B-factors of X-ray structures using  
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 The macromolecules, is computationally expensive, which makes it impossible to 
analyse large proteins with this method. To overcome this limitation, simplified 
alternatives in the form of elastic network models (ENM) have emerged recently, 
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Gaussian Network Analysis 
 
Bahar32 et al., proposed an elastic network model using Tirion potential, which is 
popularly known as Gaussian Network Model (GNM). In GNM, junctions of network 
undergo Gaussian potential; these junctions were recognized by Bahar et al., as Cα 
atoms of protein backbone. Their model accounts for the eﬀect of chain connectivity 
by automatically including the constraints of the backbone, by the use of an 
appropriate cut-oﬀ. In the protein elastic network model the fluctuations ∆R in the 
separation between Cα atoms i and j follow a Gaussian distribution 
ࡼሺ∆ࡾ࢏࢐ሻ ൌ 	 ቀࢽ࣊ቁ
૜/૛
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Kirchhof of connectivity matrix id given by ߬௜௝	and rc is cut-off distance 7 Å 
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Anisotropic Network Analysis  
 
Atilgan33 et al. presented an extension to the GNM called the anisotropic network 
model (ANM). This relaxes the GNM assumption of isotropic fluctuations and 
addresses the directions of collective motions. The fluctuation vectors for each residue 
are determined as well as the magnitudes of fluctuations. The forces acting on a 
residue due to neighbouring residues in the network must sum to zero in equilibrium 
(Bf = 0). The forces are given by Hooke’s law in the GNM, f = γI∆s. The fluctuations 
of the springs in the network, ∆s, are related to the fluctuations of the residues, ∆R, by 
the matrix of cosines of the angles between the springs and each of the Cartesian axes 
B, ∆s = B ∆R. The ANM equivalent of the GNM N dimensional Kirchhoﬀ matrix G is 
then the 3N dimensional matrix BBT. This larger matrix leads to correspondingly 
longer computational times of the order of hours rather than seconds. However, the 





which can be compared to traditional NMA, whilst still being computationally much 
faster than standard NMA. 
2.5.3 Geometry Simulations 
The next level of coarse graining can be applied with geometric simulations in which 
rigid and flexible clusters are identified distinctly. The fast combinatorial algorithm34 
“pebble game” identifies the flexible (un-constrained) regions and rigid (constrained) 
by counting binding rotational degree of freedom in the network. The FIRST (Floppy 
inclusion and Rigid substructure Topology) approach identifies flexible and rigid 
regions without any computational cost. This prediction can be further tuned by 
adjusting energy cut-off. Using flexibility information, The FRODA35 (Framework 
Rigidity Optimized Dynamic Algorithm) approach moves flexible part of a molecule 
stereochemically allowed regions of conformational space using random Brownian 
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Aims and Objectives  
This thesis examines how CDK5 can be targeted in different ways as well as advantages and 
disadvantages various methods. Methodologies developed in this work definitely throw light 
on new insights to design CDK5 selective drugs. This thesis begins with very general and 
fundamental aspects of drug discovery i.e. structural modelling, understanding the functional 
and structural role of various residues and analysis of protein-ligand interactions that are 
significant for the designing of new molecules. Then we proceed to identify novel inhibitors 
that impede phosphorylation by positioning themselves in the ATP binding pocket. We 
devised multi-step screening procedure based knowledge acquired from the previous studies. 
Understanding short comings of ATP competitive inhibitors, we formulated an advanced 
strategy using peptide inhibitors that target substrate binding site located in proximity to t-
loop. In the next step, we explored an alternative way to target CDK5 through the N-terminal 
fragment of p35. At the end, we studied how dynamics of CDK5 can be exploited to design 
novel inhibitors such as CIP.  
Chapter 4 aims to construct reliable model of inactive CDK5 and explore application of 
network paradigm to understand key structural features.  Lack of inactive CDK5 has been 
main predicament in understanding structural anomaly of CDK5. One of the main objectives 
of this work is to construct reliable model of inactive CDK5. As a next step, we would like to 
understand the behaviour of various critical residues and structural motif s in active and 
inactive states of CDK5. To interpret the significance of various residues in terms of their 





topological parameters such as closeness centrality and betweennness centrality were 
calculated. An attempt was also made to predict the residues that play critical role in 
structural transformation (hinge residues) from inactive to active and vice versa. 
Chapter 5 aims to construct active /inactive CDK5/ATP models as suitable templates so as 
to use them to create wealth of CDK5/inhibitors complexes. For any drug discovery efforts, it 
is important to understand protein-ligand interactions. To address the lacuna duo to lack of 
extensive information of CDK5-ligand, we have modelled CDK5-ATP complexes in both 
active and inactive conformations to use them as templates to create CDK5-lignad 
complexes. Then the wealth of CDK5-ligand complexes was generated using molecular 
docking strategy. In order to explore the additional possibilities to target ATP binding site, 
dynamics behaviour of the ATP site was simulated and an inconspicuous secondary pocket 
was identified.  
Chapter 6 aims to set out multi-step virtual screening procedure to identify selective ATP 
competitive inhibitors of CDK5. Using an extensive knowledge that gained from the CDK5-
inhibitors interactions, we devised a multi-step virtual screening protocol to identify potential 
ATP competitive inhibitors. To consider geometric properties of ligands in addition to 
physico-chemical properties, geometric pharmacophore and reside potential (PLP) were used 
and final hit molecules were chosen based on their blood brain barrier (BBB) properties. In 
addition, to confirm their selectivity toward CDK5, comparative docking analysis was 
performed with CDK2.  
Chapte7 aims to design peptide inhibitors to prevent hyperphosphorylation of tau protein by 
CDK5. Although ATP competitive inhibitors are known to be very effective, they suffer from 
selectivity issues because of highly conserved ATP binding site among the kinases. To 
circumvent this issue, we explored tau binding site as a potential new way and peptides as an 





CDK5/p25/HHASPRK complex to create a reference complex. Then different 
CDK5/p25/substrate complexes were created using 7mer fragments excised from full length 
substrate proteins of CDK5 based on consensus sequence.  Using the knowledge gained from 
CDK5/p25/substrate complexes, a de novo peptide design strategy was formulated and 
successfully potential inhibitors were identified. Stability and efficacy of these peptide 
inhibitors was evaluated using MD simulations.  
Chapter 8 aims to study alternative drug design possibilities using N-terminal domain of p35 
activator (P10) of CDK5. Given the difficulties in targeting p25 and p35 selectively because 
of their similarities in sharing substrate binding site, we explored N-terminal region of p35 
(147 residues aka p10) as an alternative target. The main challenge in this study is to model 
p10 because of non-availability of suitable template. Ab initio modelling was used to predict 
the model of p10 and validated. The next key challenge is to predict the correct orientation of 
p10 with respect to CDK/p25. Putative binding site was predicted on N-terminal region of 
p35 and its similarity to stachman-like domain of microtubule was identified. 
Chapter 9 aims to understand collective motions of CDK5 that in turn help targeting 
dynamically.  Static pocket or static structure may not be sufficient always for the structure 
based drug design studies but the understanding dynamics of the proteins and their complexes 
offer novel insights to the drug targeting and design. In this study, we explored dynamics of 
CDK5 and its complexation with p25 (an activator) and CIP (an inhibitor) using MD/EDA 
and Anisotropic network model (ANM). In this systematic study, we explored collective 
dynamics of inactive CDK5, active CDK5 including with and without p25 and CIP. In 
addition, influence of CDK5/p25 and CDK5/CIP on substrate binding also analysed. This 
study highlights possibility of impeding large domain motions with a suitably designed 
peptide fragment like CIP rather than traditionally targeting a cavity or shallow a pocket to 





Chapter 4  
 
Computational Modeling of inactive 
Cyclin-Dependent Kinase 5 - Residue 
Interaction Network Analysis 
 
Preface 
Cyclin-Dependent Kinase 5 is an important target in Alzheimer’s pathology and its 
structural understanding help in selective drug design. Since inactive structure of 
CDK5 is not available, we undertake to construct a reliable homology model which is 
expected throw light on several CDK5 specific structural details. Thorough validation 
of the model proved that more than 98% of residues in sterically allowed regions of 
Ramachandran plot and MD simulation proved that structure is stable enough. 
Networking analogy was applied to the structures of CDK5 to understand intricate 
interactions between the amino acid residues. Various network based topology 
measures such as closeness centrality, betweenness centrality and nodal degree were 
calculated to weight relative significance of each residue. Moreover, comparative 
analysis of active and inactive conformations of CDK5 was performed using 
centrality measures. Further using betweenness centrality, hinge residues that 
responsible for domain motions were predicted and this prediction was substantiated 








Cyclin-Dependent Kinases 51 (CDK5) is a serine/threonine kinase belongs to CDK 
family, mainly responsible for the phosphorylation of target proteins on serine on 
threonine sites.  Contrary to other CDKs which are known to be cell cycle regulators, 
CDK5 is known to play key role neurophysiology and neuronal regulation. Due to the 
peculiar behavior of CDK5, the structure of CDK5 has generated immense interest in 
scientific community. 
The crystal structure CDK5-p252 shed light on some key structural aspects of CDK5 
organization and activation pattern. P25 activator, the truncated form of p35 suggests 
that it interacts with CDK5 through cyclin box like domain that is observed 
exclusively in other CDK activator proteins like cyclins. In addition, the CDK5/p252 
suggests phosphorylation independent activation on t-loop of CDK5 (Ser159). On 
contrary, phosphorylation of t-loop (Thr160 in CDK2) has been suggested as 
mandatory to achieve complete activation.  Despite the availability of active form of 
CDK5, lack of monomeric form of CDK5 restricts comprehensive understanding of 
CDK5 function and activation mechanism. In addition, given significant structural 
similarities and functional differences between active CDK5 and other CDKs, 
monomeric form or inactive form is expected to shed light on intricate structural 
aspects relating various inter-residual interactions, key hinge residues, and 
interactions of various structural motifs i.e. DFG and HRD.   
In the recent times, growth of sophisticated structure prediction algorithms is resulting 
in high quality protein structures that can be directly be used as reference structures in 





simplicity and their ability to predict long range interactions which play significant 
role in various inter domain interactions.  
Networking Analysis 
Recent penetration of network paradigm3 into structural biology of proteins brought 
revolutionary changes, in which protein structure is represented as complicated 
network that is traversing between residues,  is also commonly known as residue 
interaction networks4 (RINs). RINs decrease the visual complexity of 3D protein 
structures and allow the user to focus on individual residues and their molecular 
interactions. In essence, a RIN is derived from the atomic 3D coordinates of a protein 
structure model that has been either determined experimentally or predicted by 
computational methods. Each RIN consists of nodes that represent amino acid 
residues, as well as edges that correspond to non-covalent interactions between the 
residues. Exploration and analysis of the network of interacting residues can provide 
additional insights into the structural and functional role of residues. Networking 
representation of protein structure allows applying conventional network topology 
analysis. Illustration of a comprehensive set of well-known topological network 
centrality measures4 (based on shortest paths, current flows, or random walks) for 
relating spatially distant residue nodes, and discovering crucial residues and their 
long-range interactions in protein structures. Several past studies emphasize the 
application of network analogy to protein structures.   Vendruscolo5 et al., proved that 
highly connected hub residues act as a nucleation center for protein folding. 
Dokholyan6 et al., further correlated weak impact of folding kinetic to interaction 
network.  Amitai7 et al., proved tendency of active site to be highly connected and 





In this study, we focused on modeling of inactive CDK5 structure and subsequent 
validation.  Networking analogy was applied to the both predicted inactive structure 
and crystal structure of active CDK5 and several  network based topological 
parameters such closeness centrality, degree , and betweenness centrality were applied 
to identify critical residues responsible for various functions. Using these parameters 
various structural motifs such as DFG and HRD were analyzed extensively.  In 
addition, betweenness centrality was applied to identify hinge residues. Further 
transition pathway of CDK5 from active state to inactive state was simulated using 
constrained geometry simulation which was used to support the existence of hinge 
residues that responsible for huge structural changes.  
 
4.2 Methods & Methodology 
4.2.1 Sequence Analysis: 
All sequence analysis studies were performed using CLC sequence viewer which is 
facilitated with several algorithms (CLUSTAL, MUSCLE, and MAFFT) for sequence 
alignment and phylogenic tree generation and all calculations were performed using 
default parameters. Phylogeny tree was generated from sequence alignment of all 
CDK sequences using Neighborhood-joining (NJ) method. Further to confirm the 
credibility of branching, boot strap analysis of 100 steps was performed.  
4.2.2 Homology Modeling 
Homology modeling was carried out using MODELLER8,9 (Sali et al) which 
constructs structural models by satisfaction of spatial restraints. The template for 
structural modeling was obtained from RCSB database and CDK5 sequence was 





1pw2) were aligned using SALIGN implemented in MODELLER9 and this process 
was repeated for 10 times to ensure the robustness of the alignment. Thus obtained 
alignment was examined carefully and overhangs were removed. Then the alignment 
along with template structure was fed to the MODELLER program with enhanced 
optimization settings including 500 step of conjugate gradient minimization and two 
rounds of optimization. 50 models were generated and final model was selected based 
on DOPE score and PDF potentials. 
4.2.3 Model Validation 
Inactive CDK5 model generated from MODELLER was thoroughly validated first 
with Ramachandran plot which measures number of residues in sterically allowed 
regions. PROCHECK10 was used to generate G-score or total quality score which was 
derived from 200 high quality x-ray crystal structures. Furthermore, exhaustive 
QMEAN11 validation method was used  
4.2.4 MD simulations 
The initial structure of CDK5 was obtained from homology modeling described in the 
previous section. Molecular dynamic simulation of 5 ns was performed using 
GROMACS12 package.  G43a1 force field was used and all-atom model containing 
3000 atoms with net charge of +1. Hence, one chloride ion was added to neutralize 
the positive charge.  The entire system was immersed in SPC water molecules 
enclosing cubic box of 10 Å in all directions.   The simulation was carried out using 
explicit solvent water and periodic boundary conditions.  In the protocol, 800 steps of 
steep descent minimization were performed to minimize the entire system to remove 
all possible steric clashes. The system then was submitted for 100 ps of restrained 





another around of restrained NPT simulation was performed to stabilize the 
temperature. Finally, unrestrained MD simulation was carried out under periodic 
boundary conditions in the isobaric–isothermal (NPT) ensemble at 300 K with the 
Berenson temperature coupling and constant pressure of 1 atm with isotropic 
molecule-based scaling. The LINCS13 algorithm, with a 10−5 Å tolerance, was applied 
to fix all bonds in the system and no additional restraints were added. The electrostatic 
interactions were evaluated by particle-mesh ewald method with a charge spacing of 1 
Å. The Lennard-Jones interaction were evaluated using 10 Å atom based cutoff. 
Equations were allowed to integrate at 2 fs step interval and trajectories were recorded 
with 10 ps interval.  The analysis of trajectories was performed by native  Gromacs 
tools such g_energy, g_rms,  and g_rmsf for measuring energy related properties, root 
mean square deviation  during simulation,  and root mean square fluctuations, 
respectively. Data was plotted using Gnuplot and Grace. 
4.2.5 Conservation Analysis 
Conservation analysis was performed using Consurf server where sequence was 
searched for homologues with the e-value cut off of 0.001.  Thus obtained sequences 
were subjected to multiple sequence alignment and phylogeny tree construction using 
MAFFT14 and Bayesian algorithm  respectively. Using the resulting tree, conservation 
scores were assigned to each residue in the CDK5 structure. These scores were 
visualized in PyMol.  
4.2.6 Residue Interaction Network 
Residue interaction Network15 (RIN) was calculated using RING implementation 
(www.ring.com/help).  All residues were represented as nodes and interactions 





parameters, structure was optimized for hydrogen’s and protonation states with 
REDUCE16. Missing hydrogen’s and missing atoms were added. In addition to 
interactions, solvent accessibility was calculated using probe of 1.4 Å radius and 
conservation score included that calculated from Consurf server as a nodal property. 
Table 4.1: Cut-off distances for calculating various interactions in RIN 
Interaction type Distance Cut-off (Å) 
Hydrogen bond 2.5 
Close atom 6 
Minimum disulfide bridge 3 
Minimum salt bridge 
distance 
4 





4.2.7 Networking Analysis 
Network topology analysis was performed using network analyzer plugin 
implemented in Cytoscape. Various topological parameter of structural importance 
were calculated based on literature reports. Topological parameters were calculated as 
follow: 
Closeness centrality 
Closeness centrality17 is a measure of how fast information spreads from a given node 
to other reachable nodes and is defined as the reciprocal of average shortest path 
length and is calculated as follow: where L(n,m) is the length of the shortest path 
between two nodes n and m. The closeness centrality of each node is a number 
between 0 and 1. 








The betweenness centrality18 of a node reveals the amount of regulation that this node 
exerts over the interactions of other nodes in the network.  The betweenness 
centrality  Cb(n) of a node n is computed as follows: 
where s and t are nodes in the network different from n, σst denotes the number of 
shortest paths from s to t, and σst (n) is the number of shortest paths 
from s to t that n lies on. 
                                             Cb(n) = ∑s≠n≠t (σst (n) / σst), 
Node Degree  
In undirected networks, the node degree of a node n is the number of edges linked 
to n. A self-loop of a node is counted like two edges for the node degree. The node 
degree distribution gives the number of nodes with degree k for k = 0,1. 
Clustering coefficient 
In undirected networks, the clustering coefficient Cn of a node n is defined as 
Cn = 2en/(kn(kn-1)) 
Where kn is the number of neighbors of n and en is the number of connected pairs 
between all neighbors of n. 
4.2.8 FIRST/FRODA Geometry simulation 
A FRODA simulation19 is a geometric simulation method that explores the internal 
motions of proteins. The details of algorithm can be found in reference. The FRODA 
simulation was performed with the FIRST 6.2 suite. Using FIRST rigid cluster 
decomposition was performed by applying hydrogen bond energy of -1.0 kcal/mol 
and together with hydrophobic interactions. The random displacement distance of the 






4.2.9 Gaussian Network Model 
GNM20 is an elastic network model in which residues are identified by Cα atoms and 
interaction between them are represented by harmonic springs. GNM was applied 
using PRODY protein dynamics suite. The intermolecular distance was set to be 7 Å 
and spring constant gamma was set to be 1.0. Total of 20 non-trivial modes were 
generated.  
4.2.10 Visualization 
PyMol was used for visualization of protein structures and Cytoscape was used for all 
network visualizations. In addition, CLC sequence viewer was used for viewing 
sequence alignments and phylogeny trees. Cytoscape was used for network 
visualization and analysis 
 
 
4.3 Results and Discussion 
In this study, we report construction and validation of inactive CDK5 model and 
novel networking   method was used to study key functional residues and their role in 
integrity of structure. 
4.3.1 Multiple Sequence Alignment and Phylogenetic analysis 
All CDK sequences were subjected to multiple sequence alignment using MAFFT 
algorithm.    Interestingly, MSA was observed to have well aligned with all secondary 
structural elements as shown in the Fig 4.2, suggesting high degree conservation 
among the sequences of CDK family. Further close examination of MSA revealed 
that key structural motifs were observed to be conserved which including g-loop (11-





(P46SSTLRI52 in CDK5).  Furthermore, D144F145G146 activation motif and 
H124R125D126 gate way motif were also found to be well conserved. 
To explore evolutionary relationship between CDKs, Phylogeny analysis was 
performed using MSA by applying Neighborhood-Joining algorithm. It is obvious 
from the tree (shown in fig 4.1) that CDK1 CDK2, CDK3 and CDK5 belong to one 
clad and CDK4 and CDK6 to another. Other CDKs (CDK7, CDK8 and CDK9) were 
branched off separately. Out group helped to identify the root. First group of CDKs 
(CDK1 and CDK2, and CDK3) except CDK5 are key regulator of cell cycle in G0 
phase of Cell cycle. Whereas second clad (CDK4 and CDK6) is known play crucial 
role in M phase of Cell cycle. The rest of the kinases are known to be important for 
transcription regulation, in other words, acts as transcription factors. CDK10 is 
relatively recent and little is known about this kinase. Pho8521 is a homologous 
protein, is known to be essential for phosphate synthesis mechanism, and is most 
ancestral protein to all CDKs which is evident from its early branching from the 
others.  
 





























4.3.2 Comparative Modeling of Inactive CDK5 
From the phylogenetic analysis, it was clear that CDK5 share higher homology with 
CDK1, CDK2, and CDK3. Due to the lack of experimentally solved crystal structures 
of CDK1 and CDK3, we were forced to select CDK2 template for model building of 
inactive CDK5 structure. However, from sequence alignment between CDK2 and 
CDK5, it is very clear that they share very high homology (60.1% of sequence 
identity and 78% sequence similarity), suggesting the possibility of building high 
quality model.  This alignment was constructed using SALIGN program and 
alignment was iterated until all known structural features (motifs) were aligned 
properly. For final model building, inactive CDK2 structure (PDB ID: 1PW2) was 
chosen as template.  The final homology model is shown in the Fig 4.3. 
Model of inactive CDK5 is found to be very within rmsd of 0.1Å with CDK2 
template, indicating backbone similarities. The inactive CDK5 structure is found to 
have bilobal configuration which is known to be characteristic global configuration of 
protein kinases. The N-terminal lobe (1-85) predominantly shows 8 β-sheets, and the 
C-terminal (86 – 292) consists of 13 ά–helix including pseudo-ά-helices (ά8, ά11 and 
ά13). All these secondary structural elements are connected by flexible loops (L1-
L13).The deep cleft formed in between two lobes serves as ATP binding site and is 
known to mediate phosphorylation activity. Most of the residues lining the ATP 
binding pocket are found to be hydrophobic and  are conserved across the CDK 
family with  the exception of  Ala31 (Glu in CDK8), Phe82 ( His CDK4 and CDK6, 
Tyr in CDK8 and CDK10) and Cys83 (Leu83 in CDK2).  Other prominent structural 
motifs are indicated in Fig 4.3 are including PSSLARI helix (also known as activator 





in the binding site shown in cyan), DFG motif (it is also known as 
activation/inactivation motif shown in blue) and T-loop (this is activation loop blocks 
active site partially in inactive form and upon activation, it moves away and remove to 
create substrate binding site shown in red color)  
 
 






4.3.2.1 Model Validation 
The final model was evaluated using different quality indices (Procheck, ProsaII22, 
Veriefy3D23 and QMEAN11) proposed for assessing quality of experimental crystal 
structures. Ramachandran plot is one of front line algorithm that   assesses stereo 
chemical quality of protein structures. Ramachandran plot suggested that majority of 
residues in sterically allowed regions, only small fraction of residues (0.4%) found to 
be in disallowed regions. ProCheck is a versatile tool that performs variety of 
structural checks on proteins and reporting combined total score, popularly known as 
G-score, which varies from 0 to -1.0 (best to worst). Our model was proven to have 
best quality scores close zero (-0.01). In addition, QMEAN score (0.825) was used to 
validate the model comprehensively, which estimate the global quality of protein 











4.3.2.2 Molecular Dynamic Simulations 
A molecular dynamic simulation of inactive CDK5 structure was carried out to 
confirm the structural stability of the model.  Molecular dynamic simulations are 
helpful to establish dynamic behavior of the system as well as stability of the system. 
Analysis of 5ns simulation suggests that the apoCDK5 model is stable. During the 
simulation, RMSD with respect to initial structure is found to rise rapidly during first 
0.5ns before stabilization is achieved. Over the last 3 ns of simulation, RMSD of the 
trajectory is 2.5±0.2 Å, suggesting reasonable stability of the model. Flexibility of the 
model is assessed by the RMSF values from the trajectory of MD simulation. RMSF 
of the model is comparable to the B-factor of CDK2, indicating the consistency of the 
model with that of template. Radius of gyration is another important measure in 
molecular dynamics simulation that suggests compactness of system in three-
dimensional space. During the simulation, system is found to be very compact and 
stable. A plateau of RMSD for the system was achieved within 2 ns of unrestrained 
simulation, suggesting that 5 ns unrestrained simulation was sufficient for stabilizing 
fully relaxed models. From the molecular dynamic simulations, we proved that 
apoCDK5 structure is dynamically stable and its suitability for structure based drug 
design is beyond the doubt. 
                  






4.3.3 Structural Changes During Activation 
Active and inactive forms of CKD5 were superposed to locate major regions that 
undergo conformational changes during the activation process.  RMSD plot (Fig 4.6) 
clearly indicates places where major structural changes taking place. First major 
change is observed in N-terminal region between 40-50 residues and this can be easily 
understood from the fact that CDK activators (i.e. cyclins) interact with Cα-helix 
located in this region. In monomeric state of CDK5, P35 or p25 are known to 
approach CDK5 from Cα-helix side and CBF of p35 drive the Cα-helix into ATP 
binding site and it is found to be stabilized by E51-K33 interaction. Conformational 
changes exerted on the Cα-helix are eventually be carried forward into downstream of 
the structure, which is evident in the rmsd plot. The second and third major peaks in 
RMSD plot correspond to reorganization of N-terminal region and subsequent 
changes in hinge region of ATP binding site respectively.  The major structural 
change can be observed in between residues 145-170 which is corresponding to t-
loop. Transmitted activation from N-terminal region, drives way the t-loop (~24 Å) 
from the activation site and interestingly, small peak (Fig 4.6) can be seen at the 
beginning of t-loop conformational change. This change corresponds to DFG motif 
which is known to be key motif in controlling activation/inactivation process.   






4.3.4 Networking Analysis of CDK5 
 In recent times, protein structures are treated as information processing networks and 
it would be reasonable to assume that amino acids are critical for reception and 
propagation of information. In several studies3, 4 as mentioned in introduction, it was 
proven that the critical residues are highly interconnected and vice versa was proven 
to be reasonable estimate.  
In this study, we represented inactive CDK5 model that was constructed previously, 
as a network of amino acid residues connected by various interatomic interactions 
such as hydrogen bonds, salt bridges, and various close contacts (details in 
methodology section). Further various network based centrality measurements such 
closeness centrality, betweenness centrality, degree, average short path coefficient, as 
well as coefficient of clustering were used in prediction of important residues as well 
as to understand folding pathway. In addition, active forms of CDK5 and CDK2 as 
well as inactive CDK2 were also used in the analysis. Standard network parameters 
were calculated from network of CDK5 and CDK2 structures.  
Table 4.2: List proteins structures used in network analysis 
Name PDBID Chain Functional State 
CDK5 Model A inactive 
CDK5 1UNL A Active 
CDK5 1UNL A,D Active 
CDK2 1PW2 A inactive 
CDK2 1JST A,B Active 
CDK2 1FIN A,B Active 
    
 
Topological parameters of biological networks were suggested to follow inverse 
power law because of their small world properties. In our analysis of network inactive 





unambiguously suggest that reliability of various topological measures and insights 
derived.  Clustering coefficient indicates local cohesiveness of the network networks, 
in other words clustering coefficient of nodes reflects how commonly neighboring 
nodes are connected in the network.  Closeness centrality is a reciprocal of average 
short path length which is related to link number of pathways (edges) between two 
nodes. Degree of node denotes total number of neighboring nodes present.  These two 
measures (closeness centrality and Degree) indicate highly interconnected nodes or 
hub nodes which indirectly suggest structural and functional significance of a residue. 
These two measures were used in this study to identify functionally key residues. 
The analysis of both inactive and active CDK5 networks suggests an average of 10 
neighboring nodes for every node (Fig 4.7).  The complete network of amino acids in 
both forms CDK5 presented in Fig 4.1SM (supplementary material)  
   
Fig 4.7: Distribution of average clustering coefficient and topology coefficient in residue network of 
inactive CDK5 are shown to have obeyed inverse power law. 
 
4.3.4.1 Networking Analysis: Identification of Critical Functional Residues   
As suggested earlier, combination of closeness centrality (CLC)  and nodal degree 
(DG) was accepted as criteria to identify key residues that are critical for the 
functioning of CDK5. Networks of both conformations were analyzed to unravel 
possible role of each key residue as well as their respective roles in each state.  The 





larger the size of node indicates higher closeness centrality and red indicates higher 
the degree of node.    
Close look at the Network of inactive CDK5 network reveals that several known 
residues (F145, H124, D126, R125, D144, and L127, I183, W183) which are functionally 
known to be critical, were scored very high. F145 is known to be part of DFG motif 
which acts as “turning wheel” that switch conformations. In addition H124 and D126 are 
part of HRD motif that coordinates catalytic activity and is known to play very critical 
role in positioning of substrate and phosphotransfer. D126 is known to coordinate with 
phosphate catalytic activity ranks way down in inactive conformation due its possible 
insignificant role in inactive form.  Furthermore, hydrophobic residues are found to be 
significantly large in number among top ranking residues. Interestingly, G146, K33, T14, 
Y15 were not found among top50 residues of active CDK5, mainly because of their 
known coordinating role with ATP in active form and play trivial role in inactive 
form.  It is very intriguing to know that most top ranking residues which are highly 
interconnected (L127, M185, Y167, I183, L147) are hydrophobic residues and importantly, 
exact structural role most of these residues is not well established.  Most of these 
residues are very well conserved. So this proves the fact that centrality measures, 
especially closeness centrality and degree of distribution, are very good measures to 











Table 4.3: Closeness centrality and nodal degree of top residues calculated from RIN’s of active and 
inactive CDK5. 
 Network of Inactive CDK5 Network of Active CDK5 
SNo Residue Closeness Degree Residue Closeness Degree 
1 184:ASP 0.301554 17 127:LEU 0.298156 13 
2 145:PHE 0.294833 14 184:ASP 0.296939 14 
3 127:LEU 0.292169 12 167:TYR 0.294833 17 
4 114:LEU 0.290419 14 110:LEU 0.289552 14 
5 167:TYR 0.286982 13 142:LEU 0.289264 14 
6 186:TRP 0.2867 19 114:LEU 0.288119 14 
7 142:LEU 0.285574 12 186:TRP 0.288119 19 
8 188:ALA 0.284457 11 188:ALA 0.287266 12 
9 191:ILE 0.283902 12 124:HIS 0.2867 12 
10 125:ARG 0.283626 9 163:VAL 0.283074 11 
11 124:HIS 0.280077 11 191:ILE 0.28225 13 
12 189:GLY 0.279003 11 125:ARG 0.281977 13 
13 128:LYS 0.276353 10 129:PRO 0.281159 10 
14 126:ASP 0.275829 7 126:ASP 0.281159 9 
15 132:LEU 0.274011 13 130:GLN 0.280888 7 
16 123:LEU 0.273754 10 132:LEU 0.279539 14 
17 110:LEU 0.273496 12 144:ASN 0.279539 10 
18 129:PRO 0.272472 9 183:ILE 0.279003 14 
19 185:MET 0.271455 12 111:LEU 0.278736 15 
20 183:ILE 0.270446 13 185:MET 0.278203 15 
21 187:SER 0.270195 11 187:SER 0.277143 10 
22 107:LEU 0.270195 14 107:LEU 0.274528 15 
23 168:ARG 0.268698 12 128:LYS 0.273496 7 
24 131:ASN 0.268203 10 131:ASN 0.271202 9 
25 144:ASP 0.268203 7 123:LEU 0.271202 14 
26 169:PRO 0.267956 10 88:LYS 0.270698 10 
27 163:VAL 0.267463 11 266:LEU 0.270446 14 
28 118:HIS 0.267218 12 122:VAL 0.269944 12 
29 122:VAL 0.265511 8 164:THR 0.268203 7 
30 141:LYS 0.265027 14 118:HIS 0.266728 12 
31 111:LEU 0.265027 13 145:PHE 0.26624 13 
32 63:ILE 0.264786 12 182:SER 0.265996 10 
33 148:ALA 0.264786 9 113:GLY 0.265996 11 
34 266:LEU 0.264065 12 190:CYS 0.265027 12 
35 116:PHE 0.261926 11 116:PHE 0.264545 12 
36 147:LEU 0.261456 10 168:ARG 0.264305 16 
37 153:ILE 0.260753 9 169:PRO 0.263348 8 
38 194:GLU 0.25959 13 117:CYS 0.263348 12 
39 190:CYS 0.25959 13 194:GLU 0.262635 14 
40 113:GLY 0.259127 11 106:PHE 0.262635 14 
41 143:ALA 0.258437 7 147:LEU 0.262162 8 
42 14:THR 0.257979 9 112:LYS 0.262162 11 
43 117:CYS 0.257979 10 274:ARG 0.261691 16 
44 193:ALA 0.25684 12 189:GLY 0.261691 9 
45 140:LEU 0.25684 10 140:LEU 0.260519 10 
46 184:ASP 0.301554 17 127:LEU 0.298156 13 
47 145:PHE 0.294833 14 184:ASP 0.296939 14 
48 127:LEU 0.292169 12 167:TYR 0.294833 17 
49 114:LEU 0.290419 14 110:LEU 0.289552 14 
50 167:TYR 0.286982 13 142:LEU 0.289264 14 





We further compared several residues in inactive and active form to understand their 
dominant functional roles in respective conformations.  Fig 4.8 depicts relative 
significance of some of known key residues in active and inactive conformations.  
Residues like Glu51 (E51), Arg125 (R125) and Tyr167 (Y167) have gained significant 
number of contacts upon activation; whereas Phe145 (F145) and Gly146 (G146) remain 
dominant in inactive conformation.  Interestingly, Val163 exhibit no significant 
changes in number of surrounding residues in both conformations evident from nodal 
degree, but significant spike in closeness measure indicating formation of new 
contacts necessary for substrate binding site creation in active form (discussed in 
detail in following paragraphs). 
 
 
Fig 4.8: Relative dominance of top critical residues based on closeness centrality and nodal 





We understand from the previous reports that the major conformational changes are 
originated at two regions (motif): DFG (Reorganize the ATP pocket and induce 
structural changes in activation loop), HRD (reorganizes the catalytic center and 
transmit information to C-terminal region).  
D144F145G146 motif: DFG motif is one of well conserved segment that appears in 
kinases, and is situated at the N-terminus of activation of segment, forming polar 
contact with ATP.  The DFG phenylalanine makes hydrophobic contacts with the αC-
helix and the nearby His–Arg–Asp (H124R125 D126) motif from the catalytic loop. The 
phenylalanine is considered to be responsible for proper positioning of the DFG 
aspartate and accommodation of the Cα- helix facilitating the K33–E51 contact (Fig 
4.9). The DFG glycine is highly conserved among kinases, but its exact role yet 
unclear.  
F145 is found to have high closeness centrality (CLC) scores in both in active and 
inactive conformations. Comparatively, one in inactive was scored higher than that of 
active conformation due to extensive hydrophobic network (L55, L58 from αC-helix 
and L127, L142, L123, V122).  Leucine residues located around the Phe145 in inactive 
form seems to be helping CDK5 to attain original conformation after withdrawal of 
activator protein.   On the other hand, D144 is known to be pivotal for catalytic 
activity, form fewer connections in inactive form, interacting with H124 of HRD and 
K33 from β3 strand.  These two residues (H124 and L33) along with D144 play key role 
in proper positioning of phosphate of ATP in P-site as well as in coordinating with 
magnesium ion.  In active form of CDK5, D144 gained significantly higher score 






A . DFG in inactive Conformation B. DFG in Active Conformation 
Fig 4.9 Network of DFG motif in inactive (A) and active (B) conformations of CDK5, showing random 
and highly organized way of interactions in respective conformations. 
 
This is very clear from active conformation of DFG (Fig 4.9) that D144 plays central 
role by side-lining F145. The G146 seems slightly dominant in inactive form, because of 
its ability to form backbone hydrogen bonding in inactive conformation. But G146 
performs an extreme twist due to less steric hindrance from the side chain, changing 
its dihedral ϕ angle by 140o., resulting initiation of huge structural changes in the 
downstream.   This can be easily explained from the cascade of structural changes that 
occur during activation process.  Upon P35 or p25 binding to cyclin box region, αC-
helix is pushed into the cavity, resulting hydrophobic residues residing on αC-helix 
and other hydrophobic  residues surrounding F145, exercise rotational shift of F145  side 
chain.  This shift is known to reorient the side chain conformation of D144 and this 
effect is further stabilized by forming hydrogen bond between D144 and G146. This is a 
hallmark of active site conformation that is identified in most of the kinases (Fig 4.9). 
But this is not observed in our analysis of active CDK5 conformation, due to the 
mutation of D144 to N144 in available crystal structures (PDB ID: 1UNL). This active 





It is evident from the Fig 4.10 that D144 in active conformation is readily interacting 
(hydrogen bond) with D126 from HRD motif, which is not observed in inactive state.  
In addition, it is observed that G146 interaction with Arg50 render additional stability to 
active conformation.  
 
Fig 4.10: DFG motif alignment from CDK2 (green – inactive and cyan –active). 
 
HRD motif:  HRD motif is an important structural feature that is strategically situated 
between N-terminal and C-terminal where phosphotransfer and substrate binding 
events take place. Network of interactions associated with HRD motif help to 
understand relative significance of these three residues (Histidine, Arginine, and 
Aspartic acid).  H124 appears to be relatively maintaining similar interactions in both 
conformations evident from the CLC and DG scores. D126 is slightly dominant in 
active conformation, which is obvious from role (transfer of phosphate) that D126 play 
in active state. R125 appears to be surrounded by larger number of residues in active 






Fig 4.11: HRD motif network representation with neighboring interactions of active CDK5. Color code 
of residues indicates secondary structure (red – helix, blue – sheet, grey – loop).  
 
Fig 4.12: P25 interactions with CDK5 (S234 of p25 directly interacts with R50 of CDK5 which in turn 
make contact with G146 of DFG motif)  
Further analysis of close contacts (edges) of HRD motif unveils interesting facts about 
its strategic role. Network View (Fig 4.11) clearly demonstrates the strategic 
organization of HRD to maintain functional active state of CDK5. H124 of HRD which 





organizing center that remains in contact (F145, A148, Leu142, D144,, A143, L114 and D184)  
with several residues from N-terminal region and helps to transfer the information 
from N-terminal region.  In other words, H124 acts as a gateway to relay the structural 
changes those originated at N-terminal (DFG) to the downstream. Further, H124 helps 
in reorientation of D126 which align phosphates groups in proper orientation and D125 
which is known to interact with several C-terminal residues in active conformation. It 
is obvious from our analysis that most of top scoring residues are directly or indirectly 
connected to HRD network. We understand from analysis that R125 establish extensive 
network with the C-terminal residues (D184, V163 I183, Y171, S159, L147, R148, Y158, and 
T164).  It is interesting to know that most of these residues are very close to substrate 
binding site and some of them residing on t-loop to facilitate substrate-in 
conformation. From Fig 4.11 it can be seen that R125 is forming two hydrogen bonds 
with V163 main chain and second hydrogen bond with D184 as well as a salt bridge 
with Y171.  V163, equivalent V162 of  CDK2, is long time known to exhibit left handed 
conformation in active form to facilitate the formation of  hydrophobic pocket for 
incoming proline residue of substrates (SPRK). The left handed conformation of V162 
of CDK2 is attained by phosphorylation of T160, which is another hallmark of active 
conformation near substrate binding site, and eventually leads to complete activation. 
The threonine phosphate (T160-PO4) of CDK2 is coordinated by triad of arginine (R50, 
R126, R150) originating from αC-helix, Catalytic domain and C-terminal respectively. 
Whereas in CDK5 lack phosphorylation on S159, yet attainment of left handed 
conformation in active state is a subject of perplexity. A closer look at the active 
CDK5 structure reveal  that the main chain of R125 from HRD motif strongly is 
interacting with main chain of T164 (close contact) and V163 (hydrogen bonding).  





friendly conformation. In addition, R125 proximity to S159 also might be helpful to 
achieve substrate friendly conformation.  
 
Fig 4.13: Alignment active (cyan) and inactive (magenta) of CDK2 
4.3.4.2 Role of Hydrophobic Clusters in Structural Transformation 
In total of top 50 high scoring (CLC) residues 30 of them are hydrophobic residues. 
This fact underscores significance of hydrophobic forces operating in Structural 
activation/inactivation process.  Analysis reveals that most of these hydrophobic 
residues either close to ATP binding site or substrate binding site. Among the top 
ranking residues in inactive state are W186, L127, F145, L114, L123, L132, L110 , L107,A143, 
A148,C117, I153  F116 located very close to N-terminal region. Most of other residues 
(Y167, W186, A188, M185, I183,) are close to substrate binding site. Further we found that 
most of residues closer to ATP site in active form are remains same as in inactive 
form.  In our analysis, we identified five most significant hydrophobic clusters in 
inactive form and they are predicted to be important for relaying massive structural 
changes. Most common notion in kinases activation process suggests that gigantic 
forces required for inducing massive t-loop motion (~24 Å shift). Identification of 





enriches our understanding of activation pattern of CDK5.  We identified four 
hydrophobic clusters (F145, L127, I183, W186) based on CLC score.  The most important 
of all clusters is F145 and surrounding residues (L47, L55, L58, from αC-helix and L142 
and V122) and these residues presumably exert “turn wheel effect” on F145 side chain 
in order initiate structural changes. The second most important cluster (L127) is located 
close to N-terminal region and several connection with N-terminal and catalytic sire 
residues. It is interesting to know that in active form L127 form very extensive network 
of with surrounding leucine residues (L142, L132, L116, A188, P129, L114, I191, and V163). 
Other two clusters (I183 and W186) are located in C-terminal regions, interacting with 
T-loop and C-terminal residues. Significance of W186 has not yet been realized and 
probably performing stabilization function of C-terminal residues so as to 
accommodate substrate protein.   
 
Fig 4.14: Hydrophobic clusters (blue) and interconnected catalytic site residues (red) 
4.3.4.3 Network Based Prediction of Hinge Residues 
Hinges are known to be critical residues where structural transformations begins and 





understanding of effective structural changes taking place during activation and might 
also help in prediction of intermediate forms which would reveal allosteric sites of 
interest.  Betweenness centrality is an interesting parameter of network topology 
which principally measures number of short paths passing through the particular node. 
In other words, it measures18 the ability of influencing the surrounding nodes 
(residues). The residues with high betweenness score are shown in the Fig 4.15. Some 
of the residues having top betweenness scoring are common in both inactive and 
active conformation. For example, D184, Y167, W186 and R125 seem to play significant 
role in both conformations. As observed earlier, D184 is connected to several important 
N-terminal and catalytic site residues. Similarly Y167 seems to help t-loop to attain 
proper substrate friendly orientation. Functional role of W186 is relatively unknown, 
seemingly control and coordinate C-terminal core.  Significance of other residues can 
be weighted from their respective conformation.  We identified that F145 and V163 are 
playing crucial role in inactive conformation in terms of mediating important 
structural changes in N-terminal region where the reorganization of ATP binding 
takes place and t- loop region where substrate friendly conformation is achieved upon 







Fig 4.15: Betweenness centrality of residues from active and inactive CDK5 
 
In addition, the residues exclusively appeared in the active conformation are found 
indeed important in the transforming structure into inactive conformation upon 
withdrawal of activator protein. The side chain of D144 forms hydrogen bond with 
glycine main chain, and break down of which leads to inactivation. Similarly, salt 
bridge between K33 – E51 is a hall mark of active conformation, which would clearly 
underscore importance of K33 in active conformation. Similarly D126 and R50 are 
known to coordinate key structural changes at catalytic site (Fig 4.11) and stabilizing 
role of DFG role (R50-G146). At last, Hinge residues (274, 266, 219) located at the C-
terminal record relatively small change and remains persistent in two way 
transformation 
4.3.4.4 Constrained Geometric Simulations: Confirmation of Hinge  
Using constrained geometric simulations, we expected to test how hinge residues 
behave during structural transformation. The intermediate conformations were 
generated and betweenness centrality score was calculated after constructing RIN for 
each intermediate conformation.  Before beginning the simulation, rigid blocks of 
both active and inactive CDK5 were predicted using FIRST module with the energy 
cut-off of -1 kcal/mol. Some of these rigid blocks match with our hydrophobic 





conformation (since this transformation is thought to be spontaneous in active to 
inactive direction) and back tracking was used to confirm the prediction. Complete 
description of the method illustrated in methods section.  
 
Fig 4.16: RMSD projection between inactive and active during simulations 
Fig 4.16 shows RMSD between inactive and active conformations, which is at the 
beginning of simulation, is 5.4 Å and is obviously receding during the course of 
simulation and trajectory of transformation is merely smooth. Total of 54 intermediate 
conformations were generated. All these conformations were closely examined for 
any possible non-physical motions.  To further authenticate the intermediate 
conformations, we performed Gaussian Network Analysis (GNA) to record all 
correlated motions. Gaussian Network Method (GNM) is simplistic representation of 
protein network wherein residues are represented by beads and they are connected by 
springs. By solving Kirchhoff matrix, collective motions are predicted and this 
method has reputation of being able to reproduce experimental b-factors. We 
observed correlation coefficient of 0.71 between experimental b-factors of active 
CDK5 and b-factors calculated in GNM, signifying the validity of GNM method. 
Square fluctuations of all intermediate conformations and two extreme conformations 
appear to have followed clear trend of transition between flexible active conformer to 
less flexible inactive conformer  and structural integrity of  all intermediate 






Fig 4.17: B-factor calculated from inactive and active conformations of CDK5 including intermediate 
conformations using GNM method, suggesting stable intermediate conformations. 
   
   
  
 
Fig 4.18: Correlated fluctuations calculated between residues of CDK5 starting from active 
conformation to inactive, conforming the stability of intermediate conformations. 
 
Furthermore, these intermediate conformations were used to construct residue 
interaction network and betweenness centrality was measured for each residue to 
identify hinge residues that exert significant impact during the structural 






Fig 4.19: Betweenness centrality during transition from active to inactive conformation of select 
residues. 
 
Fig 4.20: Hinge Residues (green – reversible hinges, pink – active to inactive hinge, cyan- inactive to 
active). 
 
The residues shown in the Fig 4.20 were confirmed as hinge residues those mediate 
huge domain motions effortlessly.  Two kinds of hinges were identified.  Hinges 
mediate complete reversible structural changes (responsible for domain motions and 
play significant role in both inactive and active conformations). Residues such as 
Phe145, Val167, Asp184, Trp186, Leu1219 and Glu279 seem to be responsible for 
reversible structural changes. Leu219 and Glu279 seems to be affecting relatively 
small magnitude structural changes, nevertheless, their contribution to reversible 
changes is significant. On the other hand, residues like Lys33, Arg50 and Asn144 





residues are known to stabilize active conformation.  Interestingly, Val163 is 
exhibiting higher betweenness in inactive state than that of active state.  Val163 is 
known to be responsible for substrate binding site creation, when CDK5 undergoes 
transformation from inactive state to active state. This explains why the role of 
Val163 is significant in inactive state than in active state. 
4.4 Conclusion 
In this work, we developed a model of inactive CDK5 using CDK2 template which 
shows 58% of identity with the sequence of CDK5. High similarity allowed us to 
construct high quality model which was confirmed by QMEAN comprehensive 
scoring function. Further, molecular dynamic simulation of inactive CDK5 
demonstrated a good stability in solution, corroborating the reliability of the model.  
Further network representation of protein structure was adopted to elucidate important 
functional residues and to identify hinge residues. Closeness centrality in combination 
with nodal degree suggested the four hub residues (Phe145, Leu127, V167 and 
Asp184) and interestingly, these residues were identified to be located in four 
strategically important locations namely, N-terminal, neck region, near substrate 
binding site and C-terminal.  Additionally, the key residues interacting with DFG and 
HRD motifs were highlighted. We identified four hydrophobic clusters centering on 
Phe145, Leu127, V167 and Trp186 that might be expected to play key role structural 
transformation.  Several hinge residues were identified using betweenness centrality.  
Further the existence of these hinge residues was confirmed by FRODA coarse grain 
simulations in which intermediate conformations between inactive and active were 
generated. We identified that Phe145 and Val163 are important hinges that transform 
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Chapter 5  
 
Molecular Modelling of CDK5-ATP 
Binary Complexes and Detailed 
Molecular Docking Analysis of CDK5-




Cyclin-dependent kinase 5 has been known as an important therapeutic target for 
Alzheimer’s disease with scanty of structural information. In this work, we aimed to 
generate active/inactive CDK5-ATP complexes to understand basic structural 
properties as well as to use them as templates for docking studies. Molecular dynamic 
simulations were performed to study intrinsic properties of binding sites in two 
conformations.  Further extensive molecular docking studies were performed with 
various chemo types to delineate key intermolecular interactions that help to 
understand inhibitory action of CDK5 inhibitors. Molecular docking studies proved 
that combined docking score obtained from active and inactive conformations 
increase the hit rate. An indistinguishable dynamic hydrophobic pocket was detected 







Cyclin-Dependent kinase5 (CDK5)1  is known to be a key target protein in 
Alzheimer’s pathology, which deregulate tau protein in the presence of p25 protein.  
So the understanding of CDK5 structure and its interactions with various inhibitor 
molecules is critical for the success of drug design efforts. In comparison to CDK2 
(272 crystal structures), meagre amount of experimental crystallographic data is 
available for CDK5. Mapplli2 et al., reported three CDK5 complexes bounds to 
inhibitors and Ahn3  et al., reported a nitro phenyl inhibitor bound to CDk5 (PDB ID: 
3o0G). In addition, several classes of molecules  have identified as potential CDK5 




Fig 5.1: Crystal Structure of CDK5 bound to Inhibitors: Roscovitine, Indirubin Alosine, and Nitro-
derivative (left to right) 
 
The target site for all these inhibitors is ATP binding cavity where natural substrate 
ATP interacts with CDK5 and facilitate phosphorylation.  In addition, most of these 
inhibitors are non-selective, mainly because of high similarities of ATP binding sites 
among CDKs.  Olomoucine10, roscovitine11 (Seliciclib) and flavopiridol12 (Alvocidib) 
are the three most widely studied CDK5 inhibitors to date.  Despite the high 
conservation of binding site, there have been a few inhibitors reported to be selective 
to particular CDK. CP68130113 (Pfizer) is the only compound reportedly at the 





681301 and a structurally related Pfizer compound, CP-66886314, were identified as 
potent and selective CDK5 inhibitors with Ki values of 2.9 and 13.7 nM, respectively. 
Tsai evaluated CP-681301 in collaboration with Pfizer in a forebrain-specific 
inducible p25 mouse model (p25Tg) to assess the potential of this CDK5 inhibitor to 
provide neuroprotection14. The ability of CP-681301 to cross the blood brain barrier 
(BBB) provided a benefit compared to other CDK5 inhibitors such as roscovitine. In 
addition, there have been fewer studies reported comparison of active and inactive 
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In contrast to CDK2, where the wealth of structural information on protein-ligand 
interactions is available, lack of extensive CDK5-ligand structural information poses 
as main barrier for CDK5 selective drug design programs.  Lack of reliable and 
comprehensive studies on protein-ligand information of CDK5 are main barriers in 
the current state of CDK5 based drug development efforts.  In addition, lack of 
CDK5-ATP complex in both active and inactive forms poses another significant issue 
for in silico studies. As ATP being natural substrate for kinases, ATP bound complex 
of kinases serves as good template for virtual high throughput screening studies, 
mainly because of ATP bound structure represent correct volume and opening of 
binding site which are critical  factors for the success of  virtual screening studies. 
The emergence of state-of-the-art computational techniques led to the development of 
novel sophisticated algorithms to generate low resolution protein structures and 
protein-ligand complexes as an alternative to experimental techniques. For instance, 
Computational protein structure prediction methodologies15 and molecular docking 
techniques16 serve as good examples for the generation of low resolution protein 
models and prediction of protein-ligand complexes, respectively. In this work, we 
would like to generate binary models of CDK5-ATP in both active and inactive 
conformations using comparative modelling strategy. These models are further 
intended to create CDK5-inhibitor complexes with various known CDK5 inhibitors 
using both active and inactive conformations of CDK5.  For a long time, inactive 
forms of kinases are largely neglected in drug design programs but recent research 
efforts strongly advocating in favour of inactive conformations due to high structural 
variability found in inactive conformations than that of active counterparts.  We 





CDK5 to elucidate possible insights. Further we intend to use these structural models 
for screening kinases proteins deposited in PDB database to identify suitable 
molecules that all fit CDK5 binding site.  Multi-target drug therapy17 has been 
suggested as an alternative to single molecule therapy for Alzheimer’s disease. This 
study could hopefully throw light on multi-target inhibition.  
5.2 Methods and Methodology 
5.2.1 Comparative Modelling 
The inactive crystal structure of hCDK2 (PDB ID: 1HCK) was selected as template 
for the modelling of inactive CDK5. The template structure was retrieved from the 
PDB database and initial homology model was constructed using MODELLER18. The 
structurally conserved regions (SCRs) between hCDK2 and CDK5 were identified 
based on sequence and functional similarity using sequence alignment. The 3D 
coordinates within SCRs were copied from the template hCDK2 to CDK5. De novo 
loop generation was employed to obtain the coordinates for variable regions (VRs) 
which consisted of loop regions not contained within the SCRs as well as to construct 
missing regions in template structure. The ATP-Mg complex and associated water 
molecule that extracted from CDK2 template was directly copied into the binding site 
of preliminary inactive model of CDK5. Each model was minimized 200 iterations of 
steep decent minimization followed by 500 iterations of conjugate gradient 
minimization to avoid possible clashes of side chains. Further two rounds of vacuum 
molecular dynamic simulations performed to optimize the entire model. The side 
chains of the inactive CDK5 structural model were checked for acceptable rotatable 
bonds and severe steric clashes using Ramachandran plot. Finally, top ten models 
were presented based on DOPE score and PDF score implemented in MODELLER. 





LIGX19 protocol implemented MOE. This model was used for further studies and 
submitted to explicit MD simulations.  The active CDK5 model was constructed 
rather directly by structural alignment followed by transferring ATP into the binding 
site of active CDK5 (1UNL). The active structure of CDK5 was retrieved from RCSB 
and co-crystal ligand was removed from the binding site.  
Table 5.1: DOPE and PDF scores of top 10 inactive CDK5-ATP models 





CDK5.B99990027 1993.98 908.26 -31563.93 
CDK5.B99990006 2003.62 921.9 -31441.57 
CDK5.B99990019 2035.02 957.76 -31722.17 
CDK5.B99990020 2039.36 937.94 -30872.42 
CDK5.B99990004 2039.71 930.85 -31283.5 
CDK5.B99990013 2044.13 959.59 -31372.64 
CDK5.B99990008 2071.59 968.17 -31202.33 
CDK5.B99990022 2074.24 980.21 -31331.01 
CDK5.B99990014 2086.18 977.83 -31076.91 
CDK5.B99990026 2086.39 994.31 -31364.46 
 
5.2.2 Molecular Docking 
All molecular docking simulations were performed by MDOCK20 program which is 
based on UCSF DOCK, a pioneering molecular docking program. Both active and 
inactive conformations were used to prepare the receptors after knocking out ATP 
molecule from the binding site. Receptor preparation is performed in series of steps: 
Generation of molecular surface, sphere generation, and define binding site.  Binding 
site was defined by choosing spheres located around bound ATP molecule inside the 
pocket. Then the docking is performed by generating 1000 conformations for each 
ligand molecules then allowed them to orient along spheres previously generated. 100 
best oriented conformations were minimized for three times.  All these conformations 





resolution X-crystallographic protein-ligand complexes. Finally, top 100 
conformations were manually examined and only top 10 for each ligand binding 
conformations were considered.  The entire procedure was thoroughly optimized 
using bound ligand conformation and the entire procedure was iterated by tuning 
different parameters such as number of spheres in the pocket, number of ligand 
conformations (1000), and grid size (8 Å) and minimization steps (3). Validation was 
performed by docking ATP molecule into binding site followed by selecting best 
conformation based on 2 Å cut-off.  
5.2.3 Molecular Dynamics Setup 
Molecular dynamic simulations of CDK5 bound to ATP were carried out for 5 ns 
using GROMACS22 4.5 package.  The force field used for these simulations was 
CHARMM2723.  Both active and inactive conformations were considered for 
simulations. Topology parameters for ATP were built by SWISSPARM24 webserver. 
Then, the complexes were immersed in a cubic box of 10 Å size and tip3p model was 
used as an explicit water model. Then the solvated system was neutralized by adding 
counter ions and minimized by steep decent algorithm to remove all close contacts 
and clashes. Then two steps of equilibration each span 100 ps.  In the first step NVT 
equilibration was performed by applying position constraints followed by NPT 
simulation of 100 ps. Finally 5 ns production run was performed at 300 K and 1 bar 
pressure. The time step for integration algorithm was set at 2 fs. Trajectory analysis 
was performed using inbuilt programs such as g_rms, g_rmsf, and g_gyrate.  For root 
mean square calculations, backbone atoms and first frame were used as reference. For 






5.2.4 Pocket Dynamics 
Pocket parameters such as hydrophobicity, pocket volumes were calculated from MD 
snapshots using FPOCKET25 algorithm. Prediction of putative binding sites was 
calculated by grid mesh size of 7 Å. 
5. 3 Results and Discussion  
In this work, we emphasize on necessity of accurate in silico modelling of CDK5-
ATP binary complexes and thus obtained structures were used for generating protein–
inhibitor complexes with various reported CDK5 inhibitors. Further, intermolecular 
interactions were studied to understand basic requirements for effective inhibitor   
development. Finally, an attempt was made to predict multi-target inhibitors. 
5.3.1 Molecular Modelling of CDK5-ATP complexes 
 
Identification of the suitable template is an important step in homology modelling 
procedure.  In this study, inactive CDK5–ATP complex was modelled by using 
inactive CDK2-ATP complex (PDB ID: 1HCK). Pairwise sequence alignment was 
performed to ensure proper alignment of all important sequence motifs and key 
conserved residues.  
 





During the modelling process, the ATP-Mg complex from template was copied into 
binding site of inactive CDK5 model using sequence alignment between CDK5-
CDK2 (PDB ID:1HCK).  The missing segments in templates were constructed in de 
novo method. Then side chains were thoroughly optimized using rotomers libraries 
and 500 steps of slow conjugate gradient optimization was used to optimize all the 
side chains. Further entire structure was optimized using vacuum molecular dynamics. 
Final output of 50 models was assessed based on DOPE score and PDE score reported 
by the modeller. Top models were reported in Table 5.1 where Smaller the dope score 
and smaller error (PDE score) indicate the best model. The best model of inactive of 
CDK5-ATP complex is shown the Fig 5.5.  The binary structure of active CDK5-ATP 
was constructed by a rather direct method in which ATP molecule from active CDK5 
(PDB ID: 1JST) transferred into CDK5 structure. This method was adopted because 
of availability of CDK5 active state structure. First, co-crystal ligand from the 1UNL 
crystal structure was knocked out. This active CDK5 structure was aligned with active 
CDK2 (1JST) and ATP bound to the active site of CDK2 was transferred to the 
CDK5. Then the binding site of active CDK5 bound with ATP was optimized using 
ligand constrained site optimization technique (LigX) implemented in MOE.   Both 
active/inactive CDK5-ATP complexes were analysed for proper intermolecular 
interactions.   
5.3.2 Molecular Dynamic Simulations  
Molecular dynamic simulations are integral part of computational protein modelling 
strategies, which evaluate structural stability during vigorous simulations.  Two 





properties were measured to substantiate conformational changes that occur during 
the simulation such as Global RMSD, RMSF, and potential energy. 
 
Fig 5.4: RMSD and RMSF of active (black) and inactive (red) CDK5-ATP complexes. 
 
The trajectories of MD simulations were analysed to check overall structural stability 
of the complexes as well as local stability of ATP bound inside the binding pocket. 
Analysis of 10 ns dynamics indicates that both inactive/active CDK5-ATP complexes 
are stable, after a rapid uprising during first 1000 ps. It is evident that  active CDK5-
ATP complex seems to be highly stable almost throughout the length of simulation 
(rmsd 1.5 Å±0.2) due to additional complexation of p25 protein, C-terminal of portion 
of natural CDK5 activator p35. But inactive CDK5-ATP complex seems to be taking 
longer time to attain stability which is evident from sharp raise during first 1000ps 
and followed by a plateau (rmsd: 2.3 Å±0.2).  This behaviour can be easily supported 
from rmsf analysis (assessment of flexibility) wherein the inactive form is evidently 
far more flexible than that of the active form.  Furthermore, stability of ATP molecule 
bound inside the binding pockets of both active and inactive forms was analysed 
which clearly states during the entire length of simulation ATP molecules did not 
undergo any significant conformational changes.  Detailed analysis of binding site for   






5.3.3 Binding site  
ATP binding site of CDK5 seems to have composed of highly conserved residues as 
shown in the Fig 5.3.  Key structural features that regulate ATP phosphorylation 
activity such as DFG, HRD, Thr14 and Tyr15 of g-loop, are also conserved.  Glycine 
rich loop (11-17) or G-loop located  on the top of binding site is known to play a key 
role26 in aligning ATP in proper orientations and also exert additional control by 
phosphorylating highly conserved T14 and Y15. Phosphorylated T14 and Y15 are known 
to inhibit ATP activity26 in all CDK’s except CDK5. In CDK5, phosphorylated Y15 is 
known to enhance27 the activity.  Hinge region (80-89) is an important structural 
feature that directly controls the ATP orientation with in the binding site.  In addition,  
it plays critical role in alignment of ATP in the hydrophobic pocket. F80, E81, F82 and 
D86 are very much conserved residues on hinge region and the other residues are 
moderately conserved.  
 





We further analysed molecular interactions of ATP with CDK5 interactions with both 
active and inactive forms to identify possible changes during the activation process. 
ATP binding site is composed of an adenine pocket that is characterized by a 
hydrogen bond recognition motif and a hydrophobic portion occupied by the 
nucleotide base.  There is also a hydrophilic region located closer to triphosphate and 
Mg/Mn+2 binding region.  Adenosine binding is mediated by hydrogen bonds between 
the adenine and backbone of Cys83, and between substituted amine as well as 
backbone carbonyl and the Glu81 backbone carbonyl. This hallmark hydrogen 
bonding pattern is popularly known as molecular fork which has been basis for the 
design of inhibitors targeting ATP site of CDKs (Fig 5.5). It is clear from the analysis 
that in the active configuration ATP site, adenosine region is tightly enveloped by 
hydrophobic residues such as Ala31, Leu133, Ile10, and Phe82.  
The ribose portion of ATP is found to be interacting with Asp86 and Gln130 which 
act as an anchor that fix ATP outside adenine site. These interactions remain 
persistent in both forms whereas Lys89 seems to be interacting only inactive form.  
The triphosphate region of binding site seems to be undergoing maximum change 
during activation process. Triphosphate region is coordinated by several residues 
lining g-loop (G11, E12, T14, Y15) and p-site region (K128, Q130, and N131).  
Divalent ions (Mn or Mg) play key role in coordinating phosphorylation activity. In 
inactive form, Mg forms octahedral coordination complex with surrounding 
phosphate groups, and water molecule nearby.  K33 from β3 strand forms a hydrogen 
bond with α-phosphate group and D144 from DFG motif also participate coordination 
with divalent ion. Other closely interacting groups that are directly forming hydrogen 





from g-loop region.  Active form of CDK5 exhibit slightly different set of interactions 
from that of inactive configuration. Upon activation, DFG loop, Hinge region and p-
site region undergoes substantial changes. These changes are responsible for 
producing active conformation of ATP and alteration of surrounding interactions. K33 
seems to undergo significant change due to salt bridge interaction with Glu51 from 
αC-helix.  K33-E51 interaction swings the K33 side chain in order to realign with 
alpha and gamma phosphates of triphosphate complex.  
Analysis of torsion angles of residues surrounding the ATP binding site suggests that 
glycine residues located in various locations play critical role in mediating structural 
transformation. Especially, Gly146 of DFG loop is observed to undergo huge changes 
(psi), which is known to be critical for reorganizing the hinge region. The realignment 
of D144 helps in formation of metallic bond with metal ion in active form, which 
ultimately helps in phosphotransfer activity. Gly16 of G-loop is another point of 
substantial conformational change (psi), which is located strategically close to Thr14 
and Tyr15 (residues critical for phosphorylation) to help reorient phosphate moieties 
of ATP. 
5.3.4 Validation of Binding site Using CDK2 inhibitors 
To validate the drug predictability of binding sites in both active and inactive forms, 
we performed comparative molecular docking analysis with CDK2 bound ligands. 
Several ligands (Table 5.1 SM) obtained from active and inactive CDK2 were used to 
test that suitability of CDK5 binding pocket for structure based drug design (SBDD).  
The correlation coefficient between inactive CDK2 and inactive is found to be around 
0.62 and between active counterparts is 0.87. This trend strongly suggests that active 





relatively weak correlation coefficient between inactive CDK2 and CDK5 suggests 
that inactive binding pocket conformations are less similar and likely offer more room 
for achieving structure based selectivity. 
        
Fig 5.6: Correlation between binding conformations calculated  pKd calculated from XSCORE of   
inactive CDK5 and inactive CDK2 (left), active CDK5 and active CDK2 (right). 
Further analysis of CDK5 and ligand complexes revealed that molecular fork plays an 
important role in tethering ligands to the pocket. Most of the ligands establish at least 
one interaction with the hinge residues.  
5.3.5 Dynamics of ATP binding site 
Volume and solvent accessible surface area (SASA) are two important factors 
determine the accessibility of binding site to target inhibitors. We explored changes in 
the binding site volume and SASA and   pocket hydrophobicity during MD simulation 
in both active and inactive conformations.  We observed that inactive conformations 
accounts for larger pocket volume and higher SASA than that of active counterpart, 
which is evident from the plots 1&2; inactive conformation of binding pocket is more 
stable and highly prone to variations. This can be further substantiated from pocket 
hydrophobicity core (plot3) wherein hydrophobicity of the inactive binding pocket is 
stable whereas active conformation is suggesting drastic changes over the time.  This 





variations in binding properties. Further RMSD of ATP bound to inactive CDK5 
suggests no drastic changes during the simulation; on the other hand, ATP bound to 
the active conformation seems to undergo reorganization. Hydrogen bonding of ATP 
with CDK5 further substantiates the fact. 
 
 
Fig 5.7: Analysis of biding site properties (Left to right) Volume , Solvent Accessible Surface area, 
Hydrophobicity (top).  Analysis of MD trajectory (Left to right) RMSD of ATP in active conformation 
(black )and inactive conformation (red) during MD simulation, number of hydrogen bonds formed by 
ATP with active (black) and inactive conformation (red) of CDK5 (bottom). 
 
5.3.6 Analysis of CDK5-Inhibitor Complexes  
In continuation of our efforts, we generated several CDK5–inhibitor complexes 
through molecular docking. This study aimed to provide wealth of structural 
information about intermolecular interactions of various CDK5 inhibitors. In addition, 
we would like to explore possible differences in binding modes of inhibitors in active 
and inactive states of CDK5 structure, which would be helpful to understand 
selectivity in drug design strategies.  Different classes of CDK5 inhibitors were 





of CDK5.  Finally, diverse set of molecules were chosen to further support the 
conclusions derived from individual series of molecules.  We chose five scaffolds for 
this study: indirubins, 2-aminothiazol derivatives, paullone derivatives, purine 
derivative, and quinozolin derivatives.  
5.3.6.1 Indirubins Derivatives  
Indirubins constitute a very promising molecular scaffold which is popularly known 
to be non-selective inhibitor for CDK5 and GSK3β (tau kinases). The crystal structure 
of indirubin-3-monoxime bound to active CDK5 is available and throws light on key 
molecular interactions responsible for the inhibition. To understand molecular 
interactions of indirubin derivatives comprehensively, we docked 19 indirubin 
derivatives reported by Polychronopoulos28 et al. to both inactive and active forms of 
CDK5. Thereafter fingerprint analysis was performed to extract key interactions. 
indirubin derivatives seems to  form very firm  contacts (hydrogen bonds) with hinge 
region (Cys83 and Glu81) with active as well as inactive binding pocket 
conformations but hydrogen bonding with Glu81 is not consistently observed among 
all derivatives, especially among less active compounds (Fig 5.8). On the other hand, 
several key hydrophobic interactions that are observed in active form are not well 
conserved with inactive form. It can be seen from the finger print chart that Ile10, 
Val18 and Leu133 interactions are absent in most of inactive complexes. In addition, 
it is obvious from Fig 5.8 that active form shows well encapsulated hydrophobic 
residues around indole moieties of indirubin derivative whereas in inactive form this 
encapsulation is not as tight as observed in active form. Overall indirubin derivatives 
interact equally with active and inactive forms of binding pocket with the exception of 





pattern with both conformation but less active compounds likely exhibit substantial 
differences in their interaction pattern.  
   
 
Fig 5.8 : Finger prints analysis Indirubin derivatives  with CDK5 inactive (left) active (right). 
 
Fig 5.8 clearly suggests that indirubin compounds are interacting with the hinge 
region of ATP binding site more or less similar fashion (molecular fork formation) in 
both active and inactive forms whereas critical hydrophobic interactions are not 
located close enough in inactive form.  Ile10 from G-loop and Phe80 from the hinge 
form key hydrophobic interactions with indol moieties of indirubin complexes in 
active form and Ph80 is not properly aligned with the inhibitor in inactive form.  
5.3.6.2 Paullones 
Paullone29 derivatives are another major potent ATP competitive class of CDK5 and 
GSK3β inhibitors. So far there has been no crystal structure of paullone derivative 





literature highlight some interesting insights about molecular interactions and 
specificity.  Most of paullone derivatives are found to interact with active CDK5 in 
normal hinge directed fashion in which hydrogen bonding interactions are established 
with main chain of Cys83. In addition, the key hydrophobic interactions such Ile10, 
Leu133 and val18 are remain conserved among inhibitors bound to active bonding 
site conformation. Whereas in case of inactive pocket conformation, most of the cases 
hinge interactions are missing as well as hydrophobic interactions are completely 
missed out. This pattern clearly suggests that Paullone compounds are sensitive to 
binding site conformation i.e. active form which is mainly because of bulky Pallone 
scaffold that conveniently hydrophobic cavity presented by active binding site 
conformation whereas the large binding site presented by the inactive binding site 
conformation lead to less specific interactions.  
   
                                 





Stronger and crowded hydrophobic forces garner in active form of binding site make 
these inhibitors interact with hinge region through hydrogen bonding interactions. 
From the Paullone derivatives seem to be essentially binds to active conformation and 
their ability to interact with inactive conformation is very minimal. This is also 
evident from the fingerprint pattern shown above wherein almost all inhibitors failed 
to form molecular fork in inactive conformation and their interaction with G-loop 
residues is almost insignificant. 
5.3.6.3 Aminothiazole30 derivatives  
 
These compounds are highly potent and belong to selective class of ATP competitive 
inhibitors so far reported for CDK5. Molecular docking analysis of these compounds 
reveals that these compounds follow hinge directed interaction pattern (H-bond with 
Cys83) and hinge (Cys83) interactions are well conserved. In addition, hydrophobic 
interactions like Ile10 and Val18 are conserved but interaction with Leu133 that was 
observed previously with other classes of inhibitors is found missing. These inhibitors 
present totally different case when bind to inactive pocket conformation. Most of all 
typical interactions are missed out including hinge (cys83, glu81) and other prominent 
hydrophobic interactions (Ile10, Val18, and Leu133) are also found missing. This 
anomalous behaviour is expected largely due to size of the molecules i.e. due to the 
smaller size and large volume of binding site.  







                              
   
Fig 5.10 Fingerprint analysis of Aminothiazole derivative with inactive CDK5 (left) and active CDK5 
(right) 
         
These compounds seem to be very effective in active conformation rather than 
inactive counterpart, which clearly evident from fingerprint chart.  Hinge interactions 
are not consistently observed in inactive form whereas strong hinge interactions are 
highly conserved when interact with active conformation. In addition, Ile10 seems to 
very important for the inhibition activity, which is rather highly conserved in active 
state. 
5.3.6.4 Purine Derivatives 
Purines31 derivatives are  one of very promising scaffold that proved to have very 
good efficacy against CDK’s. Roscovitine has been reported to have excellent 
selective agonist CDK5 and Crystal of roscovitine2 with CDK5 provided information 
of molecular interactions responsible for the selectivity and inhibitory action. In this 
study, we used a series of purine derivatives to understand their overall binding 
pattern against both inactive and active conformations of the pocket.  These 
compounds are found to have lager number of close contact in active pocket 
conformation whereas relatively smaller number of contacts is observed with inactive 
pocket conformation (Fig 5.11).  In addition to cys83, these compounds have 





found to have hydrogen bond in most of the cases. Hydrophobic interactions such 
Ile10, Val18, and Leu133 are highly conserved. Other interactions found are mostly 
selective to particular substitution. On the other hand, hinge contacts (Cys83 and 
Asp84) are conserved with inactive pocket conformation but the other hydrophobic 
contacts were not properly aligned with inhibitors. So these compounds are capable of 
interacting with both active and inactive conformation of binding pocket.  
       
Fig 5.11: Analysis of fingerprints of purine derivatives with inactive CDK5 (left) and active CDK5 
(right). 
 
5.3.6.5 Quinazolin-2 Derivatives 
Quinolin-232 compounds were reported as an important group of potent compounds 
against CDK5 and these are mainly hinge binders. This is very clear from the finger 
prints representation. Although these compounds are hinge binders, not all inhibitors 
are interacting with cys83 rather interacting with Asp84 and other signature 
hydrophobic interactions such as Leu133 and Ile10 are well conserved in active form. 
In inactive form most of signature interactions are missing, and making these 





         
                             
Fig 5.12: Analysis of finger prints with quinolin derivatives with inactive CDK5 (left) and active 
CDK5 (right).                           
However, the strong binding affinities of these compounds to the hinge region in both 
conformations qualify them to be very potent class of inhibitors. These inhibitors 
assume ‘U’ shape in the binding site wherein one end of the molecule interacts with 
Cys83 and the other end contacts Lys33.  Other critical interactions includes Lys89 
strengthen the binding the affinity of this class of compounds in favourably inactive 
conformation. 
5.3.6.6 Diverse Compounds (Scaffolds) 
Different scaffolds were docked to inactive and active forms of CDK5, including 
some of above mentioned scaffolds, to generalize the differences in interaction pattern 
between active and inactive CDK5.  Overall analysis of diverse compounds against 
CDK5 suggests that most of the active compounds form hinge based interactions with 





exhibit multiple hydrogen bonds with Cys83, Glu81 and Asp84 whereas some of 
these interactions are missing in inactive state.  
 
Fig 5.13: Analysis of finger prints of diverse compounds with inactive CDK5 (left) and active CDK5 
(right). 
In addition, several hydrophobic interactions (Ile10, val18) from G-loop region are 
not well conserved in inactive conformations. To understand priorities of various 
highly effective inhibitors (Fig 5.14) reported, we analysed their molecular 
interactions. We further analysed some of popular CDk5 inhibitors reported in the 
literature and their molecular interactions with both forms of CDK5. 
Staurosporin33 compounds are known to be dual inhibitors of CDK and GSK. Because 
of rigidity and bulkiness of the molecule, it binds in the similar fashion to both active 
and inactive conformers of binding site. It forms three bonds with hinge residues i.e. 
Glu81 and Cys83 and additional hydrogen bonds with Asp86 and Lys89. Alosine 
derivatives are another moderate potent group of compounds that interact with hinge 
resides. Hydrogen bonds with hinge residues found to be missing when interacting 
with inactive form. Flavopiridol34 is one the of most potent CDK inhibitor that is 
under clinical trial. Interestingly, this compound forms more hydrogen bonds with 
inactive pocket than active. The additional hydrogen bonds are made with Lys33 and 
Asn144. Hymenialdisine35 is an another inhibitor of CDK extracted from marine 
sponge which is found to be interacting almost in the similar fashion to both 





both conformations. But less active compounds in this category are more sensitive to 
hinge conformation.  In addition, purine derivatives like roscovitine and flavopiridol 









Fig 5.14: Interactions of some of potent CDK inhibitors with active CDK5. 
5.3.7 Docking Performance  
From the analysis of various protein-ligand complexes of CDK5, we propose that 
inclusion of inactive conformation along with active counterpart enhance the 





both conformations as final score to select right ligand conformation.  Fig 5.15 
illustrates the docking performance.   
 
Fig 5.15: ROC curve indicating Docking Performance. 
5.3.8 Identification of Secondary Pocket: Possible role in selectivity 
From the analysis of various ligands interacting with CDK5 binding pocket, some of 
the ligands were reported to have high selectivity than others. To understand the 
selectivity, ATP binding pocket was analysed using MD snapshots.  An 
indistinguishable dynamic hydrophobic pocket is located behind the adenine pocket, 
which is surrounded by Ala31, Phe80 Leu64, and Val18, appearing to play critical 
role in defining selectivity.   
 






For example, iso-propyl group attached purine ring in roscovitine inhibitor seems to 
make hydrophobic contact with this pocket. In addition, aminothiazole13, 36  
compounds from Pfizer are known to be most selective inhibitors of CDK5.  These 
molecules exhibit cyclo-propyl moiety in this position. Volume of this site seems to 
be small so it can accommodate only smaller hydrophobic substitutions. 
5.3.9 Prediction of Multi-target Inhibitors 
ATP binding cavity of inactive conformation was used to match with the target 
proteins that are relevant to Alzheimer’s disease. In this study we observed that three 
important targets (GSK3, CHK1 and CK2) of Alzheimer’s importance were identified 
which closely resembles CDK5 binding site. GSK3 is already known as an important 
target for Alzheimer’s disease and several dual active inhibitors of CDK5 and GSK3 
were proposed37 i.e. paullones38. Two key targets were identified in this study: check 
point kinas 139 (CHK1), which is a tau kinase similar to CDK5 and GSK3 and Casein 
Kinase 140 (CK1), an upstream regulator of CDK5.  These two targets have already 
proven to be potential targets of Alzheimer’s disease.  
 
Fig 5.17: Multi-target inhibitors identified using binding site conformation of inactive CDK5 (Left to 
right) check point kinase 1 inhibitor and Cassin Kinase inhibitors 
5.3.10 Discussion 
Protein-ligand interaction41 data plays crucial role in structure based drug design 





experimental techniques i.e. X-ray crystallography, NMR. In this study, we created 
reliable inactive and active binding site templates to facilitate prospective drug design 
related studies for CDK5. ATP bound conformations of kinases are known to act as 
good templates42 in SBDD studies, accounting for right pocket volume and pocket 
opening that impact significantly on the performance of virtual screening studies. 
Molecular docking studies were carried out using both inactive and active binding site 
templates to understand key molecular interactions and their influence on inhibition 
efficacy. Since most of the inhibitors are ATP competitive, their interaction pattern 
with binding site resembles adenosine moiety. These molecules were found to be 
interacting with hinge residues such as Cys83, Glu81 or Asp84 and these interactions 
were found to be conserved with inactive pocket conformation as well. This was 
found to be essentially true with highly active inhibitors (nano molar) and it can be 
easily understood from their binding energies. In other words, hydrogen bonding 
interactions of various highly active compounds were found to be essentially same 
with both pocket conformations but the variation in number of hydrophobic 
interactions was noticed. The inactive pocket conformations offer larger volume than 
that of active form so incoming ligands are greeted with several loosely binding 
hydrophobic residues whereas in active form, a few selective interactions contribute 
to the overall binding energy.   
Further energy breakdown analysis of some of select compounds revealed that total 
predicted binding energy of an inhibitor with CDK5 pocket in both conformations 
was found to be more or less close. In fact, predicted binding energy was relatively 
higher with inactive pocket conformation but correlation between biological activity 





largely because of large volume of binding site that offers several nonspecific binding 
interactions which may cause erotic results in linear correlation studies. In most of the 
cases active pocket conformation offer better results, which is mainly because of very 
specific and highly conserved hydrophobic interactions (Ile10, Val18, Leu133) as 
well as highly restricted shape of binding pocket. But because of well restricted 
binding pocket shape, there is higher possibility to predict false positives which fit in 
the pocket well.   
To circumvent these issues, we propose the use of combined binding score obtained 
from docking to both inactive and active pocket conformations. This approach would 
solve the two issues: reduces number of false positives being predicted and increasing 
chances of predicting novel compounds by inactive pocket which allows predicting 
larger and variety of scaffolds. To test this hypothesis, we performed molecular 
docking /screening by including inactive decoys obtained from DUD database. This 
study clearly suggested that (Fig 5.15) combined scoring slightly better the overall 
results.  
5.4 Conclusion   
In this study, we constructed active/inactive CDK5/ATP complexes to use them as 
templates for structure based drug design studies. These models were constructed in 
comparative modelling fashion and validated them thoroughly, as well as refined by 
the MD simulations. Molecular docking study with co-crystal ligands of CDK2 using 
both inactive and active binding conformations suggested, relatively better correlation 
of binding scores between active conformations of CDK5/CDK2 (0.87) than that of 
inactive conformations (0.62). Comparative analysis of binding pockets was 
performed to assess the intrinsic properties such as volume, SASA, hydrophobicity. 





suggests the highly dynamic nature of active conformation. Molecular docking studies 
suggested active CDK5 conformation act as good template where inactive 
conformation alone seems to be insufficient for SBDD. But the combination of both 
active and inactive conformations was found to be enhancing the performance of 
database screening. Analysis of various chemo types suggested interaction with hinge 
residues (cys83, Glu81 and Asp84) is a mandatory requisite. In addition, hydrophobic 
residues such as Ile10, Leu13, and Phe80 seem to be essential for inhibitory action. 
Analysis of MD trajectory revealed a secondary hydrophobic pocket surrounded by 
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Identification of New CDK5 Inhibitors 
based on Combined Pharmacophore 
Modelling and Molecular Docking 
 
Preface 
Cyclin-Dependent Kinases 5 (CDK5) is a key therapeutic target of interest for 
Alzheimer’s disease.  Identification of CDK5 selective inhibitors has been a challenge 
for long time. Enormous growth in computational techniques allows predicting and 
designing novel inhibitor that might interact selectively to target of interest. In this 
work, we used multi step virtual screening procedure that includes ensemble of 
protein conformations to identify most viable compounds. Then a simple four point 
pharmacophore model was used to filter most selective compounds that make 
necessary hinge site interactions. In the following step, vigorous genetic algorithm 
based molecular docking procedure was used wherein PLP scoring function was used 
to distinguish actives from the inactives. In the final step, Hit compounds selected 
based on key molecular contacts.  Among the hit compounds several triazino indole 







Cyclin-Dependent Kinases 5 (CDK5) is a key therapeutic target of interest for 
Alzheimer’s disease.  There have been several inhibitors reported1 for CDK5 and 
most of the compounds reported till today are ATP competitive inhibitors. ATP 
binding site is known to be very popular druggable site among kinases because its 
basic phosphotransfer ability that can be easily obstructed, which renders the protein 
non-functional. Despite similarities among the ATP binding sites of various kinases, 
several selective inhibitors have been reported exploiting minor structural differences. 
Gleevec2 reported as an inhibitor that selectively inhibits abl kinase in DFG-out 
conformation. Roscovitive3, a common CDK inhibitor is known to act more selective 
towards CDK5. Allosteropaullone is known a Pallone based kinase inhibitor which is 
known to exhibit more selectivity to GSK3β.  The crystal structure of CDK5 with 
Roscovitine by mappeli4 et al., highlights basic essential interactions that required by 
the CDK5 inhibition. Roscovitine suggests that purine ring conveniently settle 
hydrophobic cavity and establish two hydrogen bonds with Cys83 of hinge region and 
this interaction is known to be hall mark of CDK5 inhibitors. Further propyl group 
attached to purine ring is surrounded by several hydrophobic residues (Phe80, Ala31, 
Val64 and Leu133). In addition, phenyl ring seems to be accommodated hydrophobic 
interactions from g-loop residues (Ile10 and Val18).  
  





There have been search for CDK5 specific inhibitors and some of the recent efforts 
proven to be promising, which exploited in silico methodologies to identify potential 
inhibitors. Ahn5 et al., reported a comprehensive screening strategy to identify CDK5 
inhibitors, wherein highly effective ATP competitive inhibitor bellidin, a natural 
product, was reported. As well as a non-competitive inhibitor was reported by the 
same authors, this successfully prevented tau phosphorylation. . Weng Zhong et al., 
reported a novel class of Quinolin-2(1H)-one derivatives6 as potent CDK5 selective 
inhibitors, which were identified using structure based design. Sripiri7 et al., recently 
developed a CDK5 template for virtual screening studies which reported to have 
predicted binding energies and were found to have good correlation with experimental 
results. In addition, several classes of inhibitors are known to inhibit CDK5 activity in 
ATP competitive fashion. 
In silico techniques have become instrumental in modern day drug design programs 
mainly because of their agility. Computational techniques are especially significant in 
guiding the prospective chemical synthesis and biological screening in a more rational 
way. Rational in silico strategies8 have been proven to have great impact on early 
stages of drug development where biologically active compounds having different 
scaffolds are identified. Virtual screening, pharmacophore generation and molecular 
docking are some of very important computational techniques used in identification of 
hit molecules, rationalization of scaffolds and identification of intermolecular 
interactions, respectively. 
Virtual screening methodologies9 are used to filter millions of compounds rapidly and 
this methodology especially very effective when target structure is available. Once the 
target is available, rapid docking algorithms are used to position compounds within 





compounds is ordered by calculating binding free energy (steric and electrostatic). 
Rapidly increasing number of 3D structures and exponential growth in computational 
power   are augmenting the accuracy, reliability and ability to screen billions of 
compounds within no time.   
Pharmacophore modelling10 method is another key tool in computer aided drug 
design, has been widely used in the lead discovery and optimization. The strength of 
these methods lies in their ability to suggest a diverse set of compounds potentially 
possessing a desired biological activity.  The pharmacophore modelling involves two 
steps; generation of hypothesis and database search.  Pharmacophore methods are 
basically two types: direct methods use protein structure or protein-ligand complex 
for the generation of query. Indirect methods use biologically known active molecules 
that are known to interact with concerned target, are used for the generation query. 
This method is suitable when extensive protein-ligand experimental information is not 
available. The third most important technique is molecular docking which is a 
versatile technique that is used in most of the computer aided drug design programs.  
This technique is highly helpful in generation protein-ligand interaction data that is 
helpful to understand fundamental issues at molecular level. 
Due to high degree of similarities between CDKs, screening selective inhibitors is an 
uphill task, involving strenuous effort.  In this study, we propose a multi-step virtual 
screening procedure, combining structure and ligand based methods, to identify novel 
inhibitor chemo types against CDK5 target. Initially single and multiple CDK5 
structure ensembles were used to filter out large compounds databases. Then the 
pharmacophore model was used to identify hinge binder molecules followed by 
detailed molecular docking analysis was performed to identify most potential 





comparison with known active molecules so as to ascertain potency of newly 
identified compounds.  
6.2 Methods and Methodology 
6.2.1 Database Selection 
Chemical databases from different chemical vendors have been collected and filtered 
based physico-chemical filters specified for drug ability.  These compounds were 
thoroughly checked for their completeness of their molecular structures (no missing 
atoms) and further minimized them with MMF94 force with by applying 0.05 Å rms 
cut-off.   
6.2.2 Fast Receptor Docking 
For initial screening of databases, MDOCK11 algorithm was used, which is an 
automated simultaneous multi-conformational docking method. It also supports 
multiple receptor conformations and simultaneous minimization of protein-ligand 
complexes. MDOCK uses the sphere-ligand matching algorithm that is used in 
famous UCSF DOCK, a pioneering algorithm in molecular docking, to generate 
possible ligand conformations. 
 





 Complete process is summarized in the Fig 6.2. For scoring the pose, MDCOK uses 
ITscore11 function which is  a knowledge based scoring function derived using 786 
high quality crystal structures of protein-ligand complexes, described by Zou et al. 
6.2.3 Pharmacophore Modelling 
6.2.3.1 Dataset selection 
Inhibitory data of 100 molecules collected from the literature, which is spanning over 
4 orders of magnitude (from 2.7 to 50,000 nM). The dataset was parted out into 
training set and test set   and the training set was generated by including diverse set of 
molecules (Table 6.1SM).  Diverse set of molecules were expected to teach something 
to the pharmacophore hypothesis and help to uncover critical information to predict 
biological activity. The training set selected in this study consisted of 30 molecules 
with varied magnitudes of biological activity.  
6.2.3.2 Pharmacophore Generation 
The pharmacophore hypothesis generated was validated by the rest 70 compounds in 
initial dataset. Ten best pharmacophore models were produced using HypoGen12 
modules of discovery studio. In the initial analysis, it was identified that four 
chemical types (Hydrogen bond Acceptor, Hydrogen bond donor, Hydrophobic and 
Ring Aromatic ) are suffice to map all critical features of training set.  The chosen 
features were used to build a series of hypothesis and the default uncertainty value 3 
was used in all calculations. HypoGen identifies all common features in active 
molecules that are in conformationally allowed regions and it further estimates the 
activity of each molecule in the trading set using regression parameters. The 
parameters are calculated by the regression analysis using the relationship of 
geometric fit value versus the negative logarithm of activity. The greater the 





function includes not only feature function but also distance term between mapped 
features.  
 6.2.3.3 Pharmacophore Validation 
Hypo1 was validated using a test set of 35 compounds spanning similar activity range 
as of training set. These compounds were mapped on hypo1 and fitness values were 
calculated then estimated activities were calculated. The correlation coefficient of 
0.87 between actual and estimated activities suggests that hypo1 is reliable. Further 
large external dataset of active compounds (300) and decoys were used for testing the 
predictability of pharmacophore model (hypo1). 
6.2.4 Molecular docking 
6.2.4.1 GEMDOCK 
iGEMDOCK13 is a genetic evolutionary method for molecular docking. It is an 
integrated docking, screening and post analysis with visualization system. The main 
components of the algorithm are evolutionary algorithm and scoring function. It uses 
the new rotamer based mutations operator which is used to reduce search space in the 
ligand structure has an advantage over the Gaussian and Cauchy mutation effects 
(Nishikawa and Kimura, 1994) and the scoring function which is a simple empirical 
function instead of complicated amber like scoring function.  
E = Ebind + Epharma + Eligpre 
Where Ebind is the empirical binding energy, Epharma is the energy of binding site 
pharmacophore (hot spots), and Eligpre is a penalty value if a ligand does not satisfy the 
ligand preferences.  
Binding site was selected based on co-crystal ligand present in the CDK5 (PDB ID: 
1UNL) and 8 Å around the ligand was defined as active site where ligand 





population size of 80, was used and the top 10 poses were evaluated to select the best 
the pose. Typically, post docking or screening analysis encompass interpretation of 
binding interaction,  clustering of structures profiling the  binding interactions of 
different structures and binding interactions of different structures. Post docking 
analysis play key role in mining the key protein-ligand interactions (van der waals 
forces, electrostatic forces, hydrogen bond interactions) responsible for representative 
interactions of a target. iGEMDOCK combined strategy of structure based screening 
and post-analysis to effectively reduce number of false positives. In the post-analysis, 
resulting poses from docking simulation are subjected to clustering based on k-means 
and hierarchical methods, which enabled us to classify the inhibitors based on their 
molecular structures or their atomic compositions. In addition, pharmacophore 
consensus method implemented is very helpful to eliminate non-essential interaction 
from essential interactions and Epharma scoring function that is implemented proves to 
be highly effective in identifying true positives. iGEMDOCK was validated for its 
protein-ligand docking accuracy and screening accuracies by using a test set with 100 
protein-ligand complexes and four targets and further incorporated as a key step in 
several drug discovery programs.  
 






6.2.4.2 Molecular Docking Scoring using AUTODOCK4 
Autodock14 has been popular as an effective molecular algorithm that is capable of 
predicting bound ligand conformation accurately as well as corresponding binding 
energies. Autodock uses a grid-based approach for evaluating large conformational 
space available for a ligand around the protein and for calculating binding energy of 
intermediate conformations. In this method, the target is enclosed in a grid box then 
the interaction energy with target protein is calculated by placing a probe atom at each 
grid point sequentially and the value is stored in the grid. The grid energies are used 
as reference during docking simulations. Autodock implements Lamarckian genetic 
algorithm as principle method for conformation search, described by Morris et al. A 
population of trial conformations is created, and then in successive generations these 
individuals mutate, exchange conformational parameters, and compete in a manner 
analogous to biological evolution, ultimately selecting individuals with lowest binding 
energy. The “Lamarckian” aspect is an added feature that allows individual 
conformations to search their local conformational space, finding local minima, and 
then pass this information to later generations. A simulated annealing search method 
and a traditional genetic algorithm search are also available in AutoDock4. 
AutoDock4 uses a semi-empirical free energy force field to predict binding free 
energies of small molecules to macromolecular targets. Development and testing of 
the force field has been described elsewhere. The forcefield is based on a 
comprehensive thermodynamic model that allows incorporation of intramolecular 
energies into the predicted free energy of binding. This is performed by evaluating 
energies for both the bound and unbound states. It also incorporates a new charge-
based desolvation method that uses a typical set of atom types and charges. The 





known structure and binding energy, showing a standard error of about 2–3 kcal/mol 
in prediction of binding free energy in cross-validation studies.  
All input files for autodock simulations were created by AutoDockTool 1.5.4, 
graphical user interface for autodock4. Grid parameters and docking parameters used 
for all runs are tabulated. All docking and grid parameters were optimized through 
successive runs using co-crystal ligand (PDB ID: 1UNL) and all parameters were 
tuned to achieve rmsd of <2 Å between reference molecule and the best conformation. 
Final conformations for other molecules were chosen manually either from lowest 
energy cluster or by from the largest cluster. CDK2 (PDB ID: 1JST) was also 
prepared in the same manner as of CDK5.  
6.2.5 Clustering 
K-means clustering15 and principle component analysis (PCA) techniques were 
applied to the protein-ligand interaction data to distinguish samples.  Princomp 
method implemented R was used for PCA and subsequent analysis of samples. 
Variance in the samples was represented as biplot based on dominant principle 
components (PC1 and PC2).  
6.2.6 Analysis & Visualization 
PyMol and Discovery Studio visualizer were used for the analysis. LigPlot was used 
to generate 2D protein-ligand interactions.  
 
6.3 Results and Discussion 
In this study, we have screened for CDK5 specific inhibitors using combined virtual 
molecular screening and pharmacophore methodology. Further screened molecules 





against CDK5, through molecular docking.  This study is expected to be pivotal for 
Alzheimer’s drug discovery. Complete work flow illustrated in the Fig 6.4. 
 
                                                 Fig 6.4: Complete work flow of screening 
6.3.1 Initial Receptor based Library Screening 
After filtering all databases with physiochemical and drug filters, resulting 
compounds were subjected to receptor based screening.  Here we adopted two step 
receptor based screening methodology wherein first round of screening was 





of multiple conformations were used in second round. The main idea behind the 
ensemble docking was to exploit multiple conformations of crystal structures (1UNL, 
1UNG, 1UNH, 3o0G) simultaneously and to enrich the rate of true positives in the 
screening process. Our validation run with a set of actives and inactives proved that, 
this method indeed helps to enrich the true positives (Fig 6.1 SM).  The arbitrary cut-
off 20% was exercised based on IT SCORE to promote best compounds to the next 
level and the same procedure was used for ensemble docking. Top 20% compounds 
from ensemble screening were further processed using pharmacophore method. The 
complete description of pharmacophore generation, validation and screening is 
provided in the next section. 
6.3.2 Pharmacophore Development 
To narrow down the possible number of hit compounds and to eliminate false 
positives, we developed CDK5 specific pharmacophore model using diverse set of 
CDK5 inhibitors based primary chemical features and their spatial location that is 
responsible for activity of the molecules. Entire process of pharmacophore 
development involves following steps such as pharmacophore generation, 
pharmacophore validation and prediction.   
6.3.3 Pharmacophore Generation 
Pharmacophore models were generated and top 10 hypotheses were presented in 
Table 6.1. Most of the hypotheses showed high correlation (>0.80) and hypo1 with 
0.901.  Interestingly, highly active molecules in training set were mapped all features 
i.e.  Two hydrogen-bond donors (HBD), hydrogen-bond acceptor (HBA) and 
hydrophobic (HP). Moderately active compounds missed some of the features and 
lease active compounds were mapped poorly (Fig 6.5). Ten hypotheses were 





model based Lowest RMS (0.774) and high correlation (0.901). Most active 
molecules from the training set exhibit remarkably best fit values (6.97). 
Table 6.1: cost analysis of pharmacophore model  
Hypo No Total Cost Cost 
Difference 
Error Cost RMS Cor  
1 122.456 61.936 106.237 0.774 0.902  
2 122.257 62.135 106.709 0.795 0.896  
3 125.312 69.08 109.27 0.899 0.865  
4 126.872 57.52 110.822 0.956 0.846  
5 128.352 56.04 111.615 0.985 0.837  
6 129.064 55.328 112.5 1.015 0.825  
7 129.857 54.535 113.812 1.059 0.807  
8 130.055 54.337 114.009 1.065 0.805  
9 130.092 54.3 113.437 1.069 0.806  
10 130.309 54.083 113.624 1.053 0.811  
   Null cost : 184.392                                                                                        Fixed cost :113.584 
 
 












Error Fit value 
1 2.7 4 +1.5 6.9 
2 11 8 -1.4 6.59 
3 29 7.7 -3.7 6.61 
4 34 45 +1.3 5.84 
5 40 210 +5.3 5.17 
6 60 160 +2.7 5.28 
7 60 170 +2.9 5.25 
8 64 170 +2.6 5.27 
9 83 140 +1.7 5.34 
10 100 140 +1.4 5.34 
11 100 190 +1.9 5.22 
12 160 210 +1.3 5.18 
13 170 320 +1.9 4.99 
14 180 190 +1 5.22 
15 260 350 +1.3 4.96 
16 320 170 -1.9 5.26 
17 340 280 -1.2 5.05 
18 400 150 -2.7 5.33 
19 430 180 -2.5 5.25 
20 500 350 -1.4 4.96 
21 800 360 -2.2 4.94 
22 850 200 -4.2 5.19 
23 1000 7200 +7.2 3.64 
24 1200 590 -2 4.73 
25 1700 1200 -1.4 4.41 
26 3000 3300 +1.1 3.97 
27 10000 2900 -3.4 4.03 
28 10000 7500 -1.3 3.62 
29 14000 7300 -1.9 3.63 
 
To assess validity of the hypothesis, catalyst furnishes two theoretical costs: fixed cost 
and null cost. Fixed cost suggests the simplest model that fits all data perfectly and the 
null cost suggest the highest cost of a pharmacophore with no features. Typically 
these two costs represent lower and higher boundaries for individual hypotheses. In 
other words, greater the cost difference between null cost and total cost reflects the 
higher the reliability of the hypothesis.  All these cost are represented in bits and a 
value of 40-60 bits between the null and total cost for a pharmacophore hypothesis 
may be suggesting 75-90% probability of correlating the data. Hypo1 shows close to 













































    Fig 6.6: Correlation between experiential and predicted IC50s of trading and test sets  
To further verify the discriminating ability of hypo1, the activity of all training set 
molecules were estimated and compared against their original values. These values 
are presented in the Table 6.2 shows that most the molecules were predicted with the 
error ±2 and the correlation coefficient between actual activities and estimated 
activities is found to be 0.90. The activity of least active molecules is found to be 
poorly estimated. To assess the robustness of hypo1, the test set 30 molecules were 
matched and their activities were estimated. It was found that actives are again well 
correlated (0.77). In addition, this model was subjected to large external dataset to 
assess the versatility of the model (hypo1) and represented in the form of ROC curve.  
These results confirm the usability and reliability of the pharmacophore model to 
identify potential CDK5 binders and significantly help in reducing number of false 
positives in later stages of screening protocol. 
6.3.4 Pharmacophore Based Screening 
We employed pharmacophore model 1 (Hypo1) for further short listing the potential 
compounds from preliminary screening efforts. Pharmacophore screening identified 
500 compounds from the 20000 compounds that previously shortlisted from structure 





compounds. Since all these compounds were previously tested for their drug-like 
properties using Lipinski rule, no other filter were attempted to apply at this stage. 
Close examination of all these compounds led to further narrow down the list of 
potential compounds to 500.  Broader ranges of compounds were identified and these 
compounds were subjected to detailed molecular docking analysis to assess their 
interactions with receptor site.  
6.3.5 Molecular Docking  
At last 500 compounds were selected from pharmacophore matching and these 
molecules were subjected to two tier exhaustive molecular docking protocol. In the 
first step, stable Genetic algorithm based docking protocol (iGEMDOCK) was 
applied which allowed to implement in-depth residue level break-down of overall 
interaction energy.  Residue level analysis of interactions allowed us to understand 
priorities of active compounds in terms of their interaction energies and this strategy 
helped further to differentiate active compounds from inactive compounds efficiently.  
The consensus score (Epharma) obtained from this analysis was used to prioritize the 
active compounds. . In the second step, top candidates from the previous step were 
allowed for authentic docking analysis with AUTODOCK4.  
6.3.5.1 Interaction Profile Analysis and Filtering (Analysis of protein-ligand 
interactions (iGEMDOCK)  
Interactions between protein-ligands play important role in many biological 
phenomena’s.  In this analysis, all intermolecular interactions (van der Walls forces, 
electrostatic forces, Hydrogen bonds, pi-pi interactions, cation-pi interactions) and 
corresponding interaction energies of all compounds were obtained from 





were organized into data sets of interaction profiles and these profiles were used to 
calculate Epharma score to accentuate the predictability of active compounds.  
Further clustering analysis of various compounds was performed with similar 
interaction energies grouped into separate clusters. This analysis conveniently allowed 
used to distinguish actives from inactive compounds. Key interactions and their 
interactions were assessed from docking simulations using iGEMDOCK. Before 
analysis of test compounds, key interactions and their interaction energies were used 
to develop pharmacophore-profile from the known active compounds. This profile 
was further carefully tested by incorporating inactive compounds. We chose z-score 
of 1.645 and consensus of 50% was used to select major anchor groups as suggested 
by Hsu13 et al.  Using anchor group interactions, Epharma weight score (details in 
methods section) was calculated for each compounds and it was found that active 
compounds were significantly prioritized than inactive compounds.   
Detailed interaction energy analysis of top hits and known active compounds is 
presented in the table 6.2 SM (supplementary material). Comparison of interaction 
energies clearly suggests that predicted compounds (hits) exhibit similar interaction 
pattern as of known active compounds. This is further demonstrated from Fig 6.7 
wherein comparison of pharma weights is presented, which indicate frequency of 
binding strength of anchor residues of binding site those responsible for bioactivity. 
Active compounds and hit compounds seem to have similar weights which indicate 






Fig 6.7: comparison of Epharma weights for actives and Hit compounds 
Table 6.3: ignemdock Scores and PLP scores of Hit compounds 
 
6.3.5.2 Clustering and Principle Component Analysis     
Using k-means clustering, all top hit compounds were clustered by including non-
active, inactive and known active molecules. All these classes of compounds were 
distinctly identified as clusters and most of the top hit molecules appeared with 
known active molecules group. This unambiguously suggests that top hit molecules 
indeed possess CDK5 inhibition activity, which further reinforces the overall 
reliability of the screening method. Principle component analysis is a multivariate 
statistical analysis technique that is used to reduce the dimensionality and to identify 
Compound Energy E(pharma) H‐M‐CYS‐83 V‐S‐ILE‐10 V‐S‐PHE‐80 V‐S‐PHE‐82 V‐M‐CYS‐83 V‐M‐ASP‐84 V‐M‐GLN‐85 V‐S‐LEU‐133
Z‐Score 6.92 5 4.07 2.14 4.2 2.71 4.88 5.18
W(pharma) 1 0.96 0.79 0.41 0.81 0.52 0.94 1
 maybridge 48.pdb ‐128 ‐172.3 ‐10.50 ‐18.31 ‐6.82 ‐7.59 ‐4.06 ‐5.79 ‐5.44 ‐8.92
 asinix 35.pdb ‐126.9 ‐162 ‐7.00 ‐13.15 ‐7.88 ‐3.72 ‐5.51 ‐4.69 ‐5.20 ‐10.01
 chemdivkin 28.pdb ‐124.8 ‐159.3 ‐6.97 ‐9.92 ‐9.02 ‐3.95 ‐5.58 ‐4.12 ‐8.59 ‐8.15
 chemdiccns 5.pdb ‐124.2 ‐153.7 ‐2.99 ‐12.42 ‐8.20 ‐7.19 ‐5.87 ‐6.03 ‐6.40 ‐11.56
 asinix 9.pdb ‐122.2 ‐154.4 ‐7.00 ‐7.61 ‐7.41 ‐3.24 ‐6.10 ‐3.08 ‐5.65 ‐10.07
 asinix 21.pdb ‐121.7 ‐154 ‐7.00 ‐9.09 ‐5.88 ‐4.73 ‐5.20 ‐3.95 ‐6.19 ‐9.24
 asinix 37.pdb ‐120.1 ‐156.5 ‐6.76 ‐14.44 ‐8.02 ‐6.81 ‐6.47 ‐5.53 ‐5.26 ‐9.75
 chemdivkin 5.pdb ‐119.1 ‐141.7 ‐3.02 ‐8.89 ‐9.33 ‐5.00 ‐2.38 ‐3.50 ‐4.80 ‐6.84
 RRC‐7.pdb ‐113.3 ‐141.2 ‐3.50 ‐10.79 ‐7.77 ‐2.59 ‐4.35 ‐5.62 ‐7.23 ‐11.04
 maybridge 5.pdb ‐112.7 ‐159.6 ‐13.00 ‐14.68 ‐2.32 ‐7.74 ‐6.72 ‐6.29 ‐5.99 ‐8.43
 maybridge 25.pdb ‐112.5 ‐155.6 ‐12.20 ‐9.38 ‐4.59 ‐4.04 ‐6.41 ‐5.74 ‐7.71 ‐7.75
 chemdiccns 10.pdb ‐112.4 ‐145.7 ‐7.00 ‐8.56 ‐7.49 ‐3.61 ‐6.27 ‐5.63 ‐6.93 ‐8.41
 timtech 4.pdb ‐111.8 ‐141 ‐4.02 ‐15.32 ‐7.94 ‐6.98 ‐3.29 ‐2.83 ‐6.05 ‐8.42
 maybridge 44.pdb ‐111.7 ‐151.5 ‐8.48 ‐14.44 ‐7.02 ‐8.96 ‐6.54 ‐6.17 ‐5.69 ‐8.68
 maybridge 10.pdb ‐111.5 ‐151.6 ‐9.30 ‐14.07 ‐4.15 ‐7.66 ‐6.71 ‐6.24 ‐5.74 ‐8.90
 chemdivkin 25.pdb ‐110 ‐145.9 ‐7.00 ‐14.81 ‐5.97 ‐2.43 ‐7.08 ‐5.12 ‐6.05 ‐9.72
 chemdiccns 1.pdb ‐109.2 ‐145.1 ‐6.95 ‐14.29 ‐7.26 ‐8.52 ‐5.87 ‐5.73 ‐4.59 ‐8.97
 chemdivkin 35.pdb ‐106.6 ‐135.7 ‐7.00 ‐8.01 ‐2.87 ‐4.04 ‐5.65 ‐2.79 ‐4.64 ‐8.17





latent relationships between the variables affecting the outcome of the event. We used 
this technique to distinctly identify active compounds from inactive compounds based 
their intermolecular interactions. Most of the intermolecular interactions are highly 
correlated in active compounds whereas random correlation is observed among 
inactive and non-active molecules.  





Fig 6.8: Clustering analysis of molecular interactions A. biplot of actives compounds B. PC variance of 
compounds C. Bioplot of inactive compounds D. PC variance of inactive compounds 
6.3.5.3 Docking and Scoring   
For the final analysis, we chose 25 compounds and these were subjected to another 
around exhaustive docking simulations using AUTODOCK4. This algorithm 
performs conformational search using genetic algorithm and uses auto dock score for 
prioritizing the compounds. Final hit compounds and their binding orientation inside 
the binding site are shown in Fig 6.11.  Ten compounds were eliminated after final 





binding site.  Several triazino indol compounds were identified as hit compounds and 
these compounds were found to be making extensive hydrophobic contacts with 
adenine pocket residues of CDK5 as well as with g-loop residues. Hit1 compound 
scores very high among all compounds, which form only single hydrogen bond with 
main chain of Cyc83 from hinge region. The main hydrophobic interactions that are 
encapsulating the molecule seem to be helping, which is evident from propyl chain 
attached to the tricyclic ring. 
Table 6.4: Table of Autodock and iGemdock scores of hit compounds 




Wt PSA AlogP HBA HBD 
Hit1(Asx37) -120.1 -159.3 -9.91 54.02 383 78.949 4.74 5 2 
Hit2(Chdk5) -119.1 -145.3 -9.64 86.38 476 104.228 4.945 5 2 
Hit3(Tmt4) -111.8 -144.7 -9.52 105.13 417 114.663 2.534 4 5 
Hit4(Chdk35) -106.6 -136.6 -9.5 108.87 411 74.117 4.536 4 1 
Hit5(Asx35) -126.9 -165.2 -9.35 140.9 437 96.809 4.425 6 2 
Hit6(Mbr48) -128 -178.3 -9.32 146.85 368 85.053 5.361 4 2 
Hit7(Chdc5) -124.2 -155.3 -9.22 174.86 418 73.348 3.923 4 1 
Hit8(Asx9) -122.2 -157 -9.2 179.42 425 105.739 3.215 7 2 
Hit9(Tmt7) -103.2 -139.2 -9.18 187.16 437 73.032 4.091 2 3 
Hit10(Chdc1) -110 -150 -9.15 194.72 389 69.152 3.887 3 2 
Hit11(Chdk25) -121.7 -156.5 -9.08 221.22 347 88.092 2.599 4 2 
Hit12(Asx21) -109.2 -149.3 -9.01 248.68 387 110.401 2.449 7 2 
Hit13(Chdk28) -110 -150 -8.98 259.64 449 101.172 4.011 3 4 
Hit14(Mbr44) -121.7 -156.5 -8.92 290.66 368 78.796 4.19 4 2 
Hit15(Chdc10) -124.8 -166.3 -8.86 321.67 362 60.222 4.191 2 2 
Reference          
Roscovitine   -8.15 1006      
Indirubin   -8.77 373      
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Fig 6.11: Hit compounds and their molecular interactions 
 
6.3.6 Discussion 
In silico virtual screening and molecular docking methods have been most successful 
drug design and prediction strategies. We used multi-step virtual screening combined 
with molecular docking to predict viable inhibitors that block ATP binding site.  Since 
ATP binding site of most of kinases exhibit high degree of similarities 16 which pose 





screening and molecular docking to filter most viable compounds from all available 
chemical databases. Complete workflow is illustrated in the Fig 6.2. After initial 
screening of molecules based on physiochemical properties, the resulting compounds 
were filtered through single conformation of receptor protein followed by ensemble of 
receptor conformations used to filter the compounds. At each level, we filtered 20% 
of top ranking compounds to next level and this cut-off was determined from ROC 
curve validation.  In the next step, to avoid false positive, pharmacophore model was 
generated using 28 active compounds with varying bio actives. Model was thoroughly 
cross validated using test compounds as well as large external dataset. The main 
purpose of this pharmacophore model was to identify hinge binding ability which is 
critical for the effective ATP site recognition. Compounds narrowed down from this 
stage were used in two step molecular docking protocol. In the first step, exhaustive 
gemdock method was used to assess the efficacy of compounds and these compounds 
were scored by the receptor specific scoring function obtained by including individual 
residues contributions. This scoring function was thoroughly validated by principle 
component analysis and K-mean clustering, in which active compounds were 
distinctly identified from inactive compounds.  Finally, top raking compounds were 
again subjected to the AUTODOCK4 based molecular docking to predict all protein-
ligand interactions and to estimate binding free energy accurately. All these hit 
molecules were searched against PUBMED compound database to confirm the 
novelty of the scaffold. There were identical matches were found.  Hit compounds and 
their binding energies are presented in the table. Detailed molecular interaction 
analysis was performed on these compounds.  
The analysis of hit compounds revealed that most of the hit compounds (Hit1, Hit5, 





indol moiety is observed to be forming essential hydrogen bond with backbone of 
Cys83. In addition, sulfonyl group is forming hydrogen bond with Asp84. Rest of all 
molecules is tightly encapsulated by hydrophobic residues. Interestingly, propyl group 
attached indole ring seems to be tightly surrounded by Ala31, Phe80 and Val18.  
These interactions resemble the propyl group of roscovitine inhibitors shown in the 
Fig 6.12. Further cyclohexane moiety resembles the phenyl group attached to the 
indole ring.  Hit5 exhibits similar orientation of binding with receptor except 2-
dimethoxy benzene is replaced by cyclohexane in Hit1. Due to which this compound 
form two hydrogen bonds with Lys89 and Lys20. But number of hydrophobic 
residues that surrounding the molecules are relative less than that of Hit1 compound.  
Hit3 seems to an interesting compound forming several hinge hydrogen bonds 
including typical molecular fork. Additionally, hydroxyl group attached to the indole 
moiety forms hydrogen bond with side chain of Asp86. Hit6 is an interesting 
compound that resembles the co-crystal ligand of CHK1 kinase (PDB ID: 1ZLT). 
phenyl groups attached to the triazine ring are found to be tightly bound by 
hydrophobic residues and triazine ring forms a single hydrogen bond with Cys83. In 
addition, indol ring attached to triazine ring hydrophobic long alkyl chain residues.  
Further to test the selectivity of these compounds, molecular docking simulations 
were performed with CDK2 receptor. Most of the compounds were shown to have 
higher binding affinity to CDK5 than that of CDK2. Especially, Hit1 compound 
shows marked difference between CDK5 and CDK2 (54 nM vs 1008 nM), though 








                              Table 6.5: Autodock scores of hit compound against CDK2 
Compound Binding Energy Ki (nM) 
Asx37 8.14 1008 
Asx21 8.73 398 
Chdc5 8.17 1003 
Chdc10 8.39 703 
CDK5 8.75 384 
Cdk25 7.56 2880 
 Cdk28 8.63 470 
Cdk35 9.36 138.69 
Asx35 8.18 1001 
ChDc1 7.44 3540 
Mbr44 7.61 2650 
 
Interestingly, compounds like Hit1, Hit6, Hit11 and Hit15 are exhibiting similar 
interactions as of roscovitine.  This suggests great feasibility of these compounds to 
be potent active compounds. Further analysis of Hit compounds revealed that most of 
the compounds seem to be forming Roscovitine like interactions.  Energy breakdown 
analysis suggests that stronger hydrophobic interactions are responsible for seemingly 
better performance of these Hit compounds. 
 
Fig 6.12: Structural alignment of hit compounds with Roscovitine Hit1 (top left) hit6 (top right) Hit8 
(bottom) 
6.4 Conclusion 
In this study, we have designed a multi-step procedure for screening ATP competitive 
inhibitors of Cyclin-Dependent Kinase 5. We devised multi-step screening and 
molecular docking protocol to avoid false positive and enrich selectivity for CDK5 
inhibition. This multistep process involved initial filtering by simple lipinski rule, 





CDK5 receptor. Then the pharmacophore was generated to identify compounds those 
interact hinge site of ATP binding site. Furthermore, we developed CDK5 receptor 
based scoring function using pair wise linear potentials  and this scoring function was 
thoroughly validated by clustering and principle component analysis techniques. 
Finally, analysis revealed 15 potential compounds and these compounds were tested 
for their selectivity using molecular docking with both CDK5 and CDK2.  
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Novel Peptide Based in silico Drug 
Design Strategy: To design Tau 
Competitive Inhibitors for Cyclin-
Dependent Kinase 5 
Preface 
 CDK5 is an important target in the Alzheimer’s drug discovery, which 
phosphorylates tau protein that mediates assembly of microtubule, but the 
hyperphosphorylation by CDK5/p25 may lead to neuronal death. There is an urgent 
need for selective tau competitive inhibitors that prevent abnormal phosphorylation of 
tau in pathogenic conditions. Substrate binding site of CDK5 is largely unexplored 
and fewer peptide modeling studies were reported. In addition, given the meager 
selectivity offered by ATP binding site, substrate binding site is expected to offer 
large variation for the new ligand design and is expected to offer great selectivity. In 
this study, we could successfully model large number of CDK5/p25-substrate 
complexes using flexible docking simulations by considering back bone flexibility. 
Histone peptide (HHASPRK) that obtained from CDK2/cyclin complex (1QMZ) was 
shown to have highest rosetta score among all substrates.   In the next step, using the 
constraints obtained from CDK5/p25-substrate complexes, we designed inhibitor 
peptides by replace serine/threonine from the phosphorylation site.  Novel in situ 
peptide design strategy was applied, which optimize the peptides in the binding site, 
to design novel inhibitory peptides. All these peptides were thoroughly analyzed and 






7.1.1 Peptide Based Drug Design (PBDD) 
Traditionally, small molecules have been perceived to be main the source of 
therapeutics, which very conveniently interact with the cavities of target protein and 
obstruct natural substrate interactions. In some cases, small molecules are preferred1 
because of their ability to penetrate into deeper channel and render conformational 
rigidity which ultimately resulting inactivation of the target protein. In addition, small 
molecules offer excellent pharmacokinetic properties, bioavailability and delayed 
elimination. Despite all advantages that small molecules offer, they are ineffective 
when targeting large surface cavities2 of target proteins and protein-protein interfaces 
as well as their toxic nature.  At this juncture, peptide drugs3 offer several advantages 
over small molecules owing to their less toxic nature, higher surface area, and high 
compatibility to their target structure. Despite the availability of peptide drugs in the 
market and their success as new kind of therapeutics, peptides are usually treated poor 
drugs owing to insufficient bioavailability, poor pharmacokinetics, and low in vivo 
stability. However, recent technological advances in formulation, delivery and 
improved intracellular penetration have made peptide drugs amenable. Peptide drugs 
offer more flexibility and convenience to target shallow and wide spread pockets 
located on target protein, mainly because of their continuous architecture and ability 
to establish complex network of interaction with the target site. On the other hand, 
using small molecules for targeting shallow pockets and protein-protein interfaces is 
very arduous task.     
The recent developments in the field PBDD are likely to have significant impact on 
future drug design.   Recent discovery4 of T-20 (36 residues) peptide drug that inhibit 





life of 3.8 hours.  Another breakthrough appeared again with HIV drug candidate that 
target CCR5 trans-membrane protein. RANTES5, a 68 residue peptide, reported to 
have achieved excellent pharmacokinetics after N-terminal derivatization with 
aminooxypentane followed by nonanoic acid and together with incorporation of non-
natural amino acid.  The techniques like incorporation of unnatural amino acids and 
acylation of n-terminal capping to avoid protease degradation, help in achieving 
excellent drug like properties and improve the bioavailability.  Further peptide drug 
are known to have poor ability to cross blood  brain barrier (BBB)  and improving the 
BBB properties of peptide drugs has been challenging for long time, especially, 
extremely important while working with nervous system drugs (CNS).  Recent efforts 
such as glycosylation of enkephalin analogs6 reported to have improved both the 
stability of peptide drugs and their penetration across the BBB.  
There have been several approaches suggested to begin new peptide drug design: 
identification of sequence motifs, crystallographic protein-peptide complexes and 
knowledge based computational modeling. Many research groups use sequence 
binding motif information to design inhibitory peptides. For example, SH3 domain 
with well-known PxxP motif7, using this simple sequence based rule, templates can be 
designed. Second strategy highlights the use of crystallographic complex of protein-
peptide for deriving the necessary structural information to design the new peptide 
sequence. In 2003, the anti-HIV peptide enfuvirtide8 (Fuzeon1) was the first peptide 
(36 amino acids) to be derived from an extracellular protein interface to receive US 
Food and Drug Administration approval.  Successful application of these two methods 
depends on availability of experimental information of peptide sequence or protein-





designing as well as gaining insights in structure based peptide drug design. Two 
main issues are frequently encountered during peptide design studies: peptide pesign 
and peptide docking. 
7.1.2 Computational Peptide Modeling and Design 
Typically in the absence of any information, the design of a specific peptide sequence 
that is able to interact with target protein is a complex problem arising from the fact 
that astronomical possibilities from the pool of 20 amino acids. Evaluating such large 
number of peptide possibilities is complicated with both computational and 
experimental techniques. To cut down number of possibilities, rational approaches 
and fast computational tools have been proposed. Petsalaki9 et al., review highlights 
state-of–the-art finding of peptide drug design and importance of computational and 
experimental techniques in PBDD. Broadly the problem of peptide design can be 
divided into three steps: identification of surface binding pocket, identification of 
peptide that can interact with the protein surface and improving the stability of the 
peptide. If target protein structure is known and binding pocket is already well 
characterized, de novo approaches have been used to predict the peptide inhibitors.  
Otherwise peptide sequence is known, the most possible binding sites are predicted 
using molecular docking strategies. Several reported appeared on highlighting the 
bioinformatics approach to identify putative binding sites using molecular docking10 
i.e. Autodock.  There have been successful efforts for computational peptide design 
that exploited knowledge-based search strategies based on   diverse sets of statistical 
descriptors, different training databases, hydrophobicity scales, motif regularities, etc.  
In addition, database related techniques such protein libraries and epitope searches 





inhibitory peptides has been emerged as an important tool. This application was 
successfully applied to design inhibitory peptide against Parkinson’s disease related 
protein α-Synuclein. In addition, Singh11 et al., designed of hexapeptides against 
stromelysin protein using GA. For accurate and reliable design peptides, most the 
methods exploit prior knowledge i.e. structure of protein-peptide complex or protein 
alone. Homology modeling approaches have been used to model newly designed 
peptide over target protein based on existing protein-peptide complex.  In other cases 
where only target protein structure is available, some of interesting methods have 
been proposed. Rosetta approach12 introduced backbone flexibility in the peptide 
starting from a series of perturbed X-ray protein–peptide complexes. This protocol 
has been validated on a set of 89 peptide complexes, and it has produced models that 
show sub-angstrom deviation from the native structure. The PepSpec13 algorithm 
from the Rosetta group does not depend on a structural model of the peptide. Instead, 
it only requests a single anchor residue positioned in the binding pocket, and 
introduces implicit backbone movements in the receptor through ensemble modeling. 
This algorithm was thoroughly validated on a series of peptide-binding domain 
families, such as PDZ, SH2 and SH3. 
Application of docking techniques encompasses not only for binding mode prediction 
but also includes prediction of protein-peptide interactions. Molecular docking 
strategies are very popular in predicting binding modes of ligands and also some these 
techniques were applied to predict peptide binding conformations. Despite some 
successful efforts14, these techniques were not successful with long peptides and their 
utility was limited to small peptides (up to tetramers and pentamers). Most popular 
approaches for modeling protein-peptide interactions includes homology modeling15 





by availability of experimental protein structure. Docking approaches are most 
commonly used strategies. Autodock, a popular small-molecule docking algorithm 
based on genetic algorithm, has been used to design tetrapeptides against a selected 
hydrophobic region of α-synuclein protein16.  These methods   do not simulate 
protein-peptide interactions accurately in terms of considering backbone flexibility 
and complementarity to receptor surface as well as scoring functions specific to 
peptides. Latest development throw light on these issues to predict accurate 
conformation of peptide on protein binding site using Monte Carlo approaches and 
ensemble based approaches. FlexiPepdock17 reported by raveh et al., successfully 
predicted peptide conformation in sub angstrom scale resolution, which generate large 
number of backbone conformation before optimizing on binding site. This method use 
rosetta scoring function for differentiating native conformations from other and was 
benchmarked against several targets including PDZ domain.       
7.1.3 Tau Completive Inhibitors  
Tau protein belongs to the family of microtubule associated proteins, is known to 
express widely in central nervous system. The main functions of tau protein include 
modulation of microtubule assembly and maintaining their stability within neurons. 
There have been several potential phosphorylation sites identified along tau peptide 
and this regulated phosphorylation is instrumental for several physiological function 
of tau including microtubule assembly. More than 20 kinases are known to 
phosphorylate tau, among them CDK5, GSK3β and MARK are prominent. Tau 
protein is an important substrate for CDK5 and deregulation of CDK5 is known to be 
responsible for the hyperphosphorylation of tau, resulting disruption of tau based 
physiology. So the tau competitive inhibitors of CDK5 offer an opportunity to 






Fig 7.1: Annotated crystal structures of CDK5/p25 and CDK2/Cyclin 
There have been several proteins and peptides are known to interact with CDK5, most 
popular among them is PKTPKKAKKL18 derived from H1 histone protein. In 
addition, several proteins are known to interact with CDK5 through substrate binding 
site that located close to ATP site. The exact interacting motif of these protein can be 
easily identified using standard CDK motif ((S/T)PX(R/H/K)). The first residue refers 
the phosphorylation site, where phosphotransfer takes place from ATP of CDK5. The 
second residue is standard anchor amino acid for all CDK family peptides and third 
one can be any residue but fourth position most commonly filled with 
Lysine/Histidine/Arginine residues.  
All known CDK5 interacting proteins are presented in Table 7.1SM and their 7mer 
motif is shown with highlighted phosphorylation site.  Unfortunately, there is no 
experimental crystal structure of CDK5-peptide complex is available to use reference 
for structure based design studies. We used CDK2 bound the HHASPRK peptide 
complex (PDB ID: 1QMZ) to model CDK5 counterpart.  
7.2 Methods and Methodology 
7.2.1 Flexible Docking Simulations  
Modeling of protein-peptide interactions has been really challenging for long time 





protein-peptide docking algorithm, offers alternative to molecular docking in 
predicting peptide conformations accurately. The entire process of modeling was 
divided into four steps: 1. Identification of receptor binding site 2. Modeling of 
peptide backbone 3. Refine the peptide–protein complex to high resolution   4. In situ 
minimization.  The substrate binding site of CDK5 was identified based on 
CDK2/cyclin crystal structure (PDB ID: 1QMZ). Hydrogen’s were added and side 
clashes were removed by optimizing the CDK5/p25 (PDB ID: 1UNL). Using CDK2-
peptide reference, peptides were manually constructed and minimized in chimera then 
these peptides were positioned near binding site of CDK5 binding site to generate 
coarse CDK5-peptide Complex. Low resolution pre-optimization was performed to 
remove clashes followed by rigid body optimization and backbone optimization steps 
were performed. Final complexes were scored based on Rosetta total score and the top 
scoring complexes were further optimized using LigX module of MOE, which 
optimize side chain conformations of receptor,  in other words, simulates induce fit 
binding process. Fig 7.2 illustrates complete schematic of docking simulations. 
 





7.2.2 De Novo peptide generation 
 
We used PEPSEC algorithm, a structure based de novo peptide method, and flexible 
docking simulations to generate CDK5 specific peptide inhibitors. PEPSEC algorithm 
incorporates both coarse docking and design methodologies, which optimize both 
sequence and structure simultaneously. This method uses only anchor residues as an 
input and then the residues are added on either sides of the anchor residue to extend 
peptide to the specified length. Entire process of peptide design was carried out in five 
steps: 1. Binding site preparation 2.  Anchor residue Docking 3. De novo generation 
4. Post processing 5.Exhaustive Flexible Docking Simulations.  The substrate binding 
site of CDK5 was identified based crystal structure of homologous CDK2/cyclinA-
HHASPRK crystal structure (PDB ID: 1QMZ). The entire structure of CDK5 (PDB 
ID: 1UNL) along with p25 was pre-optimized with Rosetta minimization protocol to 
fix all possible clashes. In the next step, anchor residue proline was docked on to the 
substrate binding site, which was done by aligning the previously generated CDK5-
substrate complexes using flexible docking. Various starting conformations of the 
anchor residues were used to generate peptides. In the third step, peptides are 
generated on the surface of CDK5 substrate binding site through a complex set of 
modifications including addition of residues on either sides of anchor residue, 1000 
step conformational sampling of backbone using Metropolis Monte Carlo search, 
adding side chain, optimization of their rotomers and  removal of clashes with 
receptor through optimization.  In the next step, generated peptide sequences were 
sorted out by binding score and the best 1% scoring sequences are compiled into a 
position-weight matrix (PWM), a simple but versatile representation of sequence 
specificity. In the Final step, top ranking peptides were accepted for analysis and 





sequences were subjected detailed flexible docking analysis. Final inhibitor peptides 
were chosen based on total rosetta score and interface score calculated from in 
Flexible docking simulations. All these steps are illustrated in Fig 7.3. 
 
Fig 7.3: De novo peptide design work flow 
 
7.2.3 MD simulations 
All MD simulations were performed with GROMACS package using GROMOS96 
43a1 force field. All structural models were solvated with the single point charge 
water model in cubic periodic boxes with 1.0 nm solute-wall minimum distance. 
Counter ions were added to neutralize the system and steep decent energy 
minimization was performed with positional restraints on solute. Then 100 ps of 
position restrained simulations (NVT) was performed to remove all steric clashes and 
to soak the solute in the solvent. Second round of position restrain simulations (NPT) 





simulations of 5 ns were performed with a time step of 2 fs. All simulations were 
performed at 300 K and 1 bar pressure. Protein and no-protein component were 
coupled independently to temperature bath and pressure bath. Velocities were 
generated randomly with Maxwell distribution corresponding to 300 K and LINC 
algorithm with the order 4 was used to constrain the bond lengths to equilibrium 
position. Trajectories were recorded for every 5 ps.  The geometrical properties of 
trajectories such as RMSD, solvent accessible surface area, RMSF, gyration were 
calculated using g_rms, g_sas, g_rmsf and g_gyrate, respectively. 
7.2.4 Prediction of Peptidomemectics  
Peptidomemectic compounds were predicted using EFGRPRR peptide inhibitor 
which was proved to have best inhibition action against CDK5. This peptide was 
submitted to pepMIMIC19 database. The resulting compounds were score based on 
pharmacophore similarity score. 
7.2.5 Analysis and Visualization 
PyMol was used for all visualization and analysis protein structures and complexes. 
Peptides were built and minimized in MOE.  Logo of peptide analysis was created by 
WEBLOGO20.  
7.3 Results and discussion 
In this work, we report a novel in silco peptide based inhibitor design strategy for 
designing tau competitive CDK5 inhibitors. We mainly focused on modeling of 
various CDK5/p25 substrate complexes for understanding the CDK5 specific 
determinants of substrate specificity and designing new peptide based inhibitors. In 
addition, since no crystal structure of CDK5/p25 with peptide was reported, we used 





CDK5–peptide complexes.  These structure based insights are expected to be 
significant in designing tau competitive CDK5 inhibitors as well as peptidomemectic 
drugs. Fig 7.4 shows the complete work flow. 
 
Fig 7.4: Complete work flow of Peptide design strategy used in this study 
7.3.1 Substrate binding site of CDK5 
Fig 7.1 shows the location of substrate binding site (peptide binding site). This site is 
exposed only in active state of CDK5, upon activation by p35/p25 wherein t-loop 
conformation is stabilized and exposes a hydrophobic pocket close to Val161. Unlike 
ATP binding site, the residues around this site seem to be moderately conserved and 
solvent accessible surface area (SAS) of residues surrounding this site were analyzed 
to identify key residues that probably have impact on substrate binding. Relative SAS 





and Arg200 are shown to have large changes in their SAS upon activation. Ile153 is 
known to act as an organizing center that coordinates several hydrophobic residues 
from activator (p25). The role Arg156 is yet to be understood and Arg200 is known to 
play key role in organizing C-terminal residues.  
 
Fig 7.5: Solvent accessible surface of residues close to the substrate binding site 
7.3.2 Modeling of CDK5/p25 – HHASPRK complex  
7.3.2.1 Modeling  
To Model CDK5/p25-HHASPRK complex accurately, we adopted sophisticated 
flexible peptide docking algorithm that can mimic natural protein-peptide binding 
process. At first coarse structure of CDK5/p25-HHASPRK complex was generated by 
aligning CDK2/CylinA-HHASPRK crystal structure to CDK5/p25 structure.  Then 
the internal clashes were removed by pre-packing the complex with Rosetta protocol. 
In the next step, protein backbone and rigid body orientation were optimized by 
Monte Carlo minimization approach.  Centroid pre-optimization step was performed 
to ensure enough back bone sampling diversity further side chains were minimized. 
The entire protocol was repeated for 200 times for generating enough sampling and 





experimented with various output generations. Final suitable model was selected after 
manual examination of top scoring models.  The conformation of predicted peptide 
was validated by comparison with CDK2/Cyclin-HHASPRK structure. The complex 
is presented in the Fig 7.6. 
CDK5/p25-HHASPRK complex is expected to help in understanding CDK5 based 
substrate selectivity. Despite the similarities between CDK5 and CDK5, substantial 
differences are expected in substrate binding pattern of CDK5 because of 
phosphorylation independent activation of CDK5.  During the flexible docking 
simulation, Proline residues in the peptide (HHASP*RK) was identified as an anchor 
residue and proline was rightly placed in hydrophobic pocket located in the substrate 
binding site. The serine residue that is preceding proline is found to be correctly 
aligned to receive phosphate group from ATP, which is found to be interacting 
Asp126 and Lys128 of catalytic site residues. C-terminal Lysine (Lys8) of peptide 
which is almost conserved in all CDK substrates is found to be interacting with 
Glu240 of p25 whereas similar residue in CDK2/cyclin-HASPRK complex interacts 
with threonine phosphate (T160p of CDK2) of t-loop. In addition, Arg of HHASPRK 
is found to be actively interacting with various C-helix residues as well as p25. Role 
of activator (p25) seems to be crucial for proper alignment of incoming peptide or 
substrates in CDK5 whereas phosphor-threonine moiety take over the similar role in 
CDK2. Glu130 of CDK5 form key interactions with N-terminal residues of the 
peptide. Fig 7.8 highlights the similar interacting residues in both CDK5 and CDK5 







Fig 7.6: Predicted conformation of H2HASPRK8 
 
 







Flexible peptide docking procedure of CDK5/p25-HHASPRK peptide was thoroughly 
validated by redocking the HHASPRK to the CDK2/Cyclin crystal structure. This 
docking was performed in the presence of threonine phosphate which is essential for 
peptide interaction with CDK2. In addition, docking simulation was performed in 
both crystallographic conformation of peptide (HHASPRK) that directly obtained 
from crystal structure (PDB ID: 1QMZ) and extended conformation of the same 
peptide. In both cases, the low energy conformation is found to be very close to 
crystal structure.  Peptide starting with crystallographic conformation yielded rather 
close final conformation within rmsd of 1.5 Å. 
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Fig 7.8: comparative interaction analysis between HHASPRK with CDK5 and CDK2 (left) and 
predictive flexible docking simulation of CDK2/cyclin-HHASPRK complex, the best solution was 
found to be close to crystal structure (right).  
7.3.2.3 MD simulations  
Molecular dynamic simulations were performed to compare the dynamic stabilities of 
CDK5/p25 and CDK5/p25-HHASPRK peptide complex.   RMSD values of backbone 
atoms of both CDK5/p25 and CDK5/p25-HHASPRK complexes indicate that RMSD 
values reached a plateau at approximately after 1 ns and rmsd values ranging from 2.0 





Cα atoms suggest almost similar fluctuation profile for both systems except the 
regions between 150-170 and 200-250. Depressed flexibility (Fig 7.9 A) is observed 
in in these regions of CDK5/p25-HHASPRK complex, seemingly due to peptide 
interaction with CDK5 surface. Peptide interaction is expected to reduce the 
flexibility of residues in and around the substrate interaction site (Val163 of t-loop 
and surroundings, 200-250). Radius of gyration is another measure of system stability 
and plot of gyration is unequivocally suggesting that CDK5/p25-HHASPRK quickly 
reached to equilibration state (with in 1 ns) on the other hand, CDK5-p25 took almost 
3ns to reach equilibration state. These MD results prove unambiguously HHASPRK 
peptide strongly interacting with substrate binding site of CDK5. 
 
         
Fig 7.9: Molecular dynamic simulations:  comparative RMSF profile (top right); comparison of RMSD 
(too right); Radius of Gyration (bottom) 
7.3.3 Modeling of CDK5/p25-substrate complexes  
Further to understand the substrate specificities in detail, we selected peptides (Table 





Optimized flexible peptide docking protocol was used to dock all peptides on to the 
CDK5 binding site from their extended conformation. This offers a unique 
opportunity to model larger number of peptide complexes with CDK5 and helps to 
understand interaction preferences. All these peptides were selected from HPRD 
database based on their phosphorylation site (Serine or threonine) which followed by 
proline residue that sits in hydrophobic pocket created on t-loop of CDK5.  Out of 75 
models were constructed in this study, only best 25 complexes were chosen for the 
final consideration.  All peptides were 7mers, to have an effective comparison with 
reference peptide (HHASPRK). In addition, experimenting three lengths of peptides 
(7mer, 8mer, and 9mer) proved that 7mers are having the best binding affinity than 
the others.  
   
EPSTPYH DTVSPQR NVFTPQK 
  
 
LPVTPTR WVYSPLH  






Table 7.1: Rosetta scores of substrate peptides and their RMSD (with respect to proline anchor residue 
of HHASP*RK) 
Sequence Rosetta Score RMSD * 
EPSTPYH -695.872 0.933 
FDHSPNK -697.957 1.856 
TVTSPQR -694.312 1.347 
GFESPSK -696.820 0.682 
GFESPFK -687143 0.876 
PKASPTP -690.071 1.749 
RPSSPVT -692.265 1.643 
ASPTPQK -689.134 1.969 
APASPAP -691.259 2.918 
NVFTPQK -699.479 1.052 
PDSTPLG -689.651 4.804 
GLPSPTH -691.462 2.864 
TSSSPQP -692.959 1.732 
APSPPQS -696.261 1.209 
ASPSPQR -692.848 1.970 
HRSTPES -695.337 1.504 
LPVTPTR -694.819 2.346 
RQSSPSK -694.234 4.194 
PPASPSP -691.040 1.240 
APSSPTL -691.611 1.611 
EAKTPIK -696.433 1.880 
PTASPNH -691.998 0.785 
QLSTPKS -691.394 0.965 
RSRSPRP -684.641 1.365 
WVYSPLH -696.323 1.286 
 
After docking simulations, reliable final conformations were selected based on rosetta 
total energy as well as rmsd with the proline residue of HHASP*RK (table 7.2). In 
most of the cases (Fig 7.10), it was observed that, secondary structure of lowest 
energy conformation of the peptides was similar to that of CDK5-HHASPRK and 
CDK2-HHASP*RK.  In all cases the anchor proline residue was tightly bound to 
hydrophobic pocket and basic residues were preferred at the C-terminal end e.g. Lys, 
Arg, His.  It is evident from the Fig 7.11 that prolines are present in all positions 





its side chain.  Serine and threonine are also most preferred residues in the three 
positions preceding proline or N-terminal. P+2 position that is located immediately 
after anchor proline residue is not particularly preferred by any residues. 
 
Fig 7.11: Analysis of specificities of substrate peptides 
LNVFTPQK is one of high scoring peptide in our simulations, which forms highly 
dense network of interactions with CDK5 and p25. Especially, anchor proline 
residues is tightly encapsulated in hydrophobic cavity surrounded by the hydrophobic 
residues and C-terminal lysine forms extensive hydrogen bonding with glu161 of 
CDk5, glu240, Ile241 and Asp192 of p25. N-terminal residues are not NVF are not 
forming special interactions. EPSTPYH is another high scoring peptide that is found 
to be extensively interacting with its C-terminal histidine and tyrosine residue that is 
following anchor proline residue is found to be strongly interacting with Thr14 from 
glycine loop of CDK5. Contribution from N-terminal residues is marginal in this case. 
GFESPSK is another peptide that extensively interacts with C-terminal lysine as well 
as hydrophobic residues (Glycine and Phenylalanine) located on N-terminal is found 
to be interacting with Trp166 and Gly205.  HRSTPES peptide is also found to be 
exhibiting similar interaction as of other substrates with the exception of without 
having basic amino acid at the C-terminal. C-terminal serine is found to be interacting 





this, several hydrophobic interactions (Pro129, Pro201, and Trp166) were identified. 
LPVTPTR peptide is a moderately interacting peptide with typical C-terminal 
interactions. WVYSPLH seems to be interacting strongly with CDK5/p25, mainly due 
to extensive hydrogen bonding network formed by C-terminal Histidine and 
hydrophobic interactions that surrounding the N-terminal regions. To sum up, anchor 
proline residue should be tightly encapsulated by hydrophobic interactions; basic 
residues are found to be forming extensive hydrogen binding interactions with 
Glu240, Ile241, Asp192 of P25 and Glu161 from CDK5. Basic residue or hydrophilic 
residues (Arg or His or Lys or Ser) in the P+2 position enhance the activity by more 
hydrogen bonding interaction from αC-helix residues as well as g-loop. Bulky 
hydrophobic interactions are preferred in N-terminal regions of peptide among strong 
binders due to hydrophobic residues (Trp166, Leu165, Gly205, Gln130) surrounding 
this region.   
7.3.4 Design of in situ Peptide Inhibitors  
We designed the peptides by eliminating phosphorylation site residues to make them 
act like a competitive inhibitor.  These pseudo peptides were designed based on the 
anchor residues conformation that obtained from previously generated CDK5/p25-
substrate peptide complexes (previous section). This in situ design strategy is 
expected to be useful to design target specific peptide inhibitors mainly because of 
optimized position of anchor residues and choice of side chain selection that 
complements the receptors side chains.  Using various anchor positions extracted 
from the CDK5-substrate complexes modeled in the previous section, we generated 
large number of peptides (7mers) in de novo fashion and the top ranking peptides 





phosphorylation site (Ser or Thr in P+0 positions) were rejected and top ranking 
peptides were further subjected to the flexible docking simulations to score them 
accurately. List of top ranking peptide inhibitors are presented in the Table 7.2.   
Table 7.2: Peptide Inhibitors Designed in De novo Simulations 
SNo Peptide Inhibitor 
Sequence 
Rosetta Score  Remarks 
1 HHASPRK -702.445  Reference 
2 DMTEPHH -700.303  Inhibitor 
3 DTTEPKR -697.234  Inhibitor 
4 EDFPPRR -699.207  Inhibitor 
5 EGLAPHR -699.207  Inhibitor 
6. EMTEPRS -701.937  Inhibitor 
7 NLTGPGK -697.304  Inhibitor 
8 RSYDPTS -696.212  Inhibitor 
9 SDNAPKH -699.469  Inhibitor 
10 SDSAPHK -696.466  Inhibitor 
11 SSTDPRH -697.666  Inhibitor 
12 TDEAPRK -695.728  Inhibitor 
13 TDSAPHR -700.760  Inhibitor 
14 TESGPKK -698.451  Inhibitor 
15 TETGPAR -697.894  Inhibitor 
16 TSSAPMR -700.761  Inhibitor 
17 TTSEPHH -701.466  Inhibitor 
18 VNSGPKH -696.807  Inhibitor 
19 DLDGPGR -698.503  Inhibitor 
10 TNTAPTR -698.85  Inhibitor 
 
Interestingly, we could accurately predict (Fig 7.13 - PWM) known residue 
preferences some extent from the denovo prediction. For example, P+3 site seems to 
be preferred by basic residues such as Lys, Arg or His and phosphorylation site (P+0) 
preferences were accurately predicted. This adds credence to the de novo prediction 
and docking simulation predicted most of these predicted inhibitors binding mode 
resemble native substrates (e.g. HHASPRK). Best inhibitors were selected by 





Interface binding energy. Second criterion was useful in predicting selectivity’s with 
different target protein.  






















7.3.5 MD simulations of inhibitor Peptides 
Molecular dynamic simulations were performed to estimate the stability of CDK5/25-
inhibtors complexes. As shown in the Fig 7.12, most of the inhibitor peptides 





RMSF profile of these peptides clearly confirms their interactions with CDK5 at t-
loop regions.   
 
Fig 7.12: RMSF analysis of top ranking peptide inhibitors (Green – CDK5/p25, red – inhibitor and blue 
– HHASPRK) 
 
7.3.6 Prediction of peptidememectics 
Further, a preliminary study was performed to predict peptide mimics. EDFGPRR 
was used to scan the pepMIMIC database using hybrid shape similarity and 
pharmacophore scoring function. Top scoring compounds are presented in the Fig: 
7.13. Furthermore, these compounds were matched against drug databank. 
Interestingly most drug compounds retrieved from drug databank showed close 
similarities (average tanimato score of ~0.78) with peptide like compounds predicted. 












































Novel peptide inhibitor design has been real challenge for long time and most of the 
wisdom regarding PBDD grasped from protein-peptide and protein–protein 
interactions of known experimental structure. There have been several de novo studies 
reported, yet reliable modeling of protein-peptide interactions has been roadblock. 
Recent advances in computational biology paved way for simulating protein-peptide 
interactions accurately by considering backbone flexibility of peptide ligands.   Using 
the current state of technology, we modeled CDK5 –peptide complexes using 7mer 
peptides excised from CDK5 interacting proteins based on phosphorylation motif. 
Most of the complexes were found to align rightly along with reference peptide that 
was obtained from CDK2/cyclin complex and interestingly, these peptides assumed 
similar backbone conformation that observed in CDK2/cyclin-HHASPRK complex. 
Flexible docking simulations rightly identified hydrophobic pocket that accommodate 
proline residue of incoming peptides. In addition, as previously suggested, Glu240 
from P25 is found to be closely interacting in our models   and it is clear that Asp192, 
Ser242 also making important contribution to stabilize the C-terminal of peptides 
which is mainly composed of basic residues (K/H/R). Exceptionally, hydrophilic 
residues such as Serine or threonine also observed to form favorable interactions with 
this region.  P+2 position is not shown any conservation but hydrophilic residues are 
in general enhance binding in this region as well as smaller hydrophobic residues such 
isoleucine and valine are when C-terminal is occupied by bulky histidine.  Our 
CDK5/p25-peptide complexes show no conservation pattern from N-terminal residues 
(P-1, P-2, P-1 positions) and also sequence alignment of CDK’s suggest there are less 
conserved residues located on the surface of CDK5 around this regions which might 





ligands for CDK5, the knowledge derived from the modeling of CDK5-peptide 
complexes was further used to design new peptides by avoiding phosphorylation site.  
We followed in situ de novo peptide design strategy, to design novel selective 
peptides for CDK5 and this strategy is particularly helpful because peptides are grown 
and optimized on the surface of receptors binding site. So this strategy considers 
protein binding site for the optimal inhibitor peptides generation rather than sequence 
based or mutational studies which are purely based on sequence information without 
considering target protein. The anchor residue proline was docked on the surface of 
CDK5 substrate binding using CDK5/Peptide models previously generated in this 
study, using it as a starting point, peptides were generated by growing on either side 
on CDK5 binding site. This process was iterated several times using different various 
anchor residue positions.  The resulting peptides were score and top ranked peptides 
selected for further studies. PWM (pair wise matrix) analysis of top 10% peptides 
suggested that CDK based specificities of peptide sequences were well conserved.  
As Fig 7.13 shows, K/H/R are preferably in P+3 position and as expected 
phosphorylation site (P-site) is dominated by serine. Interestingly, threonine is also 
known as  prominent P-site residue which is not found predominantly in our de novo 
peptides but careful analysis of substrate derived peptides (Fig 7.13) also suggest that 
serine residues is more preferable than the threonine in  this position. This evidence 
adds credibility to the de novo prediction. Interestingly, P-1 site shows more 
preference for serine residue and other sites P-2 and P-3 also are found to have similar 
preference for serine residue.  As Table 7.2 suggests, many natural peptides exhibit 





Proline (pocket identifier) to locate receptor binding pocket accurately.  In addition, 
P-2 shows slight inclination to Glu and Asp (acidic residues).  
            
Fig 7.13: Pair wise matrix (PWM) analysis of residue specificities of inhibitor peptides 
 
We considered top ranked peptides from de novo generation, which are devoid of 
serine or threonine in their P-site position (P0) as possible peptide inhibitors.  To 
assess their potentiality, these peptides were further subjected to flexible peptide 
docking and MD simulations.  Analysis of top 7mer peptide inhibitors suggests some 
interesting facts such as Phosphorylation site (P0) in the absence of serine or 
threonine, is predominantly occupied by glutamic acid followed by alanine and 
glycine. C-terminal residues such P+3 predominantly occupied by R/K/H and 
interestingly, P+2 site show similar preference. Acidic residue (Glu and Asp) or 
hydrophilic residues are found in N-terminal (P-2 and P-3) sites, which are 
conveniently interacting with basic residues from CDK5 that surrounding this regions.  
Detailed analysis of Residue–Residues interactions of CDK5/p25-Inhibitor Peptide 
complexes elucidate vital interactions that responsible for the binding affinity as well 
helps in deciphering key locations  on substrate binding site.  DMTEPHH peptide 





of DMTEPHH is identified to be actively interacting with Lys128 of CDK5 and 
Thr14 from g-loop of CDK5, which is found to be interacting in the similar way as of 
serine of HHASPRK   without phosphorylation. Interestingly, N-terminal Asp of 
DMTEPHH is engaged in hydrogen bonding with Lys88 and Glu130 of CDK5. 
TTSEPHH (701) and TSSAPMR (701) seem to be strongly interacting with CDK5. 
Interestingly, both peptides appear to have similar N-terminal residues (TTS and TSS) 
and despite having similar secondary structure, these peptides exhibit slightly 
different interactions energies (15.274 and 16.364).  On close comparison of two 
peptides, we identified that anchor residue (proline) of TTSEPHH is not properly   fit 
in hydrophobic pocket. On the other hand, TSSAPMR is interacting poorly on N-
terminal side (TSSA) and establishing conserved C-terminal interactions with Arg8 
and Glu240. So the placement of anchor residue (proline) seems critically affect the 
binding pattern as well as binding affinity.  EMTEPRS is another interesting peptide 
inhibitor that is strongly interacting with CDK5 with minimal number of interactions. 
The anchor residue appears to tightly fit in pocket and C-terminal is characterized by 
arginine and serine in P+2 and P+3 positions. Serine is found to be interacting Ile241 
of p25 and Ser159 of CDK5 and whereas arginine residue seems to be closely 
interacting with thr14 from G-loop of CDK5. On the N-terminal side, Glu2 appears to 
be closely interacting with Lys88.  Despite uncharacteristic interactions on C-terminal 
side of this peptide, this one of the best peptide inhibitor with relatively high total 
rosetta score and interaction score (-701.937 and -15.438). DTTEPKR is another 
peptide with high interface score which is evident from extensive interactions that 





Overall analysis of inhibitor peptides reveals that phosphorylation site (p0) 
predominately occupied by acidic residues (Glu or Asp) which can conveniently 
interact with Lys128 as Ser residue interacts naturally. P+2 and P+3 sites seem to be 
predominantly occupied by H/K/R residues. Arginine in P+2 positions seems to 
making additional contacts with Asp41 from αC-helix and Thr14 from G-loop. 
Although Fig 7.13 shows threonine as predominant in P-3 residue, the analysis high 
scoring compounds reveals Ser or Glu are best choice in this site because of presence 
of basic residues around this site as well as flexibility of serine allows occupying the 
small charged pocked pocket.  
 
Fig 7.14: Peptide inhibitor bound to CDK5/P25 and pharmacophore interactions 
Further examination of CDK5/p25-peptide inhibitors and their interaction with 
receptor site, we propose a simple pharmacophore guide for future peptide design 
efforts. Entire substrate binding site can be divided into five regions as shown in the 
Fig 7.14. C-terminal region seems predominantly interacting with negative 
electrostatic potential (shown in red) and evidently H/K/R best the serve the purpose 





hydrophobic pocket (green). Third region is occupied by rather combination basic 
residues (blue) and hydrogen donors (yellow) and probably hydrophilic residues serve 
the purpose better. Forth region is located in a small cavity which is predominantly 
hydrophobic but surrounded by hydrogen donors. So this site is mostly preferred by 
either hydrophobic residues or residues having terminal electron acceptor groups such 
as Glu, Asp, His. The site 5 also characterized by hydrogen donors (yellow) 
These peptide inhibitors were further subjected to vigorous molecular dynamic 
simulations to test their binding ability and stability in aqueous environment. Root 
mean square fluctuations (RMSF) in the t-loop region of CDK5 (145-165) was 
observed during the simulation which evidently suggests depression of RMSF in this 
region. Magnitude of depression of RMSF suggests strength of peptide binding with 
target protein. We compared RMSF of CDK5/p25 alone with CDK5/p25-HHASPRK 
(reference) and CDK5/p25-Inhibitor complexes.  Most of the Complexes exhibited   
same degree of RMSF pattern as of CDK5/p25-HHASPRK complex, which clearly 
indicates that de novo designed peptides are indeed competitive inhibitors.  Apart 
from that, interface score that obtained from flexible docking additionally suggest 
binding strength of inhibitor peptide relative to reference. Furthermore, RMSD 
profiles of all these inhibitor peptide complexes are comparable to that of CDK5/p25 
and CDK5/p25-HHASPRK, which unambiguously prove that all complexes are 
stable.  
Using the CDK5-inhibitor complexes, we further screened peptidomemectics 
compounds. Since peptide compounds are unstable and liable for degradation by 
peptidases, peptide mimic compounds were screened to improve the 





like compounds using conformations of inhibitors already predicted in this study and 
compounds were sorted out by hybrid similarity and pharmacophore based scoring 
function (Methods). We mainly considered three points to design peptide like 
compounds 1. Proline backbone/side chain 2. C-terminal interactions 3. Acidic 
residues in N-terminal. (Fig7.14). some of the compounds and their similarities to 
known drug compounds is shown in Table 7.4 
7.4 Conclusion 
In this study, we designed tau competitive peptide inhibitors that prevent abnormal 
phosphorylation by CDK5/p25. Given the non-selectivity issues associated with small 
molecule inhibitors, peptide inhibitors are expected to help in achieving requisite 
selectivity. We successfully applied vigorous flexible peptide docking simulations to 
create CDK5-peptide complexes to understand basic specificities of amino acids. 
Using the anchor residue constraint obtained from the CDK5-peptide complexes, in 
situ design simulations were performed by adding residues on either sides of anchor 
residue and subsequent optimization to generate peptide inhibitors. Top ranking 
peptides were identified as probable inhibitors after eliminating phosphorylating 
groups in P0 position and subsequently molecular dynamic simulations were 
performed to confirm their interaction with substrate binding site of CDK5. A 
pharmacophore model was elucidated to interpret basic requirements for tau 
completive inhibitors of CDK5. At the end, peptidomemectic compounds were 
predicted using one of the best peptide inhibitor designed in this study.  
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Computational ab initio Structure 
Prediction of N-terminal Fragment of 
p35: Insights to Alternative Drug 
Design  
Preface 
P35 is a natural activator of CDK5, which play major in role modulation of several of 
neurophysiological activities. But the N-terminal truncated portion of p35, popularly 
known as p25, acts as hyper activator, leading to abnormal activation of tau protein. 
Although the major interacting domain of both proteins remain same, exact reasons 
for the abnormal behaviour is still unknown. Crystal structure of CDK5/p25 is 
available but p35 is still to be solved.  In this study, we modelled the truncated N-
terminal domain of p35 using ab initio strategies. Then the predicted model was used 
to predict the natural binding conformation with respect to CDK5. Following the 









As a major regulator of CDK5, p35 1play a pivotal role in several neuronal functions 
i.e. neuronal migration and differentiation to synaptic plasticity, through 
phosphorylation various substrates. Hence this is vital for neurophysiological function 
to maintain proper control of CDK-35 kinase activity, as evidence has suggested that 
the deregulation of CDK5 activity is implicated in several neurodegenerative diseases, 
such as Alzheimer’s.  The existence of p25, C-terminal portion of p35, is mainly 
implicated in pathology of Alzheimer’s and it was showed that p35 can be cleaved2 
into p25 in calpain dependent manner under neurotoxic conditions. Further, 
Functional similarities and differences between p35 and p25 are illustrated in Fig 8.1 
 
Fig 8.1: Functional Comparison of CDK5 activators (P35 and P25) 
The activity of typical CDK is regulated by the complexation with several activator 
and inhibitor proteins. Although CDK5 is ubiquitously expressed in all types of cells, 
it is heavily dependent on p35 or p39 for its kinases activity, expression of which is 
restricted to neuronal tissues. In addition, most of the cyclins were reported to have 
their inability to interact with CDK5 with the exception of cyclinD and viral cyclin, 





activating the CDK5 as of p35 but exists in only heterodimeric state. In contrast, p35, 
a natural activator of CDK5, forms multitude of interactions3 with several other 
proteins, resulting multi-protein complexes necessary for complexes 
neurophysiological function.  Mass spectrometry analysis and biochemical pull down 
analysis revealed that most of these proteins interact with N-terminal region of the 
p35 which is absent in p25.  
It has been reported that N-terminus of p35 is mainly responsible for interaction with 
several activating and inhibiting4 proteins. For example, importin-5, importin-β, 
importin-7 and protein kinase CK2 are known to inhibit the CDK5 activity by the 
interacting with n-terminus of p35. This interaction renders p35 conformationally 
inaccessible to CDK5 thus avoid activation. In addition to inhibitors, some of the 
proteins like nuclear protein SET5 reported to enhance the by similar interaction. 
Although CDK5 binding domain located C-terminal region of p35 (cyclin box), key 
for regulation of CDK5 located in N-terminal region. Apart from N-terminal 
interacting proteins, there have been some proteins reported to have competitive 
binding with p35. In other words, these protein inhibit the CDK5 activity by directly 
competing with p35 such as cyclins6 (Cyclin D and herpes virus cyclin) , ribosomal 
proteins7 (L34).  
This clearly emphasizes the significance of N-terminal domain of p35 (p10). The 
crystal structure of CDK5-p25 complex reported by mapelli8 et al., provided helpful 
insights of CDK5 activating domain but missing N-terminal domain is essential for 
comprehensive understanding. P10 comprises of first 98 residues of p35 (from N-
terminal end but the crystal structure solved by mapeli8 et al., also missing additional 





145 residues as p10 (Fig 8.2). State-of-the-art computational methodologies were used 
to predict the p10 structure from scratch and protein-protein interactions were 
predicted to derive key insights regarding alternative drug design.  
 
Fig 8.2: Crystal structure of CDK5/p25 and truncated P10 portion (blue) 
The word “ab initio” typically means “from the beginning”.  The goal of any ab initio 
protein structure prediction protocol is to predict the native fold from amino acid 
sequence alone. The problem of finding native structure for a  given protein sequence 
has been remains unsolved for  a long time with the exception of  comparative 
modelling where the knowledge of homologous structure is used to predict the 
structure of new protein  or threading methods where secondary structure (fold) 
information is used to model the new protein. In last 10 year, very significant 
developments have been reported in attempting the problem of ab initio prediction 
structure prediction in terms of search methodology that required for searching 
astronomical conformational space (i.e. Monte Carlo simulations or Molecular 
dynamic simulations) and the scoring functions that is used to identify the correct 
native fold.  In spite of progress, several roadblocks need to be cleared off such as 
there is no single method that fully complies with the definition of “ab initio”, most of 





currently demand huge computational resources thereby the length of protein structure 
to be predicted is limited to 100 - 150 residues.  
Ab initio modelling strategies are used when no template available in the PDB 
database or not identified by threading algorithms.  In other words, protein structure 
prediction from the scratch based on first principles. Several attempts have been made 
to achieve template less modelling of proteins but this met limited success so far. 
Duan and Kollman9 in 1997 folded the villin headpiece (a 36-mer) by MD simulations 
in explicit solvent on parallel supercomputers up to 4.5 Å. Although MD strategies 
successful, they’re limited to very small proteins and computationally very expensive. 
First practical ab initio approach was introduced by Bowie and Eisenberg10 who 
assembled protein tertiary structures using small fragments (mainly 9-mer) extracted 
from PDB database. This idea was carried forward by baker11 and co-worker who 
developed ROSETTA by implementing 3-mers and 9-mers from other proteins. This 
process was one of highly successful fragment based ab initio strategy which was 
proven in CASP7competetion (T0283, 112 residue protein was predicted with rmsd of 
1.8 Å). Another successful approach in this area is I-TASSER12 by zhang et al. in 
which 3D models are constructed based on a purely knowledge-based approach.  In 
this approach the continuous fragments of various sizes are excised from threading 
alignments and are used to reassemble protein structures using Monte Carlo 
algorithm.  This approach has been very successful in recent time and top performer 
in recent CASP8 competition. 
The study of Protein-Protein interactions13 (PPIs) is another thrust area of research in 
protein bioinformatics in which protein – protein interactions are predicted through 





protein complex starting from constituent proteins.  In Other words, protein docking 
predicts how proteins interact with each other. In recent days dramatic progress in 
crystallography and NMR techniques enabled us to solve the protein structures 
rapidly. Despite the progress due to practical difficulties associated with these 
techniques, the number protein complexes being solved are very less in number. 
Hence computation protein docking techniques are gaining increasing popularity to 
understand molecular mechanism of biological systems.  
The main objective of the study is to predict the three dimensional structure of N-
terminal fragment of p35 (p10). As mentioned earlier, p10 portion of p35 play pivotal 
role in regulating function of CDK5 through interaction with various proteins. It is 
expected that three dimensional structure of p10 helps in understanding precise 
mechanism of CDK5 regulation. We used hybrid homology and ab initio method to 
predict three dimensional structures of p10 and further its binding conformation 
relative to CDK5 was predicted using protein-protein docking methodology. In 
addition, various in silico methods were used to delineate p10 binding interface with 
CDK5 i.e. alanine scanning.  
8.2 Methods and Methodology 
8.2.1 Model Building 
Due to lack of suitable template for building homology model, in this work combined 
threading and ab initio methodologies were exploited to build p10 model. In the first 
step amino acid sequence was used to retrieve suitable protein folds from Protein 
Databank using several threading programs like LOMETS14, MGENTHREADER15, 
and FUGUE16. In the second step, the continuous fragments excised from the PDB 





simulations with the threading unaligned regions (mainly loops) built by ab initio 
modelling.. The low free-energy states are identified by SPIKER through clustering 
the simulation decoys. In the third step, the fragment assembly simulation is 
performed again for second time to remove the steric clashs as well as to refine the 
global topology of the cluster centroids. The decoys generated in the second 
simulations are then clustered and the lowest energy structures are selected. The final 
full-atomic models were obtained by REMO which builds the atomic details from the 
selected I-TASSER decoys through the optimization of the hydrogen-bonding 
network. 
8.2.2 Protein-Protein Docking Simulations  
Initial stage docking simulations were performed by ZDOCK17 algorithm to 
determine approximate conformation of p10 with respect to CDK5. ZDOCK is a Fast 
Fourier Transform based protein docking program. It searches all possible binding 
modes in the translational and rotational space between the two proteins and evaluates 
each by an energy scoring function. Search speed is greatly increased by converting 
each protein's structure to a digital signal and utilizing a Fast Fourier Transform 
technique to reduce computational time.  Top 100 conformations obtained from 
ZDOCK simulations were subjected to flexible induced fit backbone refinement by 
Fiberdock18 .  Thus obtained global score was used to identify native or near native 
conformations.   
S = PSC + DE +ELEC 
S = ZDOCK score, PSC = pairwise shape complementarity,  DE = Desolvation 







8.2.3 Rosetta High Resolution Docking 
Rosettadock19 was used to performed high quality refinement of CDK5/p25-p10 
complexes.  
8.2.4 Alanine Scanning  
computational alanine scanning 20studies usually aim to predict critical residues 
located at the interface of proteins. These algorithm simply substitute alanine for any 
residues located at the interface and compute change in energy terms. 
8.2.5 Structural Similarity search:  
COFACTOR21 Module implemented in Zhang lab was used for estimation of 
structural similarity studies  
8.2.6 Sequence alignment and phylogeny tree  
All protein sequences of cyclins and p35 were obtained from NCBI database. 
Multiple sequence alignment was performed using MAFFT algorithm and predicted 
secondary was used for proper aligning the sequences with each other. The secondary 
structure for each sequence was predicted using profile based alignments.  The 
Neighbourhood –joining algorithm (MEGA) was used to generate phylogeny tree 
from multiple sequence alignment. CLC sequence viewer was for annotating tree and   
disorder of the target sequence was predicted using DisEMBL22 and Secondary 
structure was predicted using PSIPRED23.  
8.3 Results and Discussion 
In this study, we focused on modelling of N-terminal portion of p35 (p10 – 147 
residues) using ab initio structure prediction methodology. This method was adopted 
after several futile efforts using comparative modelling and threading methods 
wherein no satisfactory results were yielded. Finally we used combination of 





dimensional structure of p10. Further protein-protein docking method was used to 
predict the correct placement p10 with respect to CDK5. The complete study was 
pursued in the following steps: Sequence analysis, model construction, validation, 
prediction of structural analogs, prediction of p10 location and novel targeting 
opportunities.  
8.3.1 Sequence analysis 
Since there was no absolute structural reference identified in PSI-BLAST analysis for 
modelling of p10, the amino acid sequence was thoroughly analysed to characterize 
various properties such as secondary structure prediction, phosphorylation sites, and 
disorder frequency. This analysis was expected to be critical for both initial model 
building and final model validation, especially in case of “tough” targets.  Disorder is 
an important indicator of protein sequence that highlight degree of unstructured 
portion in the sequence and these unstructured regions are often known to play key 
functional roles. In addition, estimation of disorder helps to delineate boundaries of 
structural domains.  Disorder of p10 is shown in the Fig 8.3 wherein three different 
disorder predictors are shown. It is obvious from the Fig 8.3 that most of p10 is highly 
disordered and the regions spanning N-terminal, C-terminal, 20-30, 50-60, and 80-90 
are less disordered, indicating the possibilities for structural elements (α-helices or β-
sheets).   
Secondary structure prediction is another important step in threading and model 
building process of “tough” targets.  Secondary structure prediction by PSIPRED (Fig 
8.4) clearly suggests that large portion of sequence constitute flexible loop regions 
and three β-sheets (residues 10-20, 45-50, 140-145) and two helices (20-30 and 50-
60) were identified. Interestingly, all these structured regions from PSIPRED coincide 





threading and ab initio modelling studies in which templates are identified based 
secondary structure similarities.  
 
Fig 8.3: Disorder prediction of P10 sequence by DisEMBL 
 





8.3.2 Phylogeny Analysis  
It is always interesting to investigate the evolutionary roots of the p35, given its 
functional anomalous behaviour. P35 and other cyclins, CDK activating proteins, 
were included in the study to track their evolutionary relationship and ph80 sequence 
of yeast, also included.  Phylogeny tree was constructed based on multiple sequence 
alignment of all protein sequences of cyclins, p35 and pho80. Since all these sequence 
share meagre similarities, predicted secondary structure based approach was used for 
multiple sequence alignment. Then phylogeny tree was constructed based on 
Neighbourhood –Joining (NJ) method. The tree is presented in the Fig 8.5. Tree is 
clearly pointing out that p35 is very closely related to pho80 of yeast then cyclinD, 
activator of CDK4 and CDK6, and viral cyclin (herpes viral cyclin activates CDK6). 
CyclinH, CyclinT, CyclinK and CyclinC are clustered separately from CyclinA, 
CyclinB and CyclinE. Former group involves in activation of transcription factors 
(CDK7, CDK9) whereas later group majorly involves in activation of CDK1, CDK2, 
CDK3, CDk4 and CDK6 which are cell cyclin regulators.   
 
Fig 8.5: Phylogeny analysis of cyclin sequences including Pho80 and viral cyclin. 
Interestingly, p35 and viral cyclin24 skip the phosphorylation step (t-loop) in their 





proximity in the tree. In addition, it was reported that CylinD6 is capable of interacting 
with CDK5 directly without functional induction . This fact may justify their position 
in the tree. 
8.3.3 Structure Modelling of P10 
Overall process of model building was detailed in methods section. Z-scores from the 
table 8.1 indicates that alignment between target sequence and templates is reasonably 
good (Z-score >1 suggests good threading alignment) and   coverage (cov) of 
templates to target seems to be good (>70%).  All these templates were procured from 
LOMETS meta server. Sequence identities of all templates were identified to be 
marginal.  Then the Monte Carlo simulations were performed to simulate the global 
folding process and native like structures were identified by clustering and ranking the 
poses with TM align score.  
Table 8.1: Templates used in the modelling process 
SNo Templates Iden1 Iden2 Cov Norm Z-Score 
1 2J16_J 0.12 0.07 0.76 1.31 
2 2EMA_A 0.07 0.17 0.89 1.23 
3 2XGF_A 0.12 0.19 0.86 1.09 
4 1Y1Y_S 0.11 0.18 0.86 1.02 
5 1Z87A 0.12 0.21 0.97 1.06 
6 2Y9Y_B 0.08 0.23 1.00 1.02 
7 3I4G_A 0.11 0.16 0.98 0.80 
8 1UNG_D 1.00 0.15 0.15 2.73 
9 2TMA_A 0.07 0.17 0.93 1.21 
10 3GV2_A 0.17 0.22 1.0 0.81 
Ident1 is the percentage sequence identity of the templates in the threading aligned region with the 
query sequence; Ident2 is the percentage sequence identity of the whole template chains with query 
sequence; Cov represents the coverage of the threading alignment and is equal to the number of aligned 
residues divided by the length of query protein; Norm. Z-score is the normalized Z-score of the 
threading alignments. Alignment with a Normalized Z-score >1 mean a good alignment and vice versa. 
This process of model building was iterated for several times and clusters of models 
with RMSD of 3.5Å were chosen for the further analysis. Final models were selected 





off of -0.1. In this work, we repeated entire model building process several times with 
varied lengths of p10 (residues 147, 166, and 185) by adding extra known portion 
from the p25. This extra length of p10 sequence was expected to guide us to identify 
correct folding of p10, as it should be located always exterior of p10.  From the best 
cluster, we chose to report best models based on their C-score (Fig 8.6). These models 
were taken for the close examination and it was found that model1 and model3 have 
got good agreement with secondary structure predicted previously. Finally, model1 
was chosen for further studies (top C-score).  All these final models of p10 
unanimously suggest that p10 structure is highly disordered and this could be 
contributing reason for unsuccessful crystallization efforts.   
  
Model1 : C-score =-2.92 Model2: C-score= -2.96 
  
Model3: C-score=-3.312 Model4: C-score=-3.40 
  
Model5 : C-score=-3.57 Model6: C-score=-3.969 
 





The model1 was accepted for the final analysis, which predominantly consists of α-
helices (residues 11-18, 34-43, 52-58, 73-82, 88-92, and 107-121)  along with  inter-
connecting loops and also characterised by two small beta sheets (residues 26-30 and 
97-101). Secondary structure of final model is found to be largely on par with the 
predicted secondary structure. As part of regular validation exercise, we performed 
several qualitative and quantitative tests that determine physiochemical and 
conformational packing quality of the models. Ramachandran plot suggested that 
more than 95% of residues in allowed regions and only 4.8% of residues accounts for 
6 residues in disallowed regions, mainly because of flexible loops. Additional 
validations (ProsaII) mentioned Supplementary material. Further analysis (Fig 8.7) of 
the model1  revealed that there are two phosphorylation sites (Ser8 and thr138) 
reported by  Kamei25 et al., are found to be located on high solvent accessible regions, 
which is a typical characteristics of phosphorylation sites. These two sites were 
reported to play vital role in ubiquitination.  The cleavage site (98-99) that leads to 
truncation by the calpain is located merely at the centre of the protein (flexible 
region). , This site is found to be located exactly where truncation p35 takes place by 
calpain, leading to the generation of pathogenic C-terminal fragment. 
                 






8.3.4 Molecular Dynamic Simulations  
To test the stability of the predicted model, we performed explicit molecular dynamic 
simulation. 5 ns simulation unambiguously suggests that p10 model is highly stable 
and well energetically minimized. Backbone RMSD variation during the simulation 
suggests that trajectory was stabilized after initial rise of 2000 ps and remains stable 
with the rmsd of 4.5+0.5 Å. RMSD calculated apparently larger than in typical 
simulations because of high flexibility and disorderedness structure. Further we 
measure radius of gyration which is an indicative of structure compactness in three 
dimensions. It is evident from the Fig 8.8 overall structure is compact and stable. 
      
                  
Fig 8.8: Molecular dynamic simulations RMSD of backbone during simulation: (top left) Potential 
energy change during simulation (top right) and Radius of gyration (bottom left) ProsaII Validation 
suggesting the p10 model quality belongs to NMR class (bottom right). 
 
8.3.5 Identification of Structural Analogs 
Since p10 was modelled in “ab initio”, there is no structural reference available to 





serve as key point of validation for this structure prediction. We performed reverse 
template search for p10 model and all templates closely match the p10 were listed in 
Table 8.2. Further we have verified the structural relevance of these analogs to CDK5 
function which led to interesting conclusions. Interestingly, most of the analogs listed 
in Table 8.2 belong to the category of ribosomal proteins.  There have been several 
reports on interaction of ribosomal protein with CDK5 and p35.  Among them L34, a 
6oS ribosome protein, was reported to exhibit inhibitory role against CDK5.  
          Table 8.2:  Structural analogs of p10 model 
S.NO PDB ID Name of Protein TM-
Score 
RMSD IDEN COV 
1 2jl6j STRUCTURE OF RF2 0.684 1.81 0.109 0.744 
2 1zaxA Ribosomal Protein 
L10-L12(NTD) 
Complex 
0.614 2.58 0.056 0.744 
3 3kirJ Structure of RelE 
nuclease 
0.571 3.00 0.071 0.738 
4 3sgfH Crystal Structure of 
Release Factor RF3 
0.569 2.82 0.057 0.726 
5 3u5iQ The structure of the 
eukaryotic ribosome 
0.547 2.70 0.058 0.689 
6 3jsyA N-terminal fragment of 
ribosomal protein L10 
(Methanococcus 
jannaschii) 
0.545 3.28 0.076 0.720 
7 3o5hM Yeast 80S ribosome 
protein 
0.544 3.10 0.057 0.707 
8 3izsS1 Localization of the 
large subunit ribosomal 
proteins 
0.540 3.27 0.058 0.713 
9 3izcs Localization of the 
large subunit ribosomal 
proteins 
0.540 3.27 0.058 0.713 
10 3iz5s Localization of the 
large subunit ribosomal 
proteins 
0.533 3.21 0.056 0.713 
 
L347 was found in proliferating HeLa cell and it was found to be responsible for the  
inhibition of CDK5 activity. LP0 is an another ribosomal protein that interacts with 





addition, several ribosomal proteins of this class have been reported7 to interact with 
CDK5. 
The p35 protein, the only known activator of CDK5, is exclusively expressed in 
differentiated nerve cells. The activation of CDK5 by p35 is responsible for the onset 
of differentiation of nerve cell. During the terminal differentiation, CDK5 activity is 
proposed to be blocked by L34 protein which keeps the CDK5 remain in inactive 
form. In addition, cyclinD, an activator of CDK4 is also known to interact with CDK5 
without eliciting any activation. It was found that L34 also interact with CDK4.  In 
nutshell, L34, cyclin D and p35 must have structural similarities evident from their 
seamless swapping of interacting partners i.e. CDK5, CDK4.  Unfortunately, due to 
the unavailability of crystal structures of C-terminal structure of Cyclin D and L34, no 
direct comparison can be made with p10 model. 
We propose that p10 analog that was identified in reverse template search belongs to 
the class of ribosomal proteins. Since L10 (PDB ID: 1ZAX), LP0, and L34 belongs to 
the same family of proteins, they presumably share similar structural architecture and 
expected to have similar interaction as of L34 (no crystal structure available). So the 
predicted structural architecture of p10 (Fig 8.7), N-terminal portion of p35, is 
expected to share resemblances with L34. This evidence points out p10 model or 
domain modelled in this study, is also expected to be close to CDK5 interacting 






Ribosomal Protein L10 
(1ZAX_A) 
N-terminal fragment of 
ribosomal protein L10 
(3JSY) 
 
Structure of RelE 
nuclease(3KIR_J) 
large subunit ribosomal 
proteins (3IZ5_S) 
Fig 8.9: structural homologues of p10 are shown superposed (p10 –green and cyan –others) 
8.3.6 Prediction of Protein-Protein Interactions (CDK5/p25 - p10) 
In the next step, we aimed to understand p10 interactions with CDK5/p25 complex. 
This step is very significant in understanding the differences between impact of p35 
(p25+p10) and p25 alone (crystal structure of CDK5/p25 is available). In a nutshell, 
this part of the study is expected to provide insights of p10 interactions with CDK5.  
Complete systemic procedure of docking simulation was represented in Fig 8.3. 
We employed computational protein-protein docking methodology to predict the 
correct orientation of p10 with respect to CDK5/p25 by means of global 
conformational search followed by local refinement. All these searches were carried 
out by ZDOCK simulations which identifies preferable binding conformations based 





methodology section). In this strategy, receptor (CDK5/p25) was fixed and ligand 
(p10) was allowed to search all over the surface of the receptor to identify minimal 
energy binding conformation. The resulting conformations (2000) were clustered with 
5 Å cut off. Interestingly, some of the top ranking clusters were identified close to the 
anticipated binding site of p10 (Fig 8.10) and these clusters (Table 8.2) were accepted 
for the final examination. Shortlisted clusters that predicted close to binding site were 
of rough models and their interface needed to be refined further.  The entire process 
was repeated by the extended length of p10 models (170 and 185 residues against the 
original length of 145) and consensus was recorded to identify most likely 
conformation of p10 in the presence of CDK5/p25. 
 
Fig 8.10: Cluster of p10 conformations from ZDOCK (most likely conformations were indicated in 
yellow). 
Top clusters (Table 8.3) were identified based on ZDOCK score and ZRANK27 score 
which serves as reranking score. The best docking conformations of p10 with respect 
to CDK5/p25 were judged from available experimental information. We mainly 
considered positions of known phosphorylation sites (Ser8 and Thr138) which are 





(between residues 97-98) . We assume these sites should be highly accessible, in other 
words, should be able to locate them on the surface, and location of calpain cleavage 








Poses ( overall 
ranking) ZRank score ZDock Score  
P10 (147) with additional 13 residues – p10 (170) 
6 (14) Top ranking (30) -83.787 16.78  Cluster Center (184) -81.789 13.20 
13 (11) Top ranking (18) -90.374 14.00  Cluster Center (238) -49.002 13.82 
P10_147 
11 (16) Top ranking (59) -78.234 13.86  Cluster Center (1055) -10.292 14.60 
13 (15) Top ranking (13) -88.001 14.50  Cluster Center (24) -81.447 15.98 
18 (13) Top ranking (62) -77.668 13.96  Cluster Center (323) -66.030 13.90 
17 (13) Top ranking (19) -89.103 12.60  Cluster Center(397) -43.694 12.42 
20 (12) Top ranking (5) -103.574 16.14  Cluster Center (17) -90.505 14.46 
 
All these prediction were taken to the next level where all top ranking predictions 
were subjected to the high resolution predictive docking by RosettaDock.  At this 
stage, extra length of p10 model (already known portion) was removed and resulting 
portion (1-146 residues) was subjected to local refinement. Top scoring 
conformations were selected from all rosettadock simulations based on rosetta scoring 







Conformation 1  --- Best Conformation 2 
 
 
Conformation 3 Conformation 4 
                Fig 8.11: Conformations of p10 from protein-protein docking simulations 
 
8.3.7 Flexible Docking and Complex Refinement 
Top ranking clusters predicted in ZDOCK simulations were further optimized in two 
step procedure. In the first step, high resolution docking simulations were performed 
by RosettaDock. Rosetta Dock is a Monte Carlo based multi-scale docking algorithm 
which in high resolution mode optimizes the rigid body orientation as well as side 
chains conformations of the binding partners. The top scoring conformations were 
further optimized by induced fit simulations using FiberDock algorithm so as to 
mimic natural protein-protein interactions. All scores of Rosetta dock and Fibredock 
are presented in the Table 8.4. Rosetta docking algorithms was used for high 
resolution docking simulation to optimize the binding positions of top ranking clusters 
predicted by ZDOCK. Rosetta Dock is a Monte Carlo based multi-scale docking 
algorithm which in high resolution mode optimizes the rigid body orientation as well 





selected for further studies.  Typical protein-protein interactions are mediated in 
induced fit fashion which is in a way slightly different from that of typical protein-
protein docking algorithms assume (rigid body assumption). To refine orientation of 
p10, we performed induced fit docking simulations using Fiberdock (methods) and 
final scores are reported (Table 8.4).  
Table 8.4: Docking scores of Rosettadock and FiberDock are shown  







VdW ACE HB 
Pose 963 -520.776 -35.36 -14.32 5.69 -0.98 0.00 
Pose 689 -520.768 -42.77 -14.99 3.99 1.52 0.00 
Pose 664 -520.280 -16.11 -17.68 9.68 -2.2 0.00 
Pose 657 -520.029 9.88 -8.27 1.15 8.37 -0.71 
Pose 437 -520.182 -25.79 -17.10 9.43 -7.04 0.00 
Pose 303 -520.360 -21.60 -16..90 8.05 -1.99 0.00 
Pose 190 -520.645 -17.32 -12.6 7.09 -4..56 -0.37 
Pose 175 -520.085 -16.17 -11.84 7.47 -4.70 0.00 
Pose173 -520.398 -28.58 -16.12 5.28 -3.75 -0.33 
Pose 116 -520.085 -33.75 -15.20 16.90 1.17 -0.65 
Pose 86 -520.363 -25.15 -15.14 8.83 -0.90 0.00 
 
Validation Protein docking  
The overall predictability of ZDOCK/Rosetta dock simulations were further verified 
by other popular algorithms. Here we report RMSD of entire CDK/p25-p10 complex 
against predicted ZDOCK prediction. It is interesting to note that GRAMM-X 
prediction very closely matches with ZDOCK then followed by Cluspro, 
PATCHDOCK and HEX.  
8.3.8 Interface analysis of CDK5-P10 
Computational alanine scanning was performed to determine hot spots or key residues 
at CDK5-p10 interface. This method basically predicts the binding energy change 
upon mutation of interface residues to alanine in sequential manner, which based on 
premise that alanine with only methyl side chain contribute insignificant proportion to 





interface residues is calculated, which suggest relative contribution of each residue at 
the interface thus helps in predicting hotspot residues. Kortemme20 et al., suggested 
residues with complex destabilization energy greater than one are most likely hotspots 
and they obtained reasonable correlation with experimental results. In addition, buried 
surface area was also estimated for all interface residues to understand their relative 
contribution and all calculations presented in Table 8.5. The modelling efforts throw 
light on interesting intermolecular interactions between CDK5-p10, which might 
render some help to understand CDK5/p25 and CDK5/p35. We identified three strong 
salt bridge interactions between CDK5-p10 namely Arg156 (cdk5) – Glu18 (p10), 
Glu161 (cdk5) – Lys53 (p10), Asp234 (cdk5) – Arg54 (p10). In addition, several 
hydrophobic interaction were also identified at the interface [Leu178 (cdk5) –Pro9 
(p10), Cys157 (cdk5)-Val149 (p10), Pro234 (cdk5)-Pro51 (p10), Val155 (cdk5) – 
Ser8 (p10)].  
Table 8.5: Computational alanine scanning CDK5–p10 Interface residues (DDG Refers the 
destabilization energy) 














Val-155 0.2 0.75 25.5 Ser-6 0.24 -0.46 30.49  
Arg-156 2.45 -0.1 104.56 Ser-8 0.68 -0.37 27.8  
Cys-157 0.02 5.55 19.8 Ser-10 0.01 0.45 14.86  
Glu-161 -0.4 -0.24 43.32 Leu-16 0.13 0.94 23.24  
Lys-177 0.21 -0.56 35.54 Phe-17 2.25 0.04 138.46  
Leu-178 0.76 0.96 45.59 Glu-18 1.54 0.04 29.14  
Lys-232 0.22 -0.24 12.34 Asp-19 -0.01 -1.28 14.02  
Leu-233 0.01 3.08 40.49 Ser-45 -0.01 0.9 56.62  
Asp-235 -0.02 -0.43 12.34 Ser-48 0.5 0.69 45.57  
Lys-237 -0.03 -0.5 23.14 Val-49 0.67 0.85 43.51  
    Leu-50 0.56 2.25 34.59  
    Trp-52 1.11 -0.07 70.73  
    Lys-53 -0.54 -1.72 40.64  
    Arg-54 1.18 0.63 71.98  






Interestingly,  all three ionic bonds are very strong and their intermolecular distances 
are less than 3 Å. in addition , two t-loop residues (Arg156 and Glu161) closely 
interacting with p10 fragment that explain possible impact of p10 on substrate binding 







Fig 8.12: A. Key hydrogen bonding interface residues B. Distance between Arg156 (cdk5) -Ser48 
(p10) during 10ns MD C. Distance between Glu161(cdk5) – Arg54(p10). 
 
8.3.9 Targeting Cleavage Site of p35 
 





P10 structure open up new possibilities for CDK5 based drug design. Calpain 
mediated truncation site is located on p10 (residues etween 97 and 98) and by 
targeting this site p25 generation can be effectively stopped. We used computational 
pocket/cavity prediction algorithms to locate druggable sites close Thr97 or calpain 
cleavage site. A pocket was identified and further we searched for similar binding 
pockets in non-redundant PDB database (nr-PDB database).  Interestingly, this site 
was found to be similar to tubulin stachmin-like domain which interacts with 
colchicine compound. Colchicine compound was minimized inside the p10 binding 
and it was noted that this compound might be able form direct hydrogen bond with 
Thr97. We predict colchicine like compounds might be able prevent p25 generation 
by blocking likely calpain binding site.  
 
8.3.10 Discussion  
As we know, CDK5 is an important therapeutic target for Alzheimer’s disease but 
targeting CDK5 selectively has been a real challenge for long time. The traditional 
ATP binding pocket of CDK5 exhibit similarities with other kinases that leads to non-
selectivity. In search of alternative strategies to drug the CDK5, its activator proteins 
p25 and p35 have been proposed to be alternative targets. P25 being pathogenic form, 
an attractive target to prevent hyperphosphorylation tau filaments. Bing28 et al., 
proposed a hydrophobic pocket located in p25 as a possible site, but this site is present 
in both p25 and p35 because of their C-terminal similarities, restricting the selectivity. 
The knowledge of N-terminal portion of p35 has been expected to shed light on 
possibilities on selective drug design between p25 and p35.  
To support these efforts, the structure of N-terminal portion that spans 145 residues is 





cleavage point of p25 and p10) residues, even further until 145 residues, no 
experimental crystal structure is reported till to date. In this study, this 147 residue 
fragment is dubbed as p10.  Interestingly, this N-terminal fragment exhibited no 
similarities with any known crystal structures available in PDB database. We used 
state–of-the-art ab initio prediction methodology developed by Zhang12 et al., to 
predict p10 structure. Interestingly, our model seems to be on par with secondary 
structure prediction and is largely comprised of non-structured loops, which might be 
responsible non-availability of crystal structure in this region.   
Typically, ab initio predicted models are difficult to validate because of non-
availability of experimental structures and experimental information to use as 
reference.  We validated the predicted model of p10 using reverse template search. 
The predicted models were allowed to search in PDB database to find matches, which 
resulted many ribosomal associated protein domains as potential hits. We were totally 
intrigued by frequent occurrence of ribosomal proteins as possible hits (Table 8.3). 
Literature search led to surprising revelation that some of ribosomal proteins such as 
L34 is p35 a competitive binder to CDK5, which possibly suggest L10 (PDB ID: 
1ZAX), the best match to p10 structure (Fig 8.9), also a ribosomal protein should be 
sharing similar tertiary structure.  
In extension to structure prediction of p10, we aimed to predict most likely binding 
conformation p10 with respect to CDK5. ZDOCK and Rosetta Dock were used to 
generate p10 conformations that likely interact with p10 site. The predicted 
conformations were further validated using other popular protein docking 
methodologies. The analysis of p10 conformation suggests several interesting facts 
including it closer proximity to t-loop of CDK5. P35 is known as normal activator of 





excessively with half-life of 50 min. Reasons for this variability is  not yet complete 
understood but some researchers proposed p35 is membrane tethered through it N-
terminal fragment whereas lack of N-terminal in p25 lead to disengagement from 
membrane. So delocalization of p25 was attributed as main reasons for the excessive 
phosphorylation by p25.  Our model suggests proximity of p10 to t-loop of CDK5 in 
p35 form, might be responsible for the weakening of substrate interaction with CDK5, 
which is evident from strong ionic interactions between t-loop of CDK5 and p10 i.e. 
Arg156 – Glu48 (p10) and Glu161-Lys53 (p10).  In other words, we envision that p10 
portion of p35 exert some control on small hydrophobic pocket (close to Val163 of 
CDK5) located near the t-loop that regulate the substrate binding ability of CDK5. On 
the other hand, absence of these interactions in p25 might lead to strong acceptance of 
substrate and resulting hyperphosphorylation.  Further we explored the opportunities 
for drug targeting using p10 portion of p35. We used p10 structure to search for all 
binding sites then using this information, similar binding sites were matched. 
Interestingly, a site was found to be located close to calpain cleavage site depicted in 
the Fig 8.13 and this site was predicted to have similarities with stachmin-like 
domain, a colchicine binding cavity.  We predict calpain cleavage site that offers an 
opportunity to stop fragmentation of p35 and resulting generation of p25.  
 
8.4 Conclusion 
In this work, we focused on modelling of p10, N-terminal domain of p35 using ab 
initio structure prediction methods.  Interestingly, p10 model was on par with 
secondary structure prediction. Further database search revealed that tertiary structure 
of p10 resembles ribosomal binding proteins (i.e. L10). Strikingly, these proteins are 





Protein-protein docking simulation, we predicted p10 conformation with respect to 
CDK5. This prediction suggest that close proximity of p10 fragment might exert some 
control on substrate binding site, evident from strong salt bridge interactions between 
Glu161-Lys53 and Arg156-Glu48 residues.  In addition, possibility of drugging 
calpain binding site was explored, which suggested that, this site resembles stachman 
–like domain that allow colchicine like compounds to interact. 
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Global Conformational Dynamics of 
Cyclin-Dependent Kinase 5: Insights to 




Global conformational motions are known to play key role in many biological 
functions of proteins. Understanding key functional motions help in designing novel 
motion-blocker type inhibitors such as CIP. In this study, we systematically analysed 
motions of CDK5 in different states (active and inactive) as well as in the presence of 
activator (p25), inhibitor (CIP), and substrate (HHASPRK) to gain basic 
understanding of principle motions. Further this study was extended to analyse p25 
activator protein and CIP inhibitor proteins. Essential dynamics and ANM were used 
to identify functionally significant modes. Overall, this study was expected to derive 









 Global conformational dynamics or Collective motions1 are essential for the various 
biological functions in biomolecules such proteins, DNA and RNA. These motions 
haven been proposed to play significant role2 in numerous biological process 
including allosteric interactions, signal transduction, catalysis, and activation-
inactivation process. Various kinds of motions were observed   that mediate above-
mentioned functions such hinge, shear and motions of entire subunits, loop motions, 
gating, folding-unfolding and rearrangements of side chains. Diverse experimental 
methods3, 4 were used to explain collective motions including nuclear magnetic 
resonance (NMR), X-ray crystallography, as well as single-molecule fluorescence or 
electron-transfer measurements. Complementary to experimental techniques, 
molecular dynamics (MD) simulations are a widely used technique to investigate 
collective motions in proteins. Principle component analysis5 (PCA) or essential 
dynamic analysis (EDA) is a sophisticated approach that is used to elucidate 
collective motions. . PCA is commonly used to extract the collective motions with the 
largest contribution to the variance of the atomic fluctuations. Alternatively, normal 
mode analysis6 (NMA) has been extensively used to identify low-frequency collective 
modes. Such modes are expected to correspond to large atomic displacements and are 
therefore assumed to be important to protein function. In addition, elastic network 
models are an established approach to assess motions intrinsic to the protein structure. 
CDK5 is an important target protein in Alzheimer’s pathology, is known to interact 
with several proteins, mainly with p35, a natural activator protein, and pathogenic 
p25.  The crystal structure of CDK5/p257 shed light on several aspects of CDK5 





conserved in all cyclin proteins, interacts directly with Cα-helix of CDK5. This 
interaction brings substantial changes through various domain motions and transforms 
the inactive conformation into active conformation. This has been long time interest to 
understand the motions of various domains relative to each other during the 
transformation.  Although static CDK5/p25 structure illustrate active conformation, 
there have been missing details of how p25 execute finer controls in stabilizing t-loop 
conformation as well as  DDDDE acidic loop that preceding  Cα-helix of CDK5. It is 
also a major interest to study if p25 interaction triggers any changes in C-terminal 
region.   
 
Fig 9.1: CDK5 in active conformation and p25 (Red is truncated region to generate CIP) 
Recent studies reported8 that N- and C-terminal truncated form of p25 (145-291) acts 
as selective inhibitor which is popularly dubbed as CDK5 inhibitor peptide (CIP). 
Although this peptide is shown to have same cyclin-box domain as P25, proved to 
have selective competitive inhibition against CDK5/p25. So this is yet not completely 
understood the structural differences and mode of interaction between P25 (activator) 





structural dynamics of CDK5 in the presence of these interacting partner i.e. p25 and 
CIP.  CDK5/p25 complexes are known to interact with several substrate proteins 
through substrate binding site. This site is known to play key role in recognition of 
substrate proteins or peptide and align them in right conformations. Since there have 
been no crystal structures of CDK5 bound to peptide substrate reported, we used a 
small peptide substrate peptide that obtained from CDK2/cyclin complex (PDB ID: 
1QMZ)  as a CDK5–Peptide complex.  Collective motions of CDK5/p25 and 
CDK5/CIP in the presence of substrate were studied.  
 Several studies reported, highlighting dynamics of CDK5 in different contexts. 
Zhang9 et al., studied role inhibitors such roscovitine and indirubin through MD 
simulations. Same group studied comparative dynamics of CDK5 and CDK2 in the 
presence of p25 and cyclin. Zhianwen10 et al., studied various levels of truncation 
P25.  Otyepk11 et al., studied various interactions of CDK5 with ATP competitive 
inhibitors and performed comparative dynamic analysis of cyclin and p25. Recently 
Vincent12.B et al., proposed an inhibitory mechanism of CDK5 by CIP peptide using 
10ns molecular dynamic simulations. Cardone13 et al., studied active CDK5, p25 and 
CIP through principle component analysis, which highlighted the existence of 
secondary substrate binding conformation.  Cardone14 et al., performed geometry 
simulations and verified flexibility hypothesis that explain structural variability 
between P25 and CIP. They concluded that CIP binding might prevent the CDK5 
from entering into the complete active conformation.  
In this study, we analysed global collective motions of CDK5 comprehensively using 
MD/EDA and ANM techniques. Various aspects of structural motions have been 





principle domain motions and their relativity as well as finer aspects of structural 
activation.  In addition, impact of P25 and CIP on CDK5 in terms of their induced 
structural changes was also studied extensively. Conformational changes that p25 and 
CIP undergo before and after complexation were studied by comparing their principle 
modes. At the end, structural dynamics of substrate binding interactions were studied 
comparatively in the presence of CDK5/p25 and CDK5/CIP, expecting to elucidate 
inhibitory mechanism of CIP.  
9.2 Methods  
9.2.1 Molecular Dynamics 
All MD simulations were performed with GROMACS package15 using GROMOS96 
43a1 force field. All structural models were solvated with the single point charge 
water model in cubic periodic boxes with 1.0 nm solute-wall minimum distance. 
Counter ions were added to neutralize the system and steep decent energy 
minimization was performed with positional restraints on solute. Then 100 ps of 
position restrained simulations (NVT) was performed to remove all steric clashes and 
to soak the solute in the solvent. Second round of position restrain simulations (NPT) 
were performed to stabilize the pressure and density of the water box. The production 
simulations of 25 ns were performed with time step of 2 fs. All simulations were 
performed at 300 K and 1 bar pressure. Protein and no-protein component were 
coupled independently to temperature bath and pressure bath. Velocities were 
generated randomly with Maxwell distribution corresponding to 300 K and LINC 
algorithm with the order 4 was used to constrain the bond lengths to equilibrium 
position. Trajectories were recorded for every 5 ps.  The geometrical properties of 
trajectories such as RMSD, solvent accessible surface area, RMSF, gyration were 





9.2.2 Essential Dynamics  
Basically Essential Dynamics Analysis (EDA) or Principle Component Analysis 
(PCA) is an orthogonal transformation that projects data from data from cartisian 
space onto a space of collective coordinates. The new coordinate system is such that 
greatest variance in the dataset lies along the first principle component axis followed 
by PC2 and PC3. The approach identical in MD is called Essential dynamics. Both 
analyses are based on covariance between the fluctuations of Cα atoms. This approach 
diagnolize the covariance matrix and examined dominant modes of structural changes 
(eigenvectors) which are associated with largest eigenvalues. Prior to EDA snapshots 
are superposed using kabsch algorithms in an iterative procedure.  
9.2.3 Anisotropic Network Analysis 
We used the anisotropic network model (ANM) as described by  Eyal16 et al., and 
implemented in the ProDy17 package, to all structures in this study. Only Cα atoms 
were considered to compute anisotropic network in which atoms are treated as nodes 
within the network and are treated as being bound to each other by springs, if they are 
within a given spatial cut-off distance.  Briefly, all Cα atoms from a structure are 
treated  as nodes within a network and are treated as being bound to one another by 
springs if they are within a given spatial cut-off distance. A uniform force constant is 
adopted for all springs. A Hessian matrix is generated by considering the individual 
Cartesian components of each spring, resulting in a 3N X 3N matrix (where N is the 
number of residues). The resulting matrix is solved for eigenvalues and eigenvectors 
which provide information regarding the mean square fluctuations of individual 
residues and correlations between them .We used cut-off of 15 Å and s=1.  





Collective modes calculated from MD and ANM were compared using Overlap18 
values (S).  Best overlapping modes were treated as related to the function .  
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9.3 Results and Discussion 
In this study, we would like to address dynamic behaviour of CDK5 in the presence of 
its pathological activator p25 and inhibitor CIP. In addition, impact of these 
complexes on substrate binding was also explored. We used molecular dynamic 
simulations coupled with Essential dynamics and Anisotropic Network modelling 
methods to explore detailed dynamic behaviour of CDK5 along with interacting 
partners. Various interacting combinations were analysed such as CDK5-P25, CDK5-
CIP, CDK5-P25-substrate, CDK5-CIP-substrate, uncomplexed p25 and CIP. 
9.3.1 Domain motions in inactive CDK5 
The homology model of inactive CDK5 that previously modelled was used in this 
study to calculate all principle motions or collective motions. These motions were 
derived from the MD trajectory by applying covariance matrix. Key motions were 
sorted out based on variance calculated (shown in the Fig 9.2D) as higher variance 
indicate the higher the magnitude of motions. To identify the collective mode that is 
significant for the activation of CDK5, ANM analysis was performed and top 10 
collective modes were compared against EDA, suggesting reasonable overlap of 
mode2 of EDA and Mode1 of ANM (Fig 9.2 A&B). Further examination of this mode 
suggests a twisting motion (Fig 9.2A) of entire N-terminal region along with t-loop. 
Especially, the loop region (38-43) preceding the Cα-helix is found to be exhibiting 





terminal (234-252) is also found to be exhibiting relative large collective motions but 





Fig 9.2 : A. Colective motions of inactive CDK5 B.  mode overlap of EDA and ANM of inactive 
CDK5 C. Mean square fluctuactions  of inactive CDK5. D. Profile of Eigenvalues of CDK5 (inactive, 
active and active with out p25).. 
Furthermore,  these motions can be easily substantiated by the the square fluctuaions 
calculated  (Fig 9.1C) from the top 10 modes of EDA. Interestingly, all these 
concerted motions are explained by single modes, which are  relevent to activation 
process.  So, EDA and ANM can be conveniently   used to decipher key functional 
motions.  
9.3.2 Domain motions in active CDK5 
Major modes of collective of motions of active and inactive CDK5 were compared, 
which clearly suggest that these conformations exhibit widely different motions in 











marginal overlap of top modes with EDA (Fig 9.1SM).  In activation state, Cα-helix 
and the loop (DDDDE) seem to be blocked by activator. T-loop that is in extended 
conformation seems to be largely stabilized by activator p25. The interaction with 
activator seems to be mainly stabilizing G-loop that is significant for ATP reception 





Fig 9.3:  A. Dominant motions of active CDK5. B. Overlap of collective modes from EDA and ANM 
of CDK5/p25.  C. Comparative square fluctuations of inactive and active D. Overlap of collective 
modes from active CDK5 and active CDK5 without p25. 
We further compared CDK5 from CDK5/p25 complex and active CDK5/nop25 to 
study local structural changes. Interestingly, significant overlap (Fig 9.3D) between 
first collective modes calculated from EDA of CDK5 with and without p25 suggests 
the possibility of structural transformation. In other words, higher the overlap (>0.6) 
between the collective modes is an indicative of structural transformation.  Upon 





spanning residues 151-161 is also gained flexibility, suggesting critical refining 
motions that are significant for achieving complete activation.  
9.3.3 Influence of P25 and CIP on CDK5 
In continuation, we compared essential modes of CDK5 in the presence of p25 
activator and CIP inhibitor to understand possible structural changes that are induced 
in CDK5 upon complexation.  Essential modes (EDA) of CDK5 calculated from 
CDK5/p25 and CDK5/CIP complexes were compared (Fig.9.4 A) and was observed 
to have poor overlap between respective modes. Mode2 of CDK5 from CDK5/p25 
shows marginal overlap with mode3 of CDK5 from CDK5/CIP, suggesting that 
collective motions of these two conformations are not similar. Further evaluation of 
square fluctuations from both CDK5 conformations unambiguously highlight that the 
acidic DDDDE loop (36-43) is making high amplitude motions in CDK5/CIP 
complex and these motions are largely supressed in CDK/p25. In addition, it is 
observed that C-terminal region of CDK5 is differentially impacted by p25 and CIP 
evident from cross-correlations of Cα atoms obtained from CDK5 of both complexes. 
CDK5 in the presence of p25 exhibit correlated motion near the cα-helix whereas 
CDK5 in the presence of CIP is observed to exhibit slightly less correlated motion 
which is consistent with high amplitude motions of acidic loop (DDDDE), suggesting 
incomplete activation achieved by the CIP. Furthermore, α3 helix of CDK5 from 
CDK5/CIP complex is observed to be forming highly correlated motions with 
surrounding regions whereas these motions are not found in CDK5/p25.  This can be 
conveniently explained by assuming the proximity of α6 helix of p25/CIP to α3 of 
CDK5. The truncated α6 helix of CIP, which undergo high frequency motion, might 
be responsible for the dislocation of α3 helix of CDK5 which in turn might be 
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Fig 9.4: A. collective modes of CDK5 from CDK5/p25 and CDK5/CIP B. square fluctuations of CDK5 
from CDK5/p25 and CDK5/CIP C. profile of correlative motion of CDK5 from CDK5/p25 D. profile 
of correlative motion of CDK5 from CDK5/CIP. 
 
9.3.4 Dynamics of P25 and CIP 
The global dynamics of CIP and P25 were analysed before and after complexation 
with CDK5. The comparison of collective motions of p25 before and after 
complexation show fairly good overlap between mode2 of cP25 and mode3 of uP25 
and square fluctuation were extracted from these two modes , suggesting that p25 
does not undergo major structural change between two states.  On the other hand, 
comparison of square fluctuation extracted from mode1 of cCIP and mode3 of uCIP, 









             
Fig 9.5  A&C. Overlap of modes from complexed and uncomplexed p25 and corresponding square 
fluctuation  B&D. Overlap of modes from complexed and uncomplexed CIP and corresponding square 
fluctuation. 
 
9.3.5 Comparison of Interface 
In this section, the interface region of CDK5/p25 and CDK5/CIP is analysed to 
elucidate possible differences in their interaction pattern. It was proposed that the 
hydrophobic clusters located at the interface of CDK5/p25 regulated substrate binding 
conformation of CDK5. Ala199, Asn200, val202, Phe203, Met237, Ile275, Ala277, 
Ph2282 of p25 are forming key hydrophobic interactions with t-loop residues such as 
Ala150, Phe151, Ile153, Pro154, Val155, and Tyr158.  The analysis of change in 
hydrophobic surface area of residues from P25 and CIP that are located at the  
interface revealed that hydrophobic surface area is constant during the simulation but 





suggesting lack of tight regulation in case of CIP interaction.  Further RMSD of α6 
helix of both p25 and CIP unequivocally reduced stability upon truncation of α6 in 
CIP, which might be affecting stability of hydrophobic cluster at the interface.  
A B 
 
Fig 9.6: A. Analysis of hydrophobicity of hydrophobic residues at the interface of CDK5-p25/cip B. 
RMSD variation of α6 helix of p25/CIP 
 
9.3.6 Impact on substrate Recognition  
In this section, we investigated impact of CDK5/p25 and CDK5/CIP on substrate 
binding interactions. For this study, we used HHASPRK peptide that obtained from 
CDK2/cyclin (PDB ID: 1QMZ) as substrate. CDK5/p25-substrate model was created 
using flexible docking strategy that mentioned in the previous chapter8. CDK5/CIP-
Substrate model was generated just by chopping of N-terminal and C-terminal 
residues as suggested by Zheng8, 19 et al., and resulting model was slightly minimized 
before subjected to the MD simulations.  Analysis of global motions of substrate 
peptide in the presence of CDK5/p25 and CDK5/CIP suggests that principle motions 
in both cases are strikingly similar evident from high (>0.7) overlap of mode1. But 
RMSD of substrate of peptide suggests slight instability in case of CDK5/CIP, yet 











        
Fig 9.7 : Analysis of global modes of substrate B. RMSD of substrate C. Distance variation between 
Glu240 of p25 and Lys8 of substrate D. Distance variation between val163 of CDK5 and anchor 
proline residue of substrate. 
Further, we analysed two key interactions of substrate peptide that determine the 
overall binding stability with CDK5 and P25/CIP were also analysed during the 
simulations. The salt bridge interaction between Glu240 of p25/CIP and C-terminal 
Lys of peptide has been proposed11 to be a key interaction that helps the incoming 
substrate to align itself rightly in the substrate binding site. In case of CDK5/p25 the 
distance between these two residues suddenly dropped after 10 ns   to 2.5 Å, which 
typical distance at which salt bridges are formed. But in case CDK5/CIP the distance 
(3.5 Å) remains constant throughput simulations, indicating weak salt bridge 
formation owing to high mobility of α2 helix of CIP.  Another important interaction 
that determines the stability of substrate is Val163 and Pro6 of the substrate. An 





known to bind tightly in the hydrophobic pocket created by Val163 of CDK5. In case 
of CDK5/p25, the distance between these two residues remain constant with an 
average distance of 3.5 Å during the long 25 ns simulation but the higher average 
distance in case of CDK5/CIP suggests possible non-substrate friendly conformation 
of t-loop.  
9.3.7 Discussion 
In this study, we emphasized on collective dynamics of CDK5 and its various 
interacting partners including p25 (residues145-291), a pathogenic activator, and CIP 
(residues 154-279), an inhibitor peptide obtained from truncation of N-terminal and 
C-terminal region of p25. Further impact of CDK/p25 and CDK5/CIP on substrate 
phosphorylation was also studied.  Analysis of collective motions of inactive CDK5 
indicates that it can undergo complete transition through single twisting motion which 
is very close to anticipated motion that occurs through activator binding interaction.  
When an activator like p25 binds to the Cα-helix of inactive conformation, Cα-helix is 
pushed into the binding cavity and also resulting twisting of N-terminal region 
through the neck located DFG motif. The second major structural changes can be seen 
in the t-loop region which seems to be severely impacted by DDDE loop during 
activation process, leading to the intermediate conformation. Along with huge domain 
shift, additional local changes can be seen in the C-terminal region spanning residues 
232-254, which might be responsible for restructuring of C-terminal region upon 
activation. Interestingly, all these collective motions are explained by single mode 
(PC2 from EDA of inactive CDK5) which demonstrates how nature exploit collective 






Inactive Active CDK5/p25 Active CDK5-noP25 
 
Fig 9.8 Collective motions of CDK5 in different states 
 
Upon activation, Ca-helix and DDDDE loop are stabilized by strong interaction with 
Cyclin-box domain of activator (p25) which in turn stabilizes the flexible g-loop 
region. Stability of g-loop is critical for the proper positing of ATP molecule inside 
pocket. In the absence of p25, it is very clear that g-loop region seems to become 
flexible (Fig 9.8). In addition, stability of t-loop is also tightly correlated with binding 
orientation of p25. Especially, simulation results suggest, upon removal of p25 from 
CDK5/p25 complex, increased flexibility is observed in the region close to Ile153. 
P25 is a pathological activator of CDK5, which was generated in the part of truncation 
experiments. Further truncation of P25 was resulted an inhibitor (CIP) which shows 
same cyclin box domain that is observed in p25. Despite the similarities between P25 
and CIP, former acts an activator and latter acts as an inhibitor. Difference in the 
mode of interaction between p25 and CIP is still a subject matter of debate. Flexibility 
hypothesis was proposed by Cardone20 et al., to account for structural differences but 
it is not verifiable owing to unavailability of crystal structure.  We analysed impact of 
p25 and CIP on CDK5 using essential dynamics which unambiguously supplied proof 





It is obvious that CIP induce different set motions from that of CDK5/p25. Two major 
structural differences are identified. DDDDE loop of CDK5 is flexible in CDK5/CIP 
whereas it is highly stabilized in CDK5/p25. The region spanning 190-210 of CDK5 
seems to be flexible in CDK5/CIP but no significant motions were identified from the 
same region of CDK5/p25. Interestingly, loop spanning 232-254 of CDK5 is 
relatively more flexible in CDK5/CIP. The higher flexibility of these two regions 
(residues 190-210 and 232-254) might have significant impact on substrate binding 
site. The relative higher flexibility of this region (190-210) might be due to proximity 
of α6 helix to the truncated α-helix of p25. 
 
CDK5 from CDK5/p25 complex CDK5 from CDK5/CIP complex 
Fig 9.9 Collective motions of CDK5 
Analysis of collective dynamics of the P25 and CIP further shed light on their 
individual mode of interaction. Closer examination of P25 and CIP in both complexed 
and uncomplexed form suggests that p25 undergoes almost no significant structural 
transformations up complexation whereas CIP is observed to undergo significant 
amount conformational transition. This observation is very much consistent with 
flexibility hypothesis in which CIP is considered to be highly flexible molecule. 
Especially, the loop regions preceding α2 and α6 are exhibiting significant 






Uncomplexed P25 Uncomplexed CIP 
Fig 9.10 Collective motions of p25 and CIP 
 It is obvious from the Fig 9.9 that α6-helix is more flexible in CIP than that of P25 
and loop region preceding Cα-helix, interestingly, lost its flexibility. These structural 
changes might be responsible inhibitory action of CIP.    RMSD of α6 helix further 
substantiate the relative instability of a6 helix.  In continuation to assess the role of 
CDK5-CIP/P25 interface close t-loop region, a cluster of hydrophobic residues 
(Ala199, Asn200, Val202, Phe203, Met237, Ile275, and Ala277) from p25/CIP that 
tightly control the motion of t-loop were analysed and this interaction was predicted 
to be critical to achieve correct substrate binding conformation close to Val163 of 
CDK5. In CDK5/p25, hydrophobicity of this cluster remains intact during long 25 ns 
molecular dynamic simulation but diminished hydrophobicity is observed in CIP.  
This change can be conveniently attributed higher flexibility of α6-helix close to t-
loop, leading to disruption of hydrophobic cluster.  
Collective motions of substrate peptide (HHASPRK) on the surfaces of CDK/p25 and 
CDK5/CIP seem to have well overlapped, indicating their global orientation peptide 
remains similar in both cases. To further probe possible local changes, minimum 
distance between Glu240 of p25/CIP and Lys from C-terminal of HHASPRK peptide 
was measured, suggesting the difference of 2.5 Å in case of CDK5/p25 and against 





of substrate to receive phosphate group.   Further the distance between Val163 of 
CDK5 and anchor proline residue that always appear following Ser/Thr residues 
among CDK substrates, is critical for the initial substrate recognition. This is constant 
(within 3 Å distance) in case of CDK5/p25 during 25 ns simulation on the other, 
CDK5 /CIP seems to exhibit higher variability with substrate anchor residue (within 
4-5 Å).  
9.4 Conclusion 
Global conformational analysis of CDK5 along with its interacting proteins illustrated 
several interesting facts.  Essential dynamics and anisotropic network analysis were 
used to identify functionally relevant motions.  Analysis of collective modes of 
inactive CDK5 suggests that it can achieve active conformation through the twisting 
motion of N-terminal region. This mode is found to be further associated with t-loop 
(residues145-175) and a flexible loop (residues 232-254) located in C-terminal 
regions. Analysis of active conformation suggests that flexibility of g-loop, DDDDE 
loop (36-43) and t-loop are completely curtailed upon activation. Furthermore, the 
analysis of collective motions derived from active CDK5 without p25   suggests ~2 Å 
deviation from the crystal structure of active CDK5 as well as reversal of g-loop 
flexibility and high degree motion associated with Ile153, signifying the requirement 
to control flexibility of g-loop to achieve stable ATP binding conformation and to 
regulate Ile153 to achieve stable substrate binding site. Further to understand the 
impact of P25 and CIP on CDK5, major collective modes of CDK5 extracted from the 
complexes of CDK5/p25 and CDK5/CIP, were analysed. This analysis clearly 
emphasized that principle modes are not similar evident from their poor overlap. 
Further analysis suggested CIP is unable to supress DDDDE loop that is critical for 





substrate binding site were observed to be associated with CIP interaction whereas 
these motions were efficiently curtailed in case CDK5/p25.  To ascertain the role P25 
and CIP, collective modes of these two were compared in complexed (cP25 and cCIP) 
and uncomplexed (uP25 and uCIP) states, which suggested CIP the higher flexibility 
of CIP and possibility to undergo structural rearrangement upon complexation. The 
analysis of hydrophobic cluster located at the interface of CDK5-p25/CIP suggested 
diminished hydrophobicity of these residues in case of CDK5/CIP complex on the 
other hand hydrophobic surface area is found constant, indicating the possibility of 
dislocation of hydrophobic residues (surrounding Ile153 of CDK5) that are critical for 
substrate binding site creation. At the end, mode of interaction of substrate peptide 
with CDK5/p25 and CDK5/CIP was analysed, which suggests overall global modes 
substrate remain similar but the distance between anchor residue of substrate and 
CDK5 is slightly more in cases of CDK5/CIP complex ( 4.5 Å vs 3 Å in CDK5/P25), 
suggesting weak interaction with binding site.  In addition, high degree fluctuations of 
C-terminal residues of substrate peptide seem to further weaken the interaction with 
Substrate binding site. These motions were found to be completely absent in 
CDK5/P25 complex. This study illustrates various motions of CDK5 in the presence 
and absence of p25, CIP and substrate (HHASPRK), which might help to design 
fragments like CIP that could block the structural activation by impeding the motions 
and this study demonstrates the potential of EDA/ANM as a tool to design novel 
inhibitors of next generation. 
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Conclusions and Future Directions 
 
10.1 Conclusions  
Cyclin-dependent kinase5 (CDK5) is known as a key therapeutic target for targeting 
Alzheimer’s disease. In this thesis work, we explored various aspects of Cyclin-
dependent kinase5 (CDK5) using bioinformatics methods, leading to the betterment 
of drug design strategies. Starting with structural modelling and application of 
networking methods to elucidate key biophysical aspects, then the molecular 
interactions with various inhibitor molecules were explored including dynamics of 
binding pocket. Following, various drug design strategies were explored and at the 
end, structural dynamics of CDK5 and its interacting partners were studied in order to 
supplement the drug design strategies.  
Understanding structure of a target protein forms first step in structure based drug 
design.  Unavailability of inactive CDK5 structure motivated us to the construction of 
inactive CDK5 using comparative modelling method and thus developed model was 
validated thoroughly for stereochemical quality (98% of residues occupy sterically 
allowed regions) as well as stability using MD simulations.  Residue interaction 
network (RIN) paradigm was applied to both inactive and active conformations of 
CDK5, wherein residues were represented as nodes and interactions between them 
represented as edges, to identify key residues. Phe145, Leu127, Y167 and Trp186 
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were identified as hub residues using closeness centrality. Betweenness centrality was 
used to predict the residues that play crucial role in domain motions i.e. hinge 
residues. Further precise role of these residues were examined using FRODA coarse 
grain simulation in which intermediate conformations between inactive and active 
were generated. We identified that Phe145 and Val163 are important hinges that 
transform the inactive conformation into fully active conformation.  
Understanding molecular interactions between protein-ligand complexes form the 
next step in structure based drug design. Lack of enough structural data of 
CDK5/inhibitor complexes was identified as   roadblock in CDK5 based drug design. 
We designed active/inactive CDK5/ATP complexes so as to use them as templates for 
generation of CDK5/inhibitor complexes. Active binding site conformation was 
observed to be more suitable for SBDD studies but the inclusion of inactive 
conformation was found to enhance the novelty and variation. Secondary binding 
pocket was identified through pocket dynamics analysis, which was observed to 
accommodate small substitutions such propyl, iso-propyl, butyl that have significant 
impact on binding affinity.   
With enriched knowledge of CDK5/inhibitors complexes, virtual screening was set 
out to identify new CDK5 selective inhibitors. Multi-step screening procedure was 
developed to identify selective CDK5 inhibitors. Incorporation of ensemble docking 
procedure and pharmacophore model helped to enhance true positives. Further 
development of CDK5 specific PLP scoring function helped to identify selective 
inhibitors. This scoring function was thoroughly validated by clustering and principle 
component analysis techniques.  
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Despite the best efforts, highly conserved nature of CDK5 binding site triggers 
significant selectivity issues.   Substrate binding site was explored as possible 
alternative to ATP binding site. We designed tau competitive peptide inhibitors that 
prevent abnormal phosphorylation by CDK5. Given the non-selectivity issues 
associated with small molecule inhibitors, peptide inhibitors are expected to help in 
achieving requisite selectivity. We successfully applied vigorous flexible peptide 
docking simulations to create CDK5-peptide complexes to understand basic 
specificities of amino acids. Using the anchor residue constrain obtained from the 
CDK5-peptide complexes, in situ design simulations were performed by adding reside 
on either sides of anchor residue and subsequent optimization. Top ranking peptides 
were identified as probable inhibitors after eliminating phosphorylating groups in P0 
position and subsequently molecular dynamic simulations were performed to confirm 
their interaction with substrate binding site of CDK5. A pharmacophore model was 
elucidated to interpret basic requirements for tau completive inhibitors of CDK5.  
To extend the possibilities of targeting CDK5 activity, activator protein p35 was 
explored as an alternative. Despite the availability of crystal structure of C-terminal 
region of p35 (p25), it was ruled out   citing reason of its highly conserved nature.  N-
terminal region of p35 (p10) was identified as potential site. Due to unavailability of 
#D structure of this domain, we constructed the model using Abinitio strategy and 
sufficiently validated by reverse template search. Class of ribosomal proteins such 
L10, L11, L34 were identified as homologues to the p10 domain and interestingly, 
these proteins seamlessly interact with CDK5.  Further protein-protein docking 
simulations were performed to predict natural binding conformation of p10 with 
respect to CDK5, suggesting close interaction with substrate binding site. Arg156 and 
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Glu161 from t-loop region of CDK5 were found to be strongly interacting with Ser48 
and Arg54 of p10. A putative binding site was identified that resembles stochman 
domain of microtubules which interacts with colchicine like molecules.  
The next level of novelty in drug design is only possible with comprehensive 
understanding of structural dynamics of target protein. We used essential dynamics 
coupled with anisotropic network analysis to elucidate dynamics of CDK5 and its 
interacting protein such as p25, CIP. Inactive CDK5 was found to undergo twisting 
motion of N-terminal region during the activation process. Flexibility of Ile153 and 
DDDDE loop was found to be critical for phosphotransfer activity. Higher flexibity 
was found in CIP than the P25, indicating possibility of strong interaction with 
CDK5. Further analysis of interface of CDK5/p25 and CDK5/CIP suggested clear 
disruption of hydrophobic cluster located, pointing the significant role of hydrophobic 
residues in achieving stability of substrate binding site. 
10.2 Future directions 
We successful applied Residue interaction network approach to interpret various 
structural motifs and to quantify the significance of various residues using network 
centrality measures. To enhance the reliability of the prediction, multiple structures 
must be used before arriving any conclusion. Although inactive and active 
conformations were studied extensively for their ability to form molecular interactions 
with inhibitors and their suitability for structure based drug design studies,   large 
dataset must be included to substantiate the conclusions. Secondary hydrophobic 
pocket identified in this study must be sufficiently validated for its ability to 
accommodate variety of substitutions.  In silico prediction of multi-target inhibitors 
must be experimentally validated for their inhibition ability against CDK5. Multi-step 
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virtual screening was used to predict CDK5 selective inhibitors. Despite the 
substantial proof that garnered   from the analysis of inhibitors for their ability to 
inhibit CDK5, they must be further evaluated experimentally. In addition peptide 
inhibitors and peptidomemectic compounds should be validated experimentally. P10 
model constructed in this study seems to be logical. Yet lack of proper template, again 
cast doubt on validity of the model.  This model must be sufficiently validated, 
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Table 5.1 SM : co-crystal ligands used in validation study 












1 1ckp 5.84 5.66 1FVV 6.45  6.22
2 1di8 5.97 6.01 1H1Q 6.05  6.1
3 1fvt 6.19 5.77 1H1R 6.22  6.23
4 1g5s 7.28 6.01 1VYW 5.97  5.67
5 1gii 6.87 6.58 2BPM 5.84  6.02
6 1jsv 5.39 5.75 2IW8 6.05  6.23
7 1ke5 6.23 5.72 2UZE 5.54  5.57
8 1ke6 6.27 6.41 2UZL 6.34  6.31
9 1ke7 6.28 6.75 2WIP 5.21  5.1
10 1ke8 6.77 6.67 3EOC 5.32  5.29
11 1ke9 6.52 6.61 3F5X 6.45  6.22
12 1oit 6.46 6.4 2IW8 6.05  6.1
13 1p2a 6.62 6.52  
14 1pye 6.84 6.76  
15 1urw 6.17 6.12  
16 1vik 6.39 6.3  
17 1vyz 6.2 6.14  
18 1w0x 5.87 5.77  
19 1y8y 6 5.53  
20 2b52 7.12 7.09  
21 2b53 7.13 7.06  
22 2b54 7.16 6.93  
23 2b55 7.21 7.29  
24 2bh3 6.57 6.49  
25 2bhh 7.12 6.8  











Molecular Docking Scores of CDK5-Inhibitor complexes 
Table 5.2 SM: Indirubin compounds and Docking score (PLANTS) 
Active  Inactive 
Comp  Total  NP  HB  BU  Comp  Total  NP  HB  BU 
Indi‐1  ‐69.203  ‐56.784  ‐4.748  6.586  Indi‐1  ‐75.825  ‐64.522  ‐5.879   
Indi‐2  ‐78.535  ‐59.300  ‐4.323  3.060  Indi‐2  ‐81.104  ‐66.669  ‐4.552   
Indi‐3  ‐66.432  ‐60.307  ‐4.480  12.415  Indi‐3  ‐76.451  65.544  ‐5.556   
Indi‐4  ‐73.055  ‐50.800  ‐5.191  ‐1.053  Indi‐4  ‐77.657  ‐58.000  ‐6.419   
Indi‐5  ‐63.581  ‐49.608  ‐3.162  0.154  Indi‐5  50.712  ‐32.917  ‐3.956   
Indi‐6  ‐74.889  ‐50.244  ‐4.176  ‐1.139  Indi‐6         
Indi‐7  ‐76.605  ‐59.404  ‐4.000  1.423  Indi‐7         
Indi‐8  ‐76.154  ‐62.016  ‐6.000  5.728  Indi‐8  ‐57.291  ‐41.798  ‐2.00   
Indi‐9  ‐77.469  ‐51.008  ‐5.956  ‐0.836  Indi‐9  ‐77.945  ‐58.389  ‐5.655   
Indi‐10  ‐81.719  ‐59.234  ‐5.890  2.647  Indi‐10  ‐78.602  ‐61.066  ‐5.041   
Indi‐11  ‐81.871  ‐61.425  ‐6.000  4.316  Indi‐11         
Indi‐12  76.601  ‐51.577  ‐4.347  ‐1.070  Indi‐12  ‐71.134  ‐56.057  ‐6.000   
 
Table 5.2 SM: AminoThiazole compounds and Docking score (PLANTS) 
Active  Inactive 
Comp  Total  NP  HB  BU  Comp  Total  NP  HB  BU 
APZ‐1  ‐72.905  ‐47.325  ‐6.00  ‐2.987  APZ‐1  ‐51.272  ‐37.188  ‐7.9911  5.756 
APZ‐2  ‐70.797  ‐49.166  ‐4.565  ‐0.387  APZ‐2  ‐66.820  ‐48.955  ‐4.000  4.539 
APZ‐3  ‐69.386  ‐55.349  ‐1.906  ‐2.313  APZ‐3  ‐40.233  ‐26.517  ‐4.000  ‐0.623 
APZ‐4  ‐70.780  ‐50.477  0.000  ‐1.784  APZ‐4  ‐52.988  ‐35.895  ‐4.000  4.259 
APZ‐5  ‐66.478  ‐50.234  0.000  1.887  APZ‐5  ‐48.474  ‐31.285  0.000  0.524 
APZ‐6  ‐71.719  ‐54.432  0.000  0.753  APZ‐6  ‐48.620  ‐30.333  0.000  ‐0.476 
APZ‐7  ‐71.677  58.763  ‐5.097  1.811  APZ‐7  ‐64.362  ‐41.743  ‐4.946  1.465 
APZ‐8  ‐60.890  ‐47.016  ‐2.400  4.074  APZ‐8  ‐51.251  ‐32.019  ‐1.518  ‐0.582 
APZ‐9  ‐70.767  ‐48.810  ‐5.771  2.626  APZ‐9  ‐39.113  ‐21.854  ‐3.996  5.177 
APZ‐10  ‐71.362  ‐51.129  ‐2.000  0.271  APZ‐10  ‐66.835  ‐49.587  ‐4.000  5.160 
APZ‐11  ‐54.511  ‐31.376  ‐7.125  0.081  APZ‐11  ‐44.836  ‐22.780  0.000  2.367 
APZ‐12  ‐52.455  ‐41.349  ‐1.971  1.609  APZ‐12  ‐47.274  ‐37.043  ‐3.483  4.529 
APZ‐13  ‐61.328  ‐44.750  ‐1.149  ‐0.487  APZ‐13  ‐61.358  ‐43.791  ‐5.919  2.229 
APZ‐14  ‐55.945  ‐44.799  ‐0.025  6.257  APZ‐14  ‐62.259  ‐48.929  ‐2.486  5.224 
APZ‐15  ‐64.917  ‐46.194  ‐2.782  0.546  APZ‐15  ‐61.628  ‐43.232  ‐1.996  1.883 
APZ‐16  ‐59.126  ‐40.164  ‐2.164  ‐2.082  APZ‐16  ‐45.475  ‐32.213  ‐3.666  8.180 
APZ‐17  ‐57.590  ‐42.218  0.000  2.781  APZ‐17  ‐46.430  ‐30.594  ‐1.815  2.814 
APZ‐18  ‐57.776  ‐43.288  ‐2.000  0.405  APZ‐18  ‐53.617  ‐42.097  ‐1.210  2.317 
APZ‐19  37.282  ‐26.411  0.000  ‐1.842  APZ‐19  ‐40.797  ‐25.837  ‐3.967  1.188 





Table 5.2 SM: Purine Derivatives compounds and Docking score (PLANTS) 
Active  Inactive 
Comp  Total  NP  HB  BU  Comp  Total  NP  HB  BU 
ROS‐1  ‐60.252  ‐56.813  ‐0.516  12.408  ROS‐1  ‐64.365  ‐43.166  ‐6.644  0.825 
ROS‐2  ‐63.284  ‐60.393  ‐3.961  17.417  ROS‐2  ‐51.843  ‐48.759  ‐1.087  14.092 
ROS‐3  ‐64.741  ‐57.634  ‐4.117  9.153  ROS‐3  ‐70.750  ‐53.594  ‐2.000  0.410 
ROS‐4  ‐53.227  ‐54.561  ‐2.055  10.707  ROS‐4  ‐33.526  ‐48.155  0.422  22.812 
ROS‐5  ‐73.056  ‐50.955  ‐1.988  ‐3.686  ROS‐5  ‐60.851  ‐53.845  ‐2.000  9.715 
ROS‐6  ‐60.087  ‐53.345  ‐2.257  8.842  ROS‐6  ‐63.041  ‐43.447  ‐2.000  3.512 
ROS‐7  ‐66.750  ‐47.367  ‐2.000  2.303  ROS‐7  ‐58.504  ‐51.176  ‐1.709  9.649 
ROS‐8  ‐72.701  ‐56.641  ‐6.802  3236  ROS‐8  ‐51.055  ‐41.094  ‐6.000  8.019 
ROS‐9  ‐61.430  ‐54.601  ‐1.507  1.507  ROS‐9  ‐35.953  ‐40.776  0.000  16.006 
ROS‐10  ‐66.180  ‐54.693  ‐5.477  7.389  ROS‐10  ‐65.659  ‐47.787  ‐2.000  ‐0.429 
ROS‐11  ‐64.536  ‐52.610  ‐1.013  3.799  ROS‐11  ‐72.512  ‐56.646  ‐2.654  4.209 
ROS‐12  ‐60.541  ‐45.813  ‐0.000  0.576  ROS‐12  ‐47.150  ‐26.516  ‐5.018  ‐1.306 
ROS‐13  ‐66.085  ‐62.141  ‐1.519  10.846  ROS‐13  ‐62.226  ‐50.681  ‐4.590  7.209 
ROS‐14  ‐77.696  ‐56.616  ‐5.714  ‐1.666  ROS‐14  ‐50.417  ‐49.375  ‐2.000  13.63 
ROS‐15  ‐77.430  ‐63.672  ‐5.088  7.723  ROS‐15  ‐78.484  ‐66.612  ‐2.000  6.150 
ROS‐16  ‐80.482  ‐57.226  ‐5.253  ‐1.510  ROS‐16  ‐50.080  ‐50.096  ‐2.000  11.471 
ROS‐17  ‐58.960  ‐55.448  ‐3.673  8.086  ROS‐17  ‐47.461  ‐54.326  0.000  13.144 
ROS‐18  ‐48.425  ‐12.693  ‐4.247  5.457  ROS‐18  ‐52.491  ‐52.491  0.000  5.226 
ROS‐19  58.495  ‐38.759  ‐3.461  ‐1.215  ROS‐19  ‐45.012  ‐45.012  ‐8.000  4.552 
ROS‐20  ‐69.737  ‐58.719  ‐5.721  10.429  ROS‐20  ‐66.384  ‐66.384  ‐1.947  1.974 
ROS‐21  ‐58.495  ‐38.759  ‐3.407  ‐1.215  ROS‐21  ‐43.385  ‐43.385  ‐6.017  3.442 
ROS‐22  ‐58.495  ‐48.710  ‐5.529  1.171  ROS‐22  ‐48.843  ‐48.843  ‐2.000  9.019 
ROS‐23  ‐69.276  ‐59.372  ‐6.466  11.103  ROS‐23  ‐61.470  ‐61.470  ‐3.368  9.013 
ROS‐24  ‐69.737  ‐58.179  ‐5.721  10.429  ROS‐24  ‐70.916  ‐70.916  ‐3.836  ‐3.292 
ROS‐25  ‐67.502  ‐56.269  ‐3.366  8.763  ROS‐25  ‐53.157  ‐53.157  0.000  11.670 
 
Table 5.2 SM: Quinolin  derivatives compounds and Docking score (PLANTS) 
Active  Inactive 
Comp  Total  NP  HB  BU  Comp  Total  NP  HB  BU 
QUN‐1  ‐54.792  ‐37.296  ‐0.000  0.565  QUN‐1  ‐71.727  ‐58.162  ‐2.000  5.767 
QUN‐1  ‐67.795  ‐45.431  ‐2.000  ‐2.556  QUN‐1  ‐67.336  ‐53.749  ‐1.594  3.236 
QUN‐3  ‐64.117  ‐41.333  ‐3.861  0.495  QUN‐3  ‐60.671  ‐39.188  ‐3.507  1.144 
QUN‐4  ‐68.270  ‐59.693  ‐2.669  11.102  QUN‐4  ‐67.563  ‐57.055  ‐2.523  10.370 
QUN‐5  ‐60.708  ‐41.535  ‐0.000  ‐1.013  QUN‐5  ‐67.239  ‐45.265  ‐2.000  ‐2.890 
QUN‐6  ‐62.562  ‐42.155  ‐2.000  6.433  QUN‐6  ‐63.997  ‐45.395  ‐0.746  ‐2.623 
QUN‐7  ‐78.347  ‐63.111  ‐4.000  6.950  QUN‐7  ‐72.759  ‐55.143  ‐1.392  1.058 
QUN‐8  ‐69.155  ‐45.336  ‐6.255  0.826  QUN‐8  ‐64.495  ‐43.804  ‐0.000  ‐1.420 
QUN‐9  ‐53.509  ‐38.107  ‐0.625  3.995  QUN‐9  ‐57.547  ‐39.305  ‐0.000  ‐1.014 
QUN‐
10 
‐60.914  ‐37.734  ‐1.852  ‐2.183  QUN‐
10 
‐66.677  ‐44.078  ‐0.000  ‐3.261 
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Table 5.2 SM: Paullone derivatives compounds and Docking score (PLANTS) 
Active  Inactive 
Comp  Total  NP  HB  BU  Comp  Total  NP  HB  BU 
Pau‐1  ‐51.115  ‐47.542  ‐7548  14.046  Pau‐1  ‐39.441  ‐35.713  0.000  6.381 
  Pau‐2  ‐84.581  ‐66.280  ‐4.00  4.294    Pau‐2  ‐70.553  ‐58.275  0.000  4.974 
Pau‐3  ‐64.440  ‐49.371  ‐2.514  1.315  Pau‐3  ‐37.490  ‐32.067  ‐0.457  9.253 
Pau‐4  ‐60.570  ‐47.766  ‐3.976  8.746  Pau‐4  ‐57.963  ‐34.255  ‐4.000  ‐1.963 
Pau‐5  ‐53.805  ‐41.276  ‐3.796  3.039  Pau‐5  ‐63.722  ‐40.773  ‐7.995  ‐2.663 
Pau‐6  ‐68.572  ‐45.696  ‐6.000  ‐2.725  Pau‐6  ‐53.461  36.003  ‐3.963  1.622 
Pau‐7  ‐69.562  ‐55.982  0.000  ‐0.394  Pau‐7  ‐59.284  40.639  ‐6.000  ‐2.084 
Pau‐8  ‐55.768  ‐38.314  ‐2.000  0.198  Pau‐8  ‐62.851  ‐39.391  ‐5.961  ‐2.300 
Pau‐9  ‐70.932  ‐54.747  ‐4.000  6.852  Pau‐9  18.816  ‐4.456  ‐2.000  43.223 
Pau‐10  ‐62.553  ‐44.243  ‐4.000  5.368  Pau‐10  ‐51.259  ‐35.094  0.000  3.817 
Pau‐11  ‐62.923  ‐41.902  ‐2.000  0.689  Pau‐11  ‐58.827  ‐35.561  ‐3.943  0.523 
Pau‐12  ‐69.652  ‐53.469  ‐6.525  3.631  Pau‐12  ‐66.893  ‐55.658  ‐0.623  8.853 
Pau‐13  ‐69.262  ‐55.367  ‐0.826  5.837  Pau‐13  ‐53.824  ‐41.380  0.000  3.023 
Pau‐14  ‐72.742  ‐56.451  ‐3.507  3.370  Pau‐14  ‐53.026  ‐31.422  ‐4.000  2.236 
Pau‐15  ‐61.371  ‐45.558  ‐7.000  6.083  Pau‐15  ‐65.991  ‐40.094  ‐4.000  ‐2.021 
Pau‐16  ‐79.168  ‐48.539  ‐3.610  1.307  Pau‐16  ‐62.982  ‐36.980  ‐3.371  ‐3.043 
Pau‐17  ‐72.915  ‐54.737  ‐0.591  1.647  Pau‐17  ‐62.925  ‐40.420  ‐3.346  0.967 
Pau‐18  ‐55.145  ‐38.697  5.725  8.372  Pau‐18  ‐63.610  ‐37.138  ‐7.001  0.328 
 




Target PDB ID Score %ID Nb-Ca RMSD 
ATP CDK2 1HCK 9.4 58..1 31 0.01 
D05 CDK2 2b54 8.6 57.4 32 0.07 
I17 CDK2 1g5s 8.3 54.6 32 0.34 
RRC CDK5 1unl 8.2 99.3 32 0.33 
purvalanol CDK2 1v0p 7.9 58.7 30 0.19 
MNY CK II 1m2r 7.4 29.3 19 0.63 
PP2 LCK KINASE 1qpe 6.9 22 22 0.43 
DFZ CHK1(checkpoint kinase) 2brm 6.7 25.2 23 0.44 
PFQ CHK1(checkpoint kinase) 2brb 6.2 25 23 0.45 
ADZ GSK3 1o9u 6.6 33.1   
537 MAPK (JNK) 1pmv 5.8 30.5 19 0.44 
AA2 FGF kinase 1oec 5.6 21.3 19 0.59 




984 MAPK (JNK) 1pmn 5.5 3.5 31 0.59 
PP1 HCK (Haemopoitic cell kinase) 1qcf 5.5 22.8 27 0.52 
IQP c-AMP dependent kinase 1ydr 5.5 20.7 21 0.63 
IQS c-AMP dependent kinase 1yds 5.5 20.7 18 0.57 
L17 Pim1 kinase 1yxx 5.5 24.8 18 0.39 
M77 c-AMP dependent kinase 1q8w 5.3 20.7 18 0.81 
DF1 CHK1(checkpoint kinase) 2brn 5.3 25 23 0.55 
DRG Death-associated pro 1p4f 5.2 24 17 0.77 
PFP CHK1(checkpoint kinase) 2br1 5.2 25 25 0.4 
D13 P38 MAP KINASE 1ian 5.1 32 15 0.74 
MNX CK II 1m2q 5 29.3 19 0.75 
STI SyK(Gleevec) 1xbb 5 18.5 19 0.51 
L16 Pim1 kinase 1yxv 5 24.8 15 0.34 
DFY CHK1(checkpoint kinase) 2brg 5 25 23 0.26 
P17 c-abl kinase 1m52 4.9 23.2 33 5.05 
SB4 ERK 3erk 4.9 33.9 23 0.7 
ACP Insulin receptor kinase 1i44 4,8 18.3 26 1.74 
HNA CK II 1m2p 4.8 29.3 17 0.71 
537 MAPK 1uki 4.8 30.5 17 0.38 
QUE HCK 2hck 4.7 23.2 21 0.68 
LY2 Pim1 kinase 1yi3 4.6 25.5 22 0.39 
DBQ Dual specificity pro 1z57 4.6 25.2 21 0.68 
MPZ c-Src kinase (Proto-Oncogene) 1y57 4.4 21.3 19 0.58 
112 Insulin Receptor Kinase 1gag 4.3 18.8 27 1.13 
1QA CK II 1oml 4.1 29.3 20 0.93 
ATU GSK3 1q3w 4 29.5 14 21 
AAZ VEGFR 1y6a 4 19.8 17 0.55 
9HP MAPK 1pnu 3.8 30.8 24 8.05 
L18 3-phosphoinositide  1z5m 3.7 24.1 23 0.63 
SU1 FGF Receptor 1 1fgi 3.6 21.7 24 2.18 
BDN CK II 1lpu 3.4 29.3 16 0.85 
084 MAPK 1ouk 3.3 34.1 29 0.97 






















































Aminothiazol erivatives  IC50 
BindingDB_50155213  5 
BindingDB_50155231  7 
BindingDB_50155209  8 
BindingDB_50155236  10 
BindingDB_50155235  12 
BindingDB_50155237  13 
BindingDB_50155207  13 
BindingDB_50155230  13 
BindingDB_50155214  16 
BindingDB_50155225  25 
BindingDB_50155232  41 
BindingDB_50155221  44 
BindingDB_50155222  44 
BindingDB_50155220  48 
BindingDB_50155206  64 
BindingDB_50155210  64 
BindingDB_50155216  91 
BindingDB_50155234  102 
BindingDB_50155211  183 
BindingDB_50155223  190 
BindingDB_50155212  321 
BindingDB_50155228  390 
BindingDB_50155226  621 
BindingDB_50155227  900 
BindingDB_50155233  1,150 
BindingDB_50155217  1,570 
BindingDB_50155208  1,600 
BindingDB_50155215  3,270 
BindingDB_50155218  3,990 
BindingDB_50155219  4,580 
BindingDB_50155229  6,530 
























BindingDB_7585  160 
BindingDB_50093390 160 
BindingDB_7576  230 
BindingDB_7579  260 
BindingDB_7580  300 
BindingDB_7577  300 
BindingDB_7581  300 
BindingDB_50093389 340 
BindingDB_7555  340 
BindingDB_7573  400 
BindingDB_7582  400 
BindingDB_7523  400 
BindingDB_7575  500 
BindingDB_7583  500 
BindingDB_50093411 500 
BindingDB_7584  500 







BindingDB_7518  2,300 
BindingDB_7517  2,300 
BindingDB_50093417 2,400 
BindingDB_7527  2,400 
BindingDB_10636  3,000 
BindingDB_50093395 3,500 
BindingDB_50093395 6,000 
BindingDB_7516  8,000 













































































BindDB ID IC50 Pharmacophore 
score 
BindingDB_20851 2.7 6.89482 
BindingDB_20868 29 6.61302 
BindingDB_20847 11 6.59169 
BindingDB_50186373 34 5.85006 
BindingDB_50186373 34 5.85006 
BindingDB_7407 100 5.34558 
BindingDB_7395 400 5.34461 
BindingDB_7401 83 5.34083 
BindingDB_7424 60 5.28874 
BindingDB_50155206 64 5.26208 
BindingDB_7339 320 5.25891 
BindingDB_7270 430 5.24705 
BindingDB_7265 60 5.24617 
BindingDB_50155211 183 5.22765 
BindingDB_7340 100 5.22359 
BindingDB_50093390 160 5.19051 
BindingDB_7266 850 5.18432 
BindingDB_7262 40 5.16731 
BindingDB_50093389 340 5.05371 
BindingDB_5655 170 4.98492 
BindingDB_50093411 500 4.96856 
BindingDB_7579 260 4.9562 
BindingDB_7358 800 4.94986 
BindingDB_7376 1,200 4.73682 
BindingDB_7333 1,700 4.41152 
BindingDB_50295873_mol_1 10,000 4.02735 
BindingDB_7343 3,000 3.97447 
BindingDB_50267160 14,000 3.63332 
BindingDB_7356 10,000 3.62892 

















SNo Substrate name Phosphorylation  site Peptide 
1 Erzin T235 DKLTPKI 
2 N-methyl D-aspartate receptor subunit 2A S1232 TMRSPFK 
3 MEK1 T286 AAETPPR 
4 c-Src S75 TVTSPQR 
5 ErbB3 S1123, T873 EAKTPIK RSRSPRP 
6 P53 S315, S33 NVLSPLP TSSSPQP 
7 Doublecortin 
S109, S368, T370, 
S378, S387, T402, 




8 PCTAIRE protein kinase 1 S101 EVQSPVR 




10 Amphiphysin S272, S276, S285 PLPSPTA, PTASPNH APASPAP 
11 Myocyte specific  enhancer factor 2A S400 EPISPPR 
12 Dynamin 1 S774, S778  
13 PAK1 T212 LPVTPTR 
14 JNK3 T131 NVFTPQK 
15 Disabled -1 S491, S515 RQSSPSK, GFESPSK 
16 Protein Phosphatase 1, regulatory subunit 1B T75 CAYTPPS 








19 Nestin T1299, T315 PDSTPLG, RLQTPGG 
20 Presenilin 1 T354 HRSTPES 
21 Amyloid bets A4 protein T743 AAVTPEE 
22 
Phosphatidylinositol 4 
phosphate 5 kinase 
type 1 gamma 
S650 SWVYSPLH 
23 WAVE1 S310, S397, S441 NRPQSPAT, LVQPSPPV IRPSSPVT 
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